var title_f4_34_4640="Effects n3 PUFA consumption";
var content_f4_34_4640=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78417&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Schema of potential dose responses and time courses for altering clinical events of physiologic effects of fish or fish oil intake",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schema of physiologic effects of n-3 PUFA consumption. The relative strength of effect denotes the relative impact of n-3 PUFA consumption on the physiologic effect (eg, triglyceride-lowering). The time course to alter clinical events denotes the expected duration of consumption for the physiologic effect to alter disease outcomes. For example, the dose-response for anti-arrhythmic effects appears to be initially steep with a subsequent plateau, and effects on disease outcomes may occur within weeks, whereas the dose-response for triglyceride-lowering is more gradual and monotonic, and effects on disease outcomes may require months or years of intake. Potentially important effects of n-3 PUFA on endothelial, autonomic, and anti-inflammatory responses are not shown because the dose- and time-responses of these effects are not well-established. Physiologic effects are not necessarily exclusive: eg, anti-arrhythmic effects may be partly mediated by effects on blood pressure (BP) or heart rate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mozaffarian D, Rimm EB. Fish Intake, Contaminants, and Human Health. Evaluating the Risks and the Benefits. JAMA 2006; 296:1885. Copyright &copy; 2006 American Medical Association. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4640=[""].join("\n");
var outline_f4_34_4640=null;
var title_f4_34_4641="Triflusal: International drug information";
var content_f4_34_4641=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Triflusal: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aflen (GR);",
"     </li>",
"     <li>",
"      Anpeval (ES);",
"     </li>",
"     <li>",
"      Disgren (AR, BR, ES, HU, MX, VE);",
"     </li>",
"     <li>",
"      Tecnosal (PT);",
"     </li>",
"     <li>",
"      Triflux (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3462655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiplatelet Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F3335274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and treatment of thrombotic complications",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F3335276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: 600-900 mg/day with meals",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3335277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsule: 300 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10509 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-D8D1174216-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4641=[""].join("\n");
var outline_f4_34_4641=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302649\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3462655\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335274\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335276\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821159\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3335277\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10509\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10509|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_34_4642="Fallen fragment sign";
var content_f4_34_4642=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65224&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 530px\">",
"   <div class=\"ttl\">",
"    Unicameral bone cyst: Fallen fragment sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 510px; height: 395px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGLAf4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5btLZ7qQpGVBAz81WhpE/9+L8z/hS6F/x9vn/AJ5n+Yr6I+AXw08NeNfDWtan4ka7U2d35YaK4MarGIlYk/meaAPnb+yZ/wC/F+Z/wo/smf8Avxfmf8K+qfhf4B+FHxJttRm0CHxDF9hkWOVLu5CMQwJVgFLfKcHGcHg8V85SKI5ZIxkhWKgnrwaAMP8Asmf+/F+Z/wAKP7Jn/vxfmf8ACtonFKKAMT+yZ/78X5n/AAo/sif+/F+Z/wAK2ieKVSDQBijSLg/xxfmf8KQ6ROP44vzP+FbyilIzQBz50qcfxx/mf8KP7Kn/AL0f5n/CtputIKAMYaVP/fi/M/4UHSp/78X5n/CtnPFBNAGN/ZU5/ji/M/4Uf2VP/fi/M/4Vsg46mgn0oAx/7Jn/AL8X5n/Cj+yZ/wC/F+Z/wrYzSljjB5oAxf7Kn/vx/mf8KX+yZ/78X5n/AArZUnFLQBi/2TP/AH4vzP8AhR/ZM/8Afi/M/wCFbJOBRu9qAMb+yZ/78X5n/Cj+yJ/78X5n/CtkNTgaAMX+yLj+/F+Z/wAKP7IuP78X5n/CtvNLmgDD/se4/vxfmf8ACj+x7j+/F+Z/wrczRmgDE/sa4/vxfmf8KP7HuP78X5n/AArdB5p3WgDA/se43Y3xZxnqf8PalGi3J/ji/M/4VuD/AFrf7o/malbItpCDggH+VAHOnRbgfxxfmf8ACj+x7jH34vzP+FfUV/8AD3wBpMvhrTbjSfFGp6vrNibyOOxu4guEjDPkyyIBwScVgeO/BXgtfg7Y+NfByavGt3cRpGt9KdwXeysGXkZyp5BI9KAPnr+yLj+9F+Z/wo/smf8Avxfmf8K6AjNIVoAwP7Jn/vxfmf8ACk/smfP34vzP+Fb2KQjn9KAML+yp/wC9H+Z/wo/sqfGd0eOmcn/CtzHNJt7dqAMP+y5v70f5n/Cj+zJv70f5n/CtsrSYNAGL/Zk396P8z/hR/Zk396P8z/hW1g0YoAxf7Mm/vR/mf8KP7Mm/vR/mf8K2sUmOaAMb+zJv70f5n/Cj+zJv70f5n/CtnBpKAMf+zJv70f5n/Cj+zJv70f5n/CtiigDH/syb+9H+Z/wpP7Mm/vR/mf8ACtkDOaTHFAGQNMmz96P8z/hSf2ZN/ej/ADP+FbFBoAx/7Mm/vR/mf8KP7Mm/vR/mf8K2KKAMgaZN/ej/ADP+FH9mTf3o/wAz/hWuDRQBj/2ZN/ej/M/4Uf2ZN/ej/M/4VsUCgDH/ALMm/vR/mf8ACj+zJv70f5n/AArXzRmgDI/syb+9H+Z/wqnIpSRkPVSQcV0gNc9df8fU3++f50AXNE/4+nx/cP8AMV9HfBtLjUvgt410PStV0rTtT1G8EKvf3PkqsTRRiQ8Ak5XcBx361846H/x9v/uH+YrZaNWOSqk+pFAH114H8IWXgj4gWmqaR4u0u80WTSl0++ju7mGObdGAImRYkVWACgfMd2CSS1fJE7A3MxBypdiCPqahMSE/cX8qdtwOMAD0oAUGkzQOKBQAZoHWikoAdvOad5nHSo+/FABoAVjk5PWkzQcbe+7NJQAtGRikPelcgnjOKAEpevQUlKPrQAo5IAGT2pD6d6MY6fnQPXv3oAU84x2pKDQDzQAUUd6XHegBKfTKcp7UALRQKB6igBQaXNJ3z60CgB45PXFGaSjvQAqf61v90fzNWWT/AEOQ+qn+VVo/9Y3+6P5mtqygL2Stjg5/nQB9JeItDtPEWqeA9ajm8IarZaVpjQ3GnavfCNZGeNQD/q5B8p55HUVzHj/TY/DX7P1voNxr+n6nepqaSiO1uPMSBC5IijydxRR0JA+grxP+zUP/ACyj/wC+RSf2cFIIiUHsQooAolB2phjya0xYykZ2n8eKaLN+uDj1AoAzinQgdD0pCjHPHBOcVo/ZWXOQePalW2ZmwqlmPQKMn8qAMto6aYjzkEV1Np4V1i7wYrCZFP8AHKNg/Wt2y+Hd06brmZQe6xD+poA84CH0P5U9baR+imvV4fBmn2mDLtZu2fmP506XQ7JP+WRYflQB5YthI3RTmp4tKlkHyoSa9FNhHGP3cEYA9RkiqMwuPMCWyP6H5KAOPOiSKmX+Xvgmqz2qISBhyP7vNbmpLcNM3nI646b1IrOkjJ5G0nuBxigDOeAj/wDVUU9vhdw7deKvsqjuM5p2FYMCO2OaAMbZSbfSrZix05pvln0oArbfWmkVbMdMMfFAFbFBFT+XTTHQBDRUhj4pNvFADKKU000ALR2pKKACkpaTjvQAorn7r/j5m/3z/OugArn7r/j5m/3z/OgC7oIJu3A5/dn+Yre8s9xWZ4QVG1KUOM/uTj67lropEwx44oAzilIV4zVpxzwOKgK8UARYop5XIppFADSOeBgemaTpTiKAOOlADR1oJ9RTqaRQAh60lLjJpwWgBmKMVKF9qUrmgCIUVJtxTdtADckdKKftpCvNACAc80lOxk0m3mgAx3ozxilxxSAZoAMd6AcUuOMUmKAFHSlWk6ClBoAU0Cg8jFHpQADJbFPIxTcUuKAFj/1jf7o/ma9E8LaX9o0C2lIyG39v9oj+ledp/rW/3R/M19CfCnR4rrwPps8i7ixl4PTiVhQBxy6TywSMufQLmrdv4avJsBbcjPduK9bTSFUgKFUDtgVKltDFjoWoA8xt/AtzJzNJEn0BJrTtvh7bqCZpppM/wjC/yrvycA4UD8KZJuIPJA9qAOXg8F6NbsDJaRuR/wA9GZv0zWnFY2NiuLe3iTH8MShf5VceMbgccd+aheToAvHTmgCpNLIvMNuvTktVCcXc4xJKAvYKDV6eXGWYqoHqaydQ1W2iG6R9/HQ8CgCM2RJy0i8deKrTra2wJYeZ3xnisrUfELkbLdAF9emKw5Jb27y/bpu6UAbF3qEcSMVMES/max5fEkKNgNJIOmEAGaE0ZpVBnZ2zyewq1BpKRD90FCjuBQBTj1eORR/xLZnUd3cKP15qK4Gl3S5lsrhSf7jd60xp0ZIMkmPYLnP50j2EKAnaWGer9qAMCSy04NmOK4c+jOP6VDLaxn7luoPoBk104tlJIEQYdAQtQy2S7iCFXHBwmMfrQByb2BAAKBc88qR/Son04qMlMnqAO9dWbNAe7gccnp+ZqJrJTkiRM9O4xQByrWynonPb5etV2tVbJ27T3xXWvYrjI3sCeQTx+FU57RQcqqkg9QelAHJSwbBnqD3qJ4sE8j8K6V7L5GCjqc5Pesm5tjHIy44FAGYY6jaOrzJ7daY8ZUkEc0AZ7JimEYNXXjqFkoAr9PpTTUrLTMUANzSUppKAFFc/df8AHzN/vn+db9YF1/x8zf75/nQB0HgK2a61eZE+8Ldj0/2lruX8P3LDCr15ziuc+D2pWeleI7yfUBuiNk6qP9reh/kDXdar43hdmFnbgJ04GP1oAw5PDl2sTNtAAx1IFU5NGljGXaP8Dmlu/EN7co43BAxHT8aypLmeXIeR2H1NAE8lkUZsshA7ZFVZIdv8Q+lRknPOT+NBJ9KABkAHWoyAO9OOTT44Sx6c0AQ4J6CnLESeBk1oRWRLYwc+gq2tj5Y3TZA/hA5zQBjmEqcEc0vlEHkHitDyWzkDaM96Y8e0kg9aAKflHvnOaXyQOucmrSx/KTg4HekCgnPWgCq6YHXmoihB54q3Im4ntUYQ7hnmgCAJigrVkpntzmkK54FAFUjFJ3qZ0x360zFADKTHNPwPTn1oxQAyinEUYoAbikUHNPxxjmkIoAQcUtJ/npTslup6UAKKKQU6gAT/AFrfQfzNfTfwfVj8ONJx0/fc/wDbZ6+ZE/1rfQfzNfUnwawPhno5bH/Lbr/12egDqPKL9CT6077KqjLY9qjur2OIHJzj0rEvdamfIjARf7x5NAGxPLDDnLZPvWVd6ksY6jHrmufup7iVzh3bPPpVSWGVgC5zx0JoA0rjWowxIJL1m3OuPkiNDz6mmi0Vjja2R+tItuMfdG4+vpQBm3N3eXJIBKL7VRFjJMSZGIJ655JroDDjjb9DSGJjxj9KAMiPTYYzlhu+oyasCBQflUYHryK0TbnryT2HSpBAMZfamOgPNAGYsKuqjl/qelSNbOyjYDg9hitWOMYHICjkDHJqYwBlBZjnsDQBirYmPBdF3ejHmmtA21coRn0NbMVqu/eyhvrz/OoZoWLZ28Z4x0FAGI8AwSzMGPXuaqvDGSAr7QONpXPP1rakiJbDDKg96j+z+gUZ9DzQBk+VtU7iSAevH8qhMBY5JJHsK2msnZT8m1fY01rUog6fQ96AMQwYPCkqo+bcOlVZ4FP3CADz0610TWMjjlgq+9R/YYRlWuOvZVoA5V4QDkrtNZGpwZmJ4GBzXby6dEQB5pxnpjNZF/pJkkYxyDrwCMZoA4ySHI9qgeMk5bOSa37myeIlZkKn3qpLbfLxgigDFeOq8kfpWtJFnpiqskWB0FAGYU5NQutaDpyaryLQBTNNNSyDBqM0ANrAuv8Aj5m/3z/Ot+sC6/4+Zf8AfP8AOgDS8MjN/IP+mR/mK6Up61g+Dk36nKAM/uT/AOhLXWtC2eEP5UAZ/l+1N2enFaD2z7clSPwqPyD3BoAp7O4oSBpGwoNbFjpUlywwCF9637fR44FGwBnHc9BQBzNtpTkgsMDqc1owabkAL8oPXIroltI09D/sjqfrSTwFVHRFHYGgDMFvHAjJnYTxkDJP0qGS28uIiNcFhnLHmtq3hy6AJvY9ycAVXvYsSFJGXbg/Kg6/jQBzZQbWb7x+mBUTRkD0BHNa0sO4BFUKh9TVWe3Ltgbdv50AZrBCcYxjtSSDk8fTitNrUIfvZVfzpiWjPJnk+nvQBl+WR1pRCduSPyroYNFnkO7y9i+rVabSoIVy+7P1oA5F0KHHX2ppDFRxwBxx0ropIraInYgZvpmoJQzDCoq4HpQBz8qHrUOyt1oCwOV981E9oMZI4oAx9tJitGW1HY1VeFlHI/GgCDFIBUhHFGKAIyMU01KRSEYoAiIoxTzk0lACCjPtQelFADhjzDj+6P5mvpf4Rb2+HGkAH5R53/o56+aF/wBYf90fzNfUfwYiD/DTSCSuSZuv/XZ6ANyS23feHNUZ7BeSBz710xtmxznbVdoM5AXn1NAHJTQlTgrmq8kS7iVjz0711E1orA5BJrLubCRWJjUY/WgDH8vGcbj9DxSx2+CCF+X35q95QQkOx47UoQsRheKAKa2258LjHerlvp6vkt0HHpWjZ2ZbkjA9q0Vg5+7gelAGMNLgbgx4PruzSSaQiDdGBkfia3REAvJ5zSqoB5H4UAc42nsgyV3E+nFRGNlGGJXHYc101xAMZwT71TuLdNvzgE9aAMQQLzgHBOcsc0jwKARnA9qsX0qW0ZLEDHaueutUlkOIfkX170AaE7QQ/eIwPU1nz6pEgKxKCR0wBzWbIpkfc5LH3OamtLLz2+bOxT8x9fagBn2m7u5GEa4A6segqdLbZks7O395hWksKKoWMAqvVaDGF6cN7jqKAM4w5/2voah8rnIHsK1WiGVPHIzxTGtwQcANn1HegDIeIBuRyT1qvLBhxnPzdA3NbDW48wKQVXvgUlzbkEmPLKvTPFAGBKisvlyxh19G7VkXulKcm3UKcZCk8H6V01xAhCjOxvUiqktsVXJHHt0oA4W4typKlQD3z1qhMhPBA49K7+90+O5UiUEMBwRz/n6Vgapok8EZdT5qDnKjBH1FAHJSx4NVZE9q1pocHH51QmjwTgkigDOkX2qs4wavyLVWVaAK561z91/x8y/75/nXREVzt1/x8zf75/nQB1vwr06bVPEU8ECguLZm57Deg/rXtln8PZ5QWml2AdgtcD+y/ALjx9qCsoYDTJGwR/01ir6rW1HOU2qOmKAPGp/AEZAEe8E9xzVb/hXs1swdmSYddoG017msMaZIAyfUcUyaCBxiSFCT60AeES2BtCUeMxsOq4yaelozqjTKAnbtXr+paLbX1uV8sGRR8rgYIrkJNBlimZI3DY6sRyKAOant44EwdoZucelUo7OJiA67iDk8V1F1pc5LFYOnBkbktUA06RdrSuIYuwxyaAOdFvuZsK/soFVl09mkc+SiLg5zXXywmFXESkbu55JqhcQKylSCc8kZoA5FrBIyAnzcdcdaiOks7YjAHOSQOTXXx6SuTNPnaOmTgmql9f21mRHDt3HsOTQBiQ6A8hZSpGTnJq6bbTtL5mYPKBg96gu9QuJVKRAxqR949aoCHc4Odxz940ASXuqSyuy2kYjT+83Ws6RHmJaUuxPfOBV9rcFgSMj0HNSLDkbTkYGcHpQBmfZztzg89BTjajpgbgPxNaSxEbeF46U8QglQOn94dqAMcW4wCBn2qNrfeGAHFdD9jC5KjI7YHaqbW5B2qjBfXvQBzc9oW/hwe1UZYivBX611T22MjaR6DuKzLizaQH5SCPWgDnJIhklfyqHbx0rVntzFIM9D1IqpcRbGPXB9qAKZWmlTU+KQigCuaaRUzLmmEUARjg9sUhHoafimn8hQAif6xv8AdH8zX078HmK/DbSBwP8AXf8Ao56+Y1AErYOflH8zX1J8HYVl+F+jEffXzv8A0c9AHVi6dSAp6VMt5kfMoqmQQWDDFRsSPqKANJZoWHAIz71DIkLk84NUMnGQaA+Tz1oAszafBODz9CBUK6SfMULJuA6AjFOSTtk1ZhlZX4+6O3agCdbXy0AAGO9MaPAIUf8A16lmnKOCclWHHtUkZjkwScfWgCqE5xgr7CpI4stnHHqaueTEBk0yQ44xwKAK0+0ADsBwawdXujErKm3eeme1amoTFEIUZPpXN3ERlb5/vjnnuKAM2eJpx+8IZzzz0rMng2ScDA+lb/lYHSq15bhuQOfrQBjx27SyqsYIJPX0rbSERoqIPlXj8aZYQbVZyOvA57VcCYHYf1oAg8o4OccjnFKyFcAMR3qYIBx1z2p4B4+6R29qAKrpgFdp9ueDTDECpDdMZwR29KuYB4IG4ihIyQNo5Jzn0oArW1uryo4B5H+RVHU1V5QFLDI7dBXQ48qAkFTJjp0IrDuiG+QklSdxx/SgDNvYcKJQTxxnv+VUthYZ4B6k571tNbgqrZ2DOQxP86oywtkZ2bFPBWgDPMZdQSvLE8n0qBo2VWOCeOgrWKYc5H8QODUEsTAjBwmSaAOQ1bT4Zv3iKEkzzgYFcrfWxikZDyR1OK9EvIwD8xG0Dgf3q5TVYco2Rwg4oA5OVcHpVSVcE1qXCEcVRmQ88UAZ7iuauv8Aj6m/3z/OuqkU+lctd/8AH1N/vt/OgD2j9khPM+I2pDOMaTIf/I0NfWJVdp6gfzr5Q/ZDXd8StSB/6BMv/o6Gvr1ojtHC/TFAGW24kBRtPTp1pfKB6qSRV14eTkcmljg5yc4oApfZlMZ4wDx9ax72zBkAAwo7AcV08q8YFUJ0XHzNx6etAHMXVrJj5eEByTisuSzUzchWPXLdvpXYXcQKbccVk3VuqsDgEgd6AOakg3M+FBJPIqpNFHaqZJFUHHT0rbvfLt1LEDfjr7V5n4q1d7yZ7e3YiIcMw4zQBX8Q+IWdmhtWy3Qv2X8Kp6ZYtsNxMGeSQZLGq9jYma4jTbnJya64W21CAhAxgUAYZhAUjJAPH40sUOwlXHT2rUe2APygnHakMPI3ZwP4cUAZflc8DGfbA+tSQwEEEruOeCav+RvJCqMj19KVIAAdwBHYelAFFIk35HG4ngipY4MbTsyp4x71dW0IPy5Knlhjp71aig8oZdWLdhQBlGMgGMY+npUQsyUJUfiTWzFbMz/MuS3zY9fxppR0kBXt69vagDnZ7fLgjLA8HilisfNWQlCuRjaTyDXVxacZIclQoJ3cnFM1W1WKAFUAd/lJFAHC3mguzjzNqkjjnkisLVrV4ptkilR05Fd9cxNFEowHGMB+mKxNUg/cqkmTn7pI5NAHBTQ7DxnFQFa6S+sOoAIyOM1gyoQ2G4I4xQBXIqNhzU7DFMbpQBXYUwjipmGKjYUANX/Wt/uj+Zr6o+CwA+GWjN/12/8ARz18rj/WN/uj+Zr6r+CuD8L9GB/6bf8Ao+SgDrLuHem9V+as5h68GtgH73PFZd4myQjGQeaAK7JxURyH9RUjEFelRg5agCRGGPerFtIu4g96qEAcgHNPhcqcmgDWXBTDcrUTLsBIY47CmwS7lAY1Iyhhk/hQAgldcAqcn3qfduXqM1UP3jz+dIJMAjjp1oApX7EtgcgcCqLgA8jj07Cr04D8nkjvULE8dwKAKjoNhIHANVpVyCcVoSjg54FV2G6QDb3FAEATyyq4Ax0Ip4BPIwfVTUtwo3ZA5NNjHqR+NACdTk9ewz0pygHGOMdsdamjjJGPmyD0A61Yjg2rjAz1wetAFUQluAAB3x2qSUrbQMThWHcnFWS0SAglQSO/JqGVEkX5xu3dBjI9aAMsnJJJz3HrmoXJfgnA64x0rQZNztngckd81XMKAcbiT69jQBnXEDKCQcoRjrVZoyBsONh6cY5rVAYHBAYdORimPErnEXDD+EmgDMlUOcj5SCFDEdainRQoIOQPUdfpV2eA5bIbJGSA1UZTkEtuY5JI6ZzQBkXcXDHbkZzyOlc5rCBY5Dgc8V106BkckkjHGe3tXM60oQKhOT1wKAOOu4z8xI/GsyZDk4FdDdR5BGefesi5jxk0AZMq81yF5/x9z/8AXRv512sq8Yri73/j9uP+ujfzoA9u/Y7IHxN1PIz/AMSiX/0dDX2JiMjkkV8e/scKW+JuqAf9AeX/ANHQV9hlADzQA0qo6c4pjn0ofjp0qNj7UAQOTu/wqvIoI7fjViQ4NVpDk0AQtGCeTWZfLgHjntWpIRtOOaxNYmMMbtjcewzQBx/iu5Plm2jYByPmPcVxUlgDH8+c+o5rrLiESuzPkOeobnNVXtcHBUbPrQBlaHpvltI7ZOMAVq3EQXC4JA4461pWFrttATn5jkU2WHaPmU5z1oAxpodpwpzjpnrmneQWA4Jx3BzV5rc5J+RScYJHWnxwqAPuqcfdxwaAM3yGZWJAO4/LnvUawORnYQAeorbjs2aMFlznqNvWnixbIOwqoH3e1AGfbRFtuEGCOM9qszWv744cnjPPStGCxcFnA2kDAGOKvwWKuPm2lyvIxQBgx24iYZ3FWPI7AVettMHLPhQDnaByK1VSG3Ys0YJXpiori5ViwUMi49OTQBjzKDMCr4GeV25qjfwPLKdq8c7cmtdpIUJ3AkdR6moyVZWIK5J6Y5x9aAOfubZWiKEorKPvdxXParD5SdTuTgZrsLy28sAqsYcnrXO30Q2s5QyY4IJ6UAcptIOJNzDOMgZxWJrtksUnmx8o/p3rp7yLy2U4PU5UVRvY4riEoEBPUjoR9KAOLZNv3u9RHvV27i8uYg54PGaqsOpoAruOajYVOwyRio5Bg0AQ4xK3+6P5mvqT4KSY+G+kKcdZv/Rz18t/8tT/ALo/ma+oPgyh/wCFb6Qy+s2f+/z0Ad8epz1PSqN+uYwSeRVyM5Xp1/Sop8GNg2Me1AGSenFQgjNWJOg6ccVXwecgUASDpS4ApqjHT8KkAz9aAHxnpzVgZwME4FV1HGDUoOFxQAjnLEseDURzt9hTyQF7mo354GeKAGt1470xxxzgg09uByBTWxQBE6dMZ96gYYkUkDINWsZU5qCRSeSc0AE6DAPHHJzTIx8vIXnkcZqYMHjAYgHGKrPIkZJwrGgC2rsF6/gR1qOa9CDbncT0xzis9pZpmPl5UHqR6VLHH5KFnIJ9OtACqoIMkxx6e9Sw3ChApwvHB6iqFxctx1Cj2qJZlYEEjJ5oA1fMcuANnuKkOOkg2j1xVH7QrAAgcCl84lArsR6UAOuFGWK529een1qsihXDEjHqamMm4YbG09T61BOp2EL83pzQBBMHLgbmAOfTFVZoH8v5gz5OOeale3kfAVC3pzU1xoep20MEksMyRzLvRs8Ee1AFDbuAjaMZA9KwdQgimckKCxGCfSt+TT5BIN0jZ7gk0+HS18wYIC45LetAHmep2RiG7a2B3rn7qLByOh79q9i1rRomtJWwJHCnnsK8uv4CpZSOc4oA5q5XaxyQMVwt/wD8f1zjn9438zXc6tCTGQM5rg7kFbmUHqHI/WgD3X9jP/kp+qf9geX/ANHwV9jOvWvjf9jdtvxO1Q/9QeX/ANHQV9jeZuGKAI3AxULHHapJePrVZ29+lADHAb2qB4+uD707fknLUKwyCeRQBTuBhT0rmdZcblRhkc54rq5uQRXL6tCRO2c/hQBzrx7snkt+lRmL58Y69q1jCpXAzkdOageMZwMnHU0ATQw4gUA8AVWlh456H8a0oseWoHXFNEIB+cHIoAyiuW2spAHOat26DaTKgGeBnvT7pWBXy8H1pywlid/Q9OaAHCVfmCpk+1KksjE4jwPepVRUBIAqpcTNkrnH05oAs7zjAPXrSx8ciQAVRjnJ5Q4UdqrTzlmHIAxwBxQBeumKBWDKcd6zZroEEsd7fXpVC7u2QnY2COmRVI3r5OEQknt6UAWrm9QfLtyc8nPQ1C119xo5GYn1FURIm77hJPOc1JhvLyBtjB4PrQBrxI86HzNwbO6qFzaMyEuuSfb9Kls7wqycHDDBJ7Voz/vImbI3KMg0AcFqtp5ErEA7ie44FZbRje5RScjJzXVapEWtGYk+Xn1ztzWBLEpI2rwB94daAOQ1uAI6kdTmsV1610/iBfnVMZK9D7Vz8i8mgCmajk6HjmrLLwahYZB6UAVT/rT/ALo/ma+oPgqf+LcaSCe83/o56+YHGJT/ALo/ma+mPgvMv/CvdLjyMgy5H/bV6APRY1yMjg1DKOGBGPwpYm46jPeppkDpkelAGJIuDioCMHvVyZSpwevtVd15oAYOtSL9OaYBUi8A9TmgB/fvg0446E8UoBx7GlIBIOMYoAbjCGo2GT65qUnJxmmgYGfWgCPHYgA9qa61KBluKQqOTk0AQnrUMg65HHWrB9c9KilXOOAaAKcnO7kjFVYYfOkOc4B55q5KMdMYqK2C+fIhzyc4oAkIEabQBVe5xGAe554qeY5fvt7e9QSoMAHJPsaAKhG8HvxVdlwy4UVZ4CsTwKiUEnnJx70AJD8vGAMnirKIx689vpUeAPuj5sVYtEYOC/p60ACwbmAB49KmSMIPnUbexPapSFGMrz7UyQhccMAO+KAHp5TNxJ8w9RwK1tI1iOK2aw1JvP0+Q8lWw0J/vL/h/k8xcSqvQ9OR7VlXMzFj+8O0+lAHSeI9IutLmRzcLcWEpzb3A5Dj09j7VjNLtlG4l2IwMDit/wCHEl1qd3No0sSXWlTAvPFM2PLx/Gh6hs46f/XrrvG3hCGLw3E+ixeXNp6lto5MqfxZ9T3/ADHegDyiWXBlTJMbAk/lXmmpJuuJCP7xru7qQMHI479a4i8DmeUdgeBQBz15GA1eZ6p/yE7v/rs//oRr1W9VscL8xryvVc/2peZAB8584OR940Aey/siyGL4k6kwOP8AiUyD/wAjQ19gRXAce/tXxz+yc234i6keP+QVJ1/67Q19Yx3TqMggc0AbbDOKruvB45qG3uckKT9KnJJ6UAVHU5yKYxPc1O+RnccVXbIJIPSgBpPHFZN+gkYMQAR3NaMr4+tUZ+WJY9fU0AZbw7RxjnJJqq6dQK0pEyOAPwNVJBzzkUAJAcYHbHNSy8qGfJ9KrrlWyKJZmwF7ntQAx1PVQAM88dqnhjwORyfT0qEO2AHAz7VYTLKTxk0ARTZwc1k3DAvxwD6VqzAkEf1rM2YfkkEUAVpmKRtsGB9ahGWxkj24q5dIAqjn3qE7QQTjFAGfeRncFZDzwD2qjLCytyMfQVvvsJ+YlR61VmQF25GOlAGP5Yx0DfpT35wBlR0wORVw2/zqCoGfTvQYGUBGwB7UAUYVDKwBPB43CuhswjWrRs2Qy55FZkFvtzkZB9q07VW8tXzjA9OKAMOe2MbzD5fKc4IPYZrnb+Hyd5YBRknGa72a1F7C7x43Lzj3rgfEYf7RsZCOBkmgDkb/ADLIWbnnjmsiaMgnit25iyzZHTvWVcRbc5HegDMdcZyKruMCr0y/hVOUUAU5f9cf90fzNfQHwnfb4I0zDbcGU/8AkVq8Am/1x/3R/M1778LoyPAmmPjKnzf/AEa9AHpNld71CyHDds961FcoAuOtcnHIAoOWAFaemX5d/LlP0Y0Aal1F5i7lABFZjDBxW1yADjjpVK8hwdy9D2oAzyB6CnLn2pWXGMZpwXHUcUAPReOlBAAz/SnfwelHLAc8dKAGDPXtSY54zgVIydAozTSoXjFADG75yO9KDnGeKXaSRjJxQRzwDQBG64HJ69KgdccfrVwjbncMg+vb6VUuHhUH5jn0xQBSdTu5ORVEvtk3ocEHtVueUEHbmqrcMeM+9AF24GQjKMqeabMAVQrnkY+lNs5A2IZDz0Umn3ACsoHYUAUpxiMrkH6Cq2QBjBz7VolVkZ8fpVNxiTHIYfrQBGzcDk5HPFSwvj5hy1VTkd+e9Oh5kGDjNAGluBG4k8VVnnCrk5x35pzuGOOg6Cqj7S/zkgjkUAQzyhwdvBHUVRZgxBP6VtvoOpy2ouIraWWGRdylMMT+A5rFlt54zsmikjbGSGUgisKWKoVm405ptb2aY3FrcZbyywzrNBI8cqnKOhwVPsRXoHhv4l3lkEt9ejN1GMfvkwJAPcdG/Q/WuCVSsW7BOTgZFR6yfLuFQAZCLk+9biNrxpaaWl5NfaRMkunXSM0apwYn7ow6j1GR/KvMtQI81ljGMEiuqUn7GxUZLsFP51zOrKEvbheoDsP1oAwrpcn1x1zXkmsc6vff9d3/APQjXr04BB64ryHWf+Qvff8AXeT/ANCNAHrP7Kxx8QdR99Lk/wDR0NfVCtxjnFfKv7LWf+Fgahj/AKBcn/o2GvqTuc4/GgC5DKUY89K0IZsheeaxVA3DgZ7mtC26YoAuyfN1OKrSDOanDZHPUVBIc9SaAK0jdelQSc8Y6VO+AetQtjn3oArSgnjtVOReTjitBwORVaRO3U+9AFIgE81DtG7Jq2yk9wMe1QOny80AM25UZ6inBivI7VLGobBGfemEUANLZOTUMgBOMA59qkxyCarSE+ZwTj6UAVr5eR9Ko7dvr+da9xEXCnA6YzVWWDYB70AVThtwPUetVZyC4Y/L29q0ViByW69Kctmr44/OgDO3HI+ZSR2quWkx90Bs+vWrdxYOhJwSM9e9VZBKDlugHHFAElvIyuDnjHQmtm3YyW5w2A/4VhRF9wyuTjHStuzDHaTnI4wKAFtopoLwsAxjYYZT0Iqn4i0SK7AwNrbcjjt6V1EawrFlx8xGM5plyqTKFwMgcGgDwrV7T7NcPHjkHpWBeJznGc+9ejfEKySK+jkXALrzx1rhLuLAHFAGFMvB45zVGUda1rmPaOO9Zsy8UAZ0/wDrv+Aj+Zr6I+ExH/CvdLDdMy/+jXr54uP9d/wEfzNe9/Cts+BtMXk4MvH/AG0agDq54DIxaM8D+GpLU4JHIPTp0q1CCFGOhqQxb8lQAaANXSrnzE8qQ89iauMo5VvpXP25aNhnhgeMd66CGX7RErj7w60AUJoijEAgg9KYqggZ4HpWnJGJI8dx0zVPy8Nz2oAi2cYI60mAHA6j0qc85Heo3XGMCgBjDPTtRjOcL1FPC/Lz1pSDjA/WgCLGDgc+ntQxPfrUmMAHHP1qrO+FIzzQBDcSge5rNcZOc81ZcZYk1CwznGPrQBXYEZx1pjEA8dKlIAznmonHTGPyoAiJwcjr/KtCBxcQHdwy9TWexP0p1tOIZ1LZKng/SgCxH8rgHnn86ilA3dCD6VcktmWbKEkHn6VDdRhXfB5xkrQBnyIc5GR7etOtTDFcx/aAzxZ+cA4JHsaQnaCTkntTCADnPA5qZR5ouPcDYkv9Hj5Gku/1uWH8qauqaZu40WMAdC1wzVjzfOhI61E2GYgnDY4rz/7JoPeU3/3Eqf8AyRfO/wCkj0ew8Q6bb6TbtLJFCxU4gi+YryeMdvxrI1XxpHIpjtbJZFPe4wR/3yP8a5FGUBS3A96imBfGOn5149Dg/L6daVaonJtt6vRa+Wr+bZo8RNqyH3V21xOJZEiTLY2xxhVH4CsXUmaa9duOWx+FW97NJli2BnjtUOxnYsfvEkivqIQjCKjFWSMNxYU2hhjK8HNclqjbruZs8l2PT3rtNm2xuGJPyLn6VxN0S7sVPXJwfc1QGTOOMV5BrX/IYv8A/rvJ/wChGvYrkEA5HNeO61/yGL7/AK7yf+hGgD1b9lr/AJKDqGf+gXJ/6Nir6hPyt1r5f/Za/wCR/wBRHH/ILk/9HQ19QHPYAn8qAHDLHnpV2yf5gAck81TBIxng1LbcTL3xzxQBqZGPc00gEUIwYcZpQO3egCrKvNRYOPXFW5BxUDL15oAruOOc1Ayg1aZcCo3HpQBTdDg5557VBKmMkGrxUDOOtVpAApGM5oArwSeW4Dc7ulSSoFYiq0g+bHPtVyBxNGQRlkwOKAKzoe2KhmQZDZAxVqRcE9u1RMAVIPWgCvnKkZ+lV5x8vOTip92CcDFMYh1I/u/rQBVXlsZ46irMfUZxntxSQxfMdwHrU5AJOOmKAGuOOgwfaoZLaNwNw4qzt+UZ7VBJuHQ4oAZFp6Hoxq0qxwcADPr61EJGU8GmsSV6k49aAFllYuBzz2pyyukWT1B9abtzzzwelNlBKOBwPT3oA5Px+BLcWpHOIu31rgLyI5J/CvQPGKj7ci54WMCuMvI9qksOKAOdvI8Icdax51AJwcgd66K8QYP1NYl0p3Hjk+lAGLdD98P93+pr2P4ZXxtvC9ijAlcyYx1HztXj19/rhnrt/qa9W8BBl8K2BC4DGTB/4G1AHq1jOk8QKNn1HpVxBjkVx+lTNE+5MgZwRng11dhdJcDC/Kw6rQBdEW8ZAwRVrTSY5SjdDTIVy2RVlFBKn+IGgC2w2tkZqCeMfeHerjDK00qShWgDPIPOelMZSeP5VM6YP0pnb3oAbjoMHNKQefWpMZGTUErbQSTj+tAEM7YGQR+NUJTuOT/OpZCWIzUL9KAITwSMcfrUb9wOKe5I4P51A/Ung0AMwM4/nUbt1HHHFOIOOtNxg+9AEJGVqGTGOfpVhhgZ71A6/L6UAbWm3PmWoJ5K/Kc8/Sqt5GwfdkkVW0ufZdBD/q5OCfetK9QxjOeDxQBkuoJ96jZDtx3NW3VSc4waiMeTQBW8tiMYIoCBXO4gt2zU0rBMYNVQTklsGgBs3KMv51HJzGBkqSPSldd2c9OvFMc8dDnFAELFY1O3+dV/MkYlnJK+lTtGSuenFRMo3DGQvvQBY1EbNBu3XjcoHJ6ciuIuTjkfdrutXGPDcvT5io/WuGuB17DHagDMuj1zn6141rX/ACGb/wD6+JP/AEI17LcD5RnrXjWt/wDIZv8A/r4k/wDQjQB6z+yrn/hYOpYx/wAgqT/0dDX1G65JIB/nXzD+yYu74jakP+oVJ/6Ohr6nmiwSRyPSgCkMA4NWYMBgT0xUDgjHHNSwnAx+NAF6M5YAdMVOGHeoYugx35p5A696AGvUTDH/AOqp8cUzGDnt70AVWXIz603ac9MAVZcDFNyM4wOaAKjL6darTr7c1oMB6DFVZ5FVSSBQBlXC9Sc46VDZ3Cx3qqfuuNrH3qLULtpJSqkKoqipIYYJznqaAN+dCshFQHOferkRW4tlfJJxzVZxtYnigCpOmDkd+tQjIYkH3+tW3PHSoCpzxQBLGAcHGCaftyeBQBnHNSpwwzQA0RnvUU0OMlWOatPjsTmq8xPRs/hQBW27gOuR7U4g46DHrSscEHnPTrimnAUB/pQA1WLOFc/hU0kQDcDK1FGmH9QOlXSQsHmnt70AcF4nzJqc4XoPlrmLqEPwc10WoSefdyPkncxzVG5tJTA1x5UhgD+X5mON2M4z0zjtQByl7EoXgZJ71g30eOR9K9I0jwfrHiNnNjCI7NOZLqc+XCg7ksev4Zp2qSeC/CdpcQW0R8T6xJG0bTy5jtISRjKgcuff8QRQB4tqAInGf7v9TXuPwzSGbwJpiSoD/rev/XVq8Q1L/Xrx2/qa9w+Fw/4ofTfU+aP/ACK1AHQTWRhx5a5T+VWLYlWUg4I/i71cgJCEcY9D3qd7RHO5MBvagDR06683bHKRv6A1qouHHpmucijaMgOMe1b2mSFhiTPH3SaANPqKTFOU0EZ4oAqSL85xUBGT6Val/wBZwKifAB4waAIZDsH3u1UJWLt14qzM5NQEcH1oAruOMnPFROPbGassvHTmoHzQBXYfKcVBIFB7ZxirTjjNVnxkkjOaAIOBUbNxgipSMZz19MVE/qcUARsMjJH1qB8AEDjFStn3x9agkHB560ANU85Un14reLefbIw5JFYHcdelamly5iePceOcYoARkJPcY61XnfqEHFakw3RnJ6dcVmOpVuQfagCnIOQTSAHPfP8AOrLg5wQKhIw4x81AEEnHA696jB2rycE+9WmABG4HJquyg9QKAImBZCCwPqB0FRrHkrt559KnVCGIzgVPbRs0oRRuYnHIoAi8Qrs8OqCedw7VwMwxnOeTXonjFBDpQjHZlBFeez8EjtzQBmXnqccV4xrfOs3/AP18Sf8AoRr2a6xg9R9a8Z1v/kNX/wD18Sf+hGgD1/8AZM/5KNqX/YJk/wDR0NfVrruBz26V8p/skjPxH1L/ALBMv/o6GvrBxnrQBnyKOcdaEXAyeuKsSJlgQMYpCnHT8aAJYR8oPqKmwduc/hTIxjgU6gBCcmmtjpTyMDJphPy80ARuOCfSmN7nFSP6VE/figCNunrWbesojY7uR2q9IxGe1Y15IsknBO31AoAypl/eMxOM81GgGeRViX6Z/Co8f5xQBr6NOSpjbkjpU10oVzxwazLOYpLHk4B4rYuP3iKR6UAZ7DNKoBpxUHqOfrSd+gzQA9FDDA6ipFjJ702EEnPFTruDbjjFAETLtUA/nVecbwPY1Ym+diQevaoJsA4zQBWIPPfjNPA4wepFJggZB5pY+MknmgBJDgEdDTbyV/7LdQcHpkmnMpYg9RVfVwI7aPK7hnJX1oAZ4T8H3PiG83yEw2KH95Njlv8AZX3/AJfpXrd5oWlx6B9g+x2ptIBvjjm4TeOhY/Xqe+TXkt7401pYEtrSSOztlXCpbRhQo+pyf1rktVv72+kZru5nuMd5ZC2PzoAh8Z+JNX1n9xezLHbwkqlpBhIkx2Cjg4xwTmvPNQQgsDyfeuqvFzHjHXue1c5fR9WxnJwKAOO1UETrkY4/qa9j+GGoJD4SsYphhQZMN/20avINb/4+EGP4f616b4BRj4XsDjIy/H/A2oA9StSJMFSpU9CKvxgDk/ia5iwuHgMag8Z5B/pXU6eyXCgnjPagC1BGsw+YYGatxR7GAxxRHFgYFWFxkZ696ALED7lwcVNVQfIQeatRtvUev1oAilGDnpVOdySRzir7kYx61nSqVYg/SgCqSckU0nI5B+tOc7T9aYTwcUARscA8VA5qds89c1C/AHHSgCBsAngmoWAxjPbpUzYHBHvUXJJwPxoAgYYPYComA/yKmkHBJHNQN09KAI2HaoXXIIxUx59fyqFiO5A/CgCAggc/Sp7GYpcA5+XgEVExzuxkjPHNMbIPAxQB0crqgUbM7qoyyEkbhuH8qsW7Ca0RjzTJmSJTt+92zQBTZABu7nsahZAOeNxqRmLnJ4NMdj60AVZXx1HPY1DIcckcVM6jGB09KZsB6gDHcUANRiAoOCTzWtpjB7lAOBnkVksVQ5x+Xerdlc+QfMHUUAReN+bDjj94M8/WvO5zjdnODXdeL5TLpkcmB80gz+tcDcN1FAFC5Jxkn25rxrW/+Qzf/wDXxJ/6Ea9guTnOa8f1r/kMX3/XeT/0I0Aeyfshf8lJ1PP/AECJf/R0NfWcirjGD1r5M/ZC/wCSk6nx/wAwiX/0dDX1nJwev4GgCAqOeeKNvHpTyPalVeeaAFUAdR701iD61KBmmFT0oAYe1RyAY5JxUrDBpjD8qAIH4ao5zjjNTuAAaqTthcntQBTvZdq4HU1jynk54q1dOXkqlM20Hvj1oAhlJAwDmoicHvSSOMc1FvyTQBZjO4HBweozW3av51uCScmudDZ4yK1dKl4Ke+RzQBO+MnGajPXPWp5UKsahZT70ALG4yBnFTF+MHkVWC/WnZK9+KAHM3P8AKmHnqaU5NGOeaAEC0bQCeODT+/BFIwzQA63QAHjiq2tx4tU6HJ71o2ygKWJ6dKqeIRiGBB16mgDkrmLd1JBxWZKnJ5+lbky5Bx8vas25jBDYGQO9AGBeKxJyoI965/UU+YtgD1AFdPdJleentXPahGVDYJxQBwviFcTxeu0/zr2L4Z2YufBGnbOJP3vP/bVq8e8Rf6+Lr0P8691+ESj/AIQPSzgZzLz/ANtXoA27bTDFIrTZOa1YF2EYwvrVuMIQN1H2fAyoJBoAu2k4YYbr61c6DJHArLhQjk54q7DPtO2Q0AWlPOf6VLGwVjjA9aqk8jBJB70gkOQMcUAXH6g9qr3SAqGAORVhG3J6U3qCD0NAGVKuRj05qNVAIJqxMm1ypFV/u8e9AEbjgkk5qCQHAqycEfX1qBx1oArHkgGo3z2JqU9elMcY5XGaAKz8r1qtIdvWrTc56c96qTcLnigCJj3qNj1GRzTyTgVE5JoAjZsMcfpTSeDk85/KhyScnI96ME9OfXNAGpoz53xk5x0p90u2Ugk/lWfp8hiulOBg+hrZvD8o3AkUAZLDBP170jplhwT+NTyx8Fozkdx3pkbkYBHXsaAK23PBA69zS85yQMdqey9c9QfypjkpngEdKAKkrEEZwT7VHE/yfNzzn2p8xxwCDnsKhTp7Y5xQBB4nP/EkgPcyk+3SuIuH4+XjrkYruPE4A0i1wePMPH4Vw9wOCQDzk0AZN0xGcivJNYOdWvT/ANN3/wDQjXrlyBk8jpXkesf8he+/67v/AOhGgD2f9j8bviXqYP8A0CJf/R0NfWsi/MeK+TP2Pf8Akpep/wDYHl/9HQ19dSLnoMmgCmE55BIqTaAOM1KEOBml29eKAIsYHFMPUk1K1McZA4oAhI5ye/pTWGDUxXpjtUb8HpQBBLwO1ZOoSlcqvINaV1IsaMSRxXPXMvmOzdqAIXYKeSciqMxDE5zkmlncs/U/QUzY2MvkUAV3FR9OnrU0q4HNMjTnpxQAgTPGKt6cfLuF9+DUQApyNsbIPQ5oA6CcZjUjmqx+XjnFWrYiWDgjNQSjDEUARg8GmkU4ZGeaVhlc96AGHNKp55pAKlSMuSF5IFADcHg0qjc44qRTjgjOKWJeQe/tQBPsLogwSRxVDxN8s0aZ4VB+dbVqmXHpn86w/EZDX8mOqgCgDn5ACDz0PpWbcDgk859a1puGPHas65UbTnn8aAMO8GM5/Guf1AEjg9PSuju1Ur0461g3qDBPb0oA8/8AEoK3EWf7pr3T4QMjeAdLVWG9TKCD/wBdXrw3xR/x8Q/7pr2D4XDHgnTTzu/eYI/66NQB6THnnPbmrkJ+TjJrKsrtJQEnyrDjdWmGEa4LEk9KAJ3RSM9G9aozMwcg81YWTcSSfwpWUOpyMY70ARQXPkgK5yCfyq6uMBlOQaw50bzMnp2q5ZXBjIV8lD79KAN23bKkfjUjrkcVFajgkdCODU+KAKV0mDuqjIOc4zWpcplKz5FyD0oAqkcdKhYetTMpCnt9DUT0AV271CTwQV5FSv0NVZjgnGeKAGO3BxgH0qncsNrCppHz157cVUnYFDx2oAhjkyg9e9Iz59u1UopQrMM8dsU9Zd3UZye9AFgkAnnOKaWIHTrTdyjPTFMZhuB9OmKAJMlSCp4Ug10RxNZq3fGeK5ckngHPXNb+iuJLIKSCVHNAFeQ4B55oc7lGcVJOmHPrnioiCBjB/GgBrcqfWqzPnepyCKn28HmmFdxJGM0AVJATIDUIQDntVuTCnjJqBN2/FAFTxSCNJtMf89Dzj2ribjPzdcdzXb+KABpVv1++T+lcNdE5OCcY6UAZd1wDXkOs/wDIXvv+u7/+hGvXLkn5uteR6x/yF77/AK7v/wChGgD2n9jv/kpmp/8AYHl/9HQ19fsoNfIP7HQz8TdT/wCwPL/6Ogr7BZaAI9vA4oAGPepMYHNNIxnFAETKKiI59qmYZpmPWgCMgcVBNgfWp2HSqN24VWOfpQBl6hJuJHbvWROOGwDV+cnnrzVGQcjOT9aAK0ceBuYfNTJgCcnrVluF71BsL+vNAFNwWJ5pFX0IzU7Jtz1x0qAjnigByij+IkAUv8IprHGMdaANvRnBjxk8HHWrVxH82RxWPpEuybDNndXQMMgEUAZ+wDPFNKnIx0NTyj5uaZt5HNAEOMH2q3briGRzjGcVGYzt4INTAMLPbngtzQBAB6dKnhTA7e2aYEzgDG361ZhRiQMd8ZoAuWagsPaub1nab2ckk9vlrqLRSFDY65rk9QJa4mJbB3HoKAMqQdTkms69TAJBGAcnitUqeRgc+9ULkYGMHIOKAMG6XjJP5CsPUQOeeMV0moAKDjJaue1JfkycNz3oA868VgC5h/3TXs/wrtvN8AaYythv3vH/AG1evGvF3/HxB9D/AEr2D4WOx8C6YgOMeaf/ACK9AHUySSQHZj5vWrFndyRHE2WT0z0+lOj2lTvHfj6VDLatu3x5Zew96AN2F0dN6HcvtRI3y4Awx681g2tw8MxPI9Vzwa1Y50nG5Gx6r3FAFlcOQrYqOWEoe5U09Djhu9WEGVI9elAFvSZD5ZRicdia0DWfFH5aACr8R3LyeRQAjDKketZ0y4bHpWk3FVrpNybu47UAZMigNnAqBumSc/Srcy89qpyY6A0AV3J5qlM/DZ69RVyQ445qhNxmgCvI23npVK5kIHBHrzU1zJhDkjFZVxcZXAI/OgCkZdr+2akjmG7isuSQkvluhqSKVcn1zQBr+aSOv50rS4GeAQKoI+O/B604v1oAth8Dg5HrWr4fnH2h4zjDVg7umTgelWtOmMV5GSflyKAOtuV+Y4yKpOvHAFaLAyQhhgkVSmHyjsaAK8gI6ZxUbg4z0qbgjrk01xwMUAZ0pOcHimKSBk5Hrmrdwu7a2cHpxVU7g5GNw9fSgCp4qP8AxK7bB43kfoa4a5OM9fbmu28V8aZbgnOXP8q4e5xjjtQBlXR6k8Z968l1f/kLXv8A13f/ANCNes3R6k15Lq5zqt6f+m7/APoRoA9t/Y3Gfidqn/YHl/8AR0FfYZHNfHv7Gv8AyU/VP+wPL/6Pgr7FbrQBE1NYdSO9PI9qaQKAIj1NMb2qRhk0x6AIJeBmsi9IZto5ArSuG2j0rHlI3Ek0AU5cgdKplScnIJ7CrcpLE96jCDjA5oAqtHnlvyqNvw/OrTjOev51XYYoAqyDIHH5VWdTk8VckPIOOPeoHIYk0ARqRt9x2qMkljmnE4OR0pnUnPNAE1tL5cq88Zrq4MNH61xoOD24rqtMffAp6mgCWWIc8DNQle4HBq64qIp09KAIoxhhkcGp5YgbdO3OaaEyeASatumIRnsOKAIIdNllGQUCHvn/AArQh0wKBvfPsBVCPdGMqSDngg1etrqXOCdw9xXy2bYXPZ3eDrRt2tZ/e+b80b05Ul8SJ/KMauEU47VyV1p16zN/o0hySeBnNdRMzMkjqcY561x0t1cKflnlGSf4zivQw1PM4UYKc4NpK9073t1ak7vz6kNwvoVrm0uIADPDLGDxllIBNZ065U9fwNaFzczzKEmnlkA5Cs5IH61nTkkY6GvUoe15P31ubyvb8SHboY18nBJJ9sdawNR5Q8c9K6C7zgluK56/wM5PetRHnfjL/j4tv90n9a9a+F6k+BdOZOSDLkDt+8avJ/GpzcW2AB8hH613Hw+vpbPw3ZmInq/HY/OaAPT4H34zj0ye1WYGZSep7ZNZNhqNveIFk/czHt2Naq5xg9T3zxQBJLDHOnHykcg1lkzWlxu3ENnr61oOwVgoIJ9fSnfLNxIoIIoAs2NytymMBJB1X1961LNSSN3y46Cufhs2jm8yMttByMV0FnMswwTh17etAGgnK81Ip2N9ahjzjntU2QRg0ASSfdqMAEbWHUU8cgg9qiHX6e9AGfdKVbB9cVmyjH/162r9RuBHcVkTDkigCpMCRxgcVlznpk1q3C5TjtWFeNjcM4zQBRvGLjanA78VlXUbJETyD64q48hDsmT14pl381q2Qcj3oA5vcSzZJ64p1vId5wfaoQ2GfOBg5qk1ztyFPJJxigDb8/kKOcHrU0bZase3lIAJxnpmr8MxxQBfB75qRDtIPcVVRgT3qbPY0Ad7o8vm26/7op95FhgAOMVleGJs26j0yOtb9wu5VJ9KAMV0Ctx1pGXIwB71ckhGSQeelRyJhRmgCk0Qzx3qM24xnnirbJk+mPap7aPew3A0Acl4yGyxtk6DcePwrhblh0IBr0Lx+gEMWOzn8sV53cgj/GgDKuSuG6/nXk+rf8hS8/67P/6Ea9WvAcE5BNeU6r/yFLz/AK7P/wChGgD2/wDYz/5Kfqn/AGB5f/R8FfY7Cvjn9jL/AJKhqn/YGl/9HwV9kkUAQketRsKnIqNxQBARUUnGTU2Mdarzng0AZt5Jk4FZ8oxz3q3cctzVVx60AUioDHIwetIwBwR8vvU5U896hmGFGAAfQUAVnOCe9QScelTOOTVeUgA8c0AV5OR7e1VmOMc5qWRuOo96qO3LcnHtQArnio2YgnPWhvrx6+tVblwgB6fjmgCbf7856Zro9BlzFhj3rlI3GQev0rb0J9sxUnr6mgDrMcZ4oxuHHFIpytPj47igBEUjqank+6oGaUDPtTlB70ARonAOR+VTwRjd0pABjFWIF5oAbfYFrIP9k1ws5wOA2O5FdxqnFpL/ALp7+1cDMeSM8eg70AQTEbsA1TmI7k49qsv3Pr2qrcjjPHp1oAybog5GOPcVg6gDg/N78it26ZSOAfzrFv2ypz+OaAPN/Gf+vtv91v6V13gkoPDVpvPTfx/wM1yXjT/j4t/o39K7bwNBHL4VsSwG7L5OOfvtQBsQXMSgcsCDx61u6Vq7wjbMRJH655FYk+myQgtH8ynJ68iooyyMFAw386AO6Vkf95bneh5PtV21UH5s/L2rmNFM0b+argKOoPQiurtLiG6HyDaw7YoAuR4wOMipfLdHDR8DrUUYHer0bYz/ACoAtQyCRM/xDrUitgdqz3YxuHj/ABAqxHMso3J09qAL0JyMnrTZBg/rTbZvmAqaUAnI70AVrvmAEdqxrhTk5AzW3PzbuB2HesafByTQBSm+4enSuaveZ+cY78V0k/CNiudvUJct1BGTQBlSKDIxHXue1R3jAWbEH24FRzSmKQgkAZ6dah1GQfZH9ucUAcheXYjDsOSeetZVrMXOSeW9+lR6/c7YwgGN/FVrKQkcDk0AdNaOMdDjPHrWlAe569qxbR+mPzrUt36ehoA0om564NWA2GBHJqnGwPQcHv6VYVvmGBxjFAHReGZSszKfUGuwbmL1xXAaI+y9XB6jGK7pGzBn+lAEe4Ac8AHmmPggZXmmucDOM+ooOCnvigBAhZmyOPrVy2QdumKolsMMccZ5q5aPk9RyOgoA5Xx+n7iI4zh/6GvNrwcnHT616f4+Q/2erD+GQH+leZXQyTgDFAGJdjKkgGvKNV/5Cl5/12f/ANCNes3anDA/qeK8m1YY1S8H/TZ//QjQB7j+xj/yVDVP+wNL/wCj4K+yiK+Nf2L/APkqOqf9gaX/ANHwV9mMKAIiKjYcVMaic0AV34qjdscECr0pxzWXcHcxNAFOTvVZxnrVpxznHFV3AEnB4FAEBA6dc1DLjA521PJgc9KqyMDjkEigCpMTzzxVWUmrErEAkgkegqpcNgHnkdMUAQTEAZJFUpScHaBmppH4yapyvjJyDQA4vxjPQVmXkxd9mR61PLLsH6k1mtKXkJOMdiKALkDk4GRWzpcgS5Qj1wM1z9u2MZGa17JyJE7YNAHfQNuj4qZTyBVXTn3RAGrag56daAJo8dqkpiDAxUgFADlHPFWYvWokHHvU8XpQBS1fH2OX/dNefMcnPtXoWtf8eUvP8Jrz51GRzyP50AVmBwP1IqvOBg7s49quN9OtVJsAZAOaAMq5zklu3esLUSNpJ/lW7d4YNyQR04rA1A/Lj1oA878aHNxb8/wt/Su58CY/4RKyIPOX4/4G1cL4zz59tznhv6V6B8PFDeE7LpwZM/8AfbUAdBazTOAgHfg4rQWzjlQb0y2MZHUU2BlEXypg+9aFoSWII+WgCslg0Iyh3Ke2OlWrcmFlZSQfarsPBJH4CnvarIQVyG70AaFncC4QJJ8rj9atbzGcMOe1Yb5hIAyGHr3qzb6isrGJyA9AGl5pztHIPWnQg28vAyj9vSqi5U4Y8HofWrUbdm5zQBrW+Aw54q0emPWqVicn6VcJ70AQyg+U4PpWLOeDW3cj90x9qwp8fw0AZ85HPWsW74zk5rYn64OcdqxrsZycAmgDl7x/9IJJBBPaq2oufsT46VZvgPOIYe4rO1F/LsJmY4CjNAHmmuT+ZdhQc7etSWbnCc9fSsmSXzbh355NXrRzhfagDprNwAMHGK1bd+nOc8VhWT9Md61rYnGB1zQBqwdMA9Kto4A681RhI4BHWrIIyfQ0AaNlNsuoySfvDmvQLbm1Gea84hYhhhgBkECvQNMcSW454xQAsp249DzUSuNnQ5pZmxxTA3yN3oAcWBIJ9MVasid4xjg1TU8cA1NZuAwx1JoAz/HKH+yJTgcMDn8a8ruD1GK9b8ZqDod0ewXP615JdMB9en0oAyLsYBNeR6t/yFb3/ru//oRr167yd2T044ryHVv+Qre/9dn/APQjQB7l+xf/AMlR1T/sDS/+j4K+zGr4y/Yv/wCSo6p/2Bpf/R8FfZrYoAYaiepDUUnANAFS5fAIrOkwDk1cuOSfSqUoGKAKznn2qpKwGeD+FWpQMZIqjP1oARzkYBznvVObg9s1Yz69aqTnNAFWVgOc1nTyAdDx6mrd0wCNg84rJuJFxnp9TQBHPIB3waotLliQOnrTJZwwPGffNV/NwM8D3NADdQnwnXr2zVEPlABjFQ6hOC6g9etQxOSRg8UAbEJz0P0rWts7VwTu9ax7bleOuK1LUEY46CgDu9GOYwfUVrDGBmsLQnBgTkdK3gF+tAEi4qRe9RKeQBTx9KAJ4+lTxnmqqYq1D9KAKmr82cvT7prz1uGJzxnjNeh6qAbSQEfwmvPJxyvHSgCtIeepIqtMcq2OD0qeYEMdvTrVSYjqxA46UAZtwdvDZ461g6k4weTn2reugCD6Yxn3rBvwoUkHmgDz3xoc3Ftxj5W/pXV+B7lovD9ptIG0v/6Ga5PxopFxb56lW/pXTeDId/h+1PGCWH/jxoA9C0zUIrg7XwD3PrW/bxAIAuBnoR0NcNZRtHjBA71t2t+8boAcjuO1AHSohQZIwamWXAyQRjk1StrxJIjg/MO2eaimvMnap6dTmgC5dyrKhQHr39Kwjby28wY5Po4q7CTzjnHWrIkXYVb5ge3pQBb029W5TZJ8rjj61oISOGrm5YzbyLLGCU65z0rd0+ZbuIEY8z2oA3dMPy5x3rQOBg1nW/7sKoHArRTDR5GKAI5xuhfHp2rBmGR0rebIHGT7Vh3K7WYcjBoAy7vjoDWNdHOcEc+tbV4BsJ54rDvRlD9OtAHKam+2XJGfYisPxTKRoN0wcr8natbWAd/U1yXji6FtoohLYkmGAM9qAOCh46k/41ctXHqetUVPHJJwKtWjfzoA6OwJKgjNbVs2AecetYFgQQB0P1rZtzxg0AbEJwRjpVlOcYNUrftnFWg2egwOxoAtKSBXfaA5a1THda4OA79y4BXFdf4YkDW0YB5Xg0Aad1948Go0OF/Cp7rOTx0qBe4P1oAan3hT4SVYcd6Yq856U8cS8evFAD/E6+Zot0p6GM/yrxu4OcnvXterKX0yYf3oz/KvE7kjgjOcc0AZk20lty9ux715JrH/ACFr3v8Av3/9CNetXJIJ6HNeSat/yFb3/rs//oRoA9y/Yv8A+So6p/2Bpf8A0fBX2a1fGX7F3/JUdU/7A0v/AKPgr7ONAEZqtOcZA61ZbvVSXrQBUlzjmqUvX2q/JyDVOWgCnMD2qjcfeNXpskf1qnMoA560AZrOASOn41BI3ByeasTJhs49s1SuCRk+lAFG/kxHgYPrXL3V4S7DIwK0ddvNq7I/vdz6VyzyE4OCAPWgC005dvvD27Copp8rkkVVZyBzwcYqlf3QjhOOuMdKAIprgy3DEduKuW5UEBVCjHGaw7Vs/N6mtm25fPb0oA27XoO1a1uNz8HjNY0BAGOfzrTt2OABxigDs/Dx/c/TjpXSRnIrkvDbnBUkcGuthxjigB6AA5zxUq9cZH1qHODj1qQUASL8rdjVmEjOaqg47VZhPP1oAbfjNs/A+6a89nGGIwMivRLsZhb6GvOrkjzXPfOOKAKU2cHj8az3OGxgFj/KtCUHHXNZ9yQG4HI5zQBmXT7gQc59qx7/AOXd+Qz1rUuXDcgckZrHvmBI64PvQB5/42OZ7XnPyt/Su18Cw48KWchGQ28cf77VxPjQ5uLb/db+Yru/AMjR+E7I9suRj/fagDf+UptVRuBB3d8elNkfapJ6diDSXbK43k4cjPFY8tzLG2Zs7Ce3agCebVJN4EWVA7962dP1RJkCz4BPAYd/rXPLJG49vUU9UXd8pOPQUAdtG43AFsZ6Y5zVoEEZxg/zrktMvXibbLlkHv0rpYXDojA7geQfWgC7C4U7WHHfPSrumwi3n85P9Wex7VRt4/NcAZPr6VtQqANoxgdqANiEhlVxjmr9uQU6flWRZnY2P4T09q07f72M9aAHSHaax9TXE2f73NbMo5xxWXqoxsP4UAYd1yDwOfwrAvD1yfwrfucEHNc/qBIU5x+FAHJatj7SqnoTXmfxHlZtYijJyscYx+Nei6zJhyQxHvXmHjp9+sKck/ux1oAxVPyD3qzbNzVNeVFWIOCKAOgsD8wPFbVueRmuds3xtrbt2yaANmBuD9MVdjbj296zbc9qvxt+NAFqNvTArrvCkn7rHoa45W5zkcV03hOT5yN3IOcHpQB2FwuWP0z9aqDPzcCrU7fKhyOlVGPWgAGBTnxuXp0phPzDJp/Bxg56UAXbnBsOccpjGK8Quv8AWMBwBxivb5zmyG4YyteIXxxJIO4Yj9aAMi8J5PTivJdV/wCQpef9dn/9CNes3XOa8n1UY1S8H/TZ/wD0I0Ae5fsXf8lR1T/sDS/+j4K+ziK+Mf2Lv+So6r/2Bpf/AEfBX2eaAIX6Gq0oq02CSKgkwDQBUk4+hqnKAG6jFXpeTxVOb+VAFC47YxiqkpGf8KnuX5/CqbyjbjigCtcqCCSDWTeOoQk+lXrqcFeQeBjrXIavfbN25sAE96AMrUJxvkYgdyAa56SZcN3PUnNO1fUg7kIfmI5+lY7zhlOeD60AaJmySVOce9Y+q3JYiPceTmnST4i684wTWJJcGW9G45VelAGzp4X5Tk4FdBaYwNpBz61z2nMD06E1vWrYKmgDUjOfzrStj83Y+mKzIGwc+vNaMRwExgY9qAOm8PSYndQR0zxXaWx+Uc8VwGhShbwAH73y13tnygoAsYwRxTx15pvTrTvSgB6+lWYuoqsv1qeDqKAJJ1/dkGvOr4bZ5VxjDEV6RKflNeeauu3UJhn+LNAGU+M4z+FU7hTj5gD7Zq5LjJ/nVG7Py8Y+tAGPc7QWA4HbNYV+p6cE1tXZ3ZPpWFeHjOe9AHCeMVK3FuDg8N/Su48DnHhGy4ycyY/77auG8YMWnt8+jf0rs/BF1GPDNnEc7lL/APoZ/wAaANtGJwWbPqMVIYgwbgMp/hNOVI5NrbsNnAPaleMgsedvtQBTksVC5tz1H3D2NVFMkZ5BDehFaoycMuTjnjjFOcLMCsgAJH3vegDMExDhsZ9hxWvpd/JDL8o3ox5UnrWPdWkscqgAsp+6wrc0m08vLON0h6HsKAO3sFQwhkJ+YZOf4far8Q7k1z+nyvEQex6j1roYmVow6kEGgC3EemRx1rRtpAWAz7Vkl+ASw4qxYTb51zjBPFAGs3XpVHVx+5DEcA1oMPSq1+ge0f1oA5efviud1ThWxn866K4HHJrnNXz5ZBJHNAHnviWbYDnPHPFedeLD5l1DIM8pgk13nixiGZc9ulcFqx861Vj1XigDJT7o+tTRfeFQqflFTREDrQBq2jcitu1bAA4zWBbHmtu0cMM45GKANm3IGDx+FXomGckbh6VmwEHHbNXY2yoFAFyPODgdfeuh8LN/pTjHXGK52MjIwTW74acJqBXOcj86AO7mwY0IB6VXwMH2qwwH2YHH5GoM/KaAIs4Pv1qUNkKRxnrTCCBkYzQpGcUAX5P+PIYz0714nqZxdT+m9v517bz9iHJwBXh+q4+1znBz5jfzoAyps9a8n1j/AJC17/13f/0I16xMQDXk+sHOr3xH/Pd//QjQB7j+xd/yVHVf+wNL/wCj4K+zm6V8Y/sXf8lR1X/sDS/+j4K+zm6UAQsMnJzUUlSkVDLxQBWk7+tU7nAB65q3J0qjcnrQBmXRGM8ZHbNZE0pDFSMZrQvyCeP0rLlXbuZzhR1PpQBla7dpZ2uZDwT+JryLxb4jBl8uBtzMex6VN8TfF32rVfsdi4MUQILA9T3rz+aVnYMxye5oA2o7guQ7MS5689ala447596yYJMJu+UCnG4y3YewoAu3U5WAlT71m2jFnZiMmo76clAvOelFk2Mc/WgDotPIBBGcda6G2b5Rg5PWucsSQMZz7Vu2rDIPrQBtRMDjJxV2JxnGRwOtZUTgEdTzWjCRnJ4zQBsaZIUuIiD39K9GsCGVTkZxXl9q5V1ZTj5u9ek6RIGhRuxAoA1WA9OtKBjGKRugpQcjkYNADx1qeM8iq44NTwnJz3oAtSYMZyK8+8Qrs1KXIwDzXoJGE55rhvFKgX2c84oA52UgA8jFULhtwPT+lXLjk8dfSs+d15zjPoBQBlXe0A4PHWufvXXfg4zXQXQGDxXN6j8rk8L9RQBxPi4gzwY/un+daXhyZl0uFVJ6twPqayfFGPPgGAPlP861tAhDaRbv3y3/AKEaAN2w1J42VCcoTyproLXUYpUwH5PGDXJ+SGG4MMipIJDG3qe5oA7JX3kA4IHXHepBCJHxGAC3SsjSb8MFUgM3rXTWiR7t6bdxH4CgCfTrQR4EgDZ657VN9l8vBtzujPUdwasRcqEzz3NTQZjyc5PpQBFAuFzkn+lX7S6+zuQRlG4I9KrzR5BkhHI5K+tZlxc7flHDdwe1AHVPJk/KflPQ1asG/wBITHY8VzWhXhbFvKeTyrHj8K6bTV/0jntzQB0IOU96jm5Qg96dbElsHvSXQ2qPrQByuop5buCPeuY1g5hf867TXI9u1x34NcZq4LRvj0oA8t8Vk789K4a75hmArufFikBiOMGuGuekgPcUAZaD5fepUqJB1qRetAGhbnkcVs2RPrgVhW56ZrWtmKnbmgDct2yPer0R5GelZts3yjI571fiJOD0FAF5M88mtjw+wTUowCemKxI+cd61dHOzUYCQOvrQB6SCTb5HSoSMg1PDzbDoKYR97jH4UARgfKc/lSAc+wp7IwGOc0ka5cZwMetAF/8A5c84/AV4dq67dQuOvEjfzr3cD/RAQBg5rw/X1A1O5BH/AC1b+ZoAwpge+K8m1j/kL33/AF3f/wBCNetyrnJ6GvJNZ/5C99/13f8A9CNAHqX7MXjDQvBXj2/1HxPffYbKXTJLdJPJkkzIZYmAwiseisc4xxX04fj/APDLH/IzD/wAuv8A43XwLRQB97n4/fDPgDxLxn/nwuf/AI3ULfHr4aY48Sc/9eNz/wDG6+DqKAPul/jv8NyTjxHn/txuf/jdUbj44fDx/u+Ic/8Ablcf/G6+JKKAPsiT4zeAWbP9v/8Akncf/G65Dx58X/D1zYm20LUmlMgIZ/IlXH/fSivmaigDs5tcsnlL/aMknOdjf4UHW7E4/wBI5H+w3+FcZRQB26a7p4GPtH/jjf4Uo13T+9x/443+FcPRQB2j6zYSzIDdBUzyxRuP0qeHXNNT5TdA89RG/wDhXCUUAeo2nijRkUl74KRjA8qTn/x2tS38Z6Ci/NqGD/1xk/8Aia8aooA90h8eeHBjdqOP+2En/wATV2P4h+GAADqZH/bCX/4mvn6igD6IT4i+FVYf8TU/+A8v/wATXbaP8Y/A0NtGk+t7GAwR9knP8kr5BooA+1P+F2fD3aB/wkH/AJJXH/xukHxt+H/Gdf7/APPncf8AxuviyigD7VX42/D4E58Qf+SVx/8AG6lj+OHw8HXxD/5JXH/xuviWigD7kPx0+HJXH/CRdv8Anxuf/jdcx4j+MHgS8kja21zfjg/6HOP5pXyFRQB9NTfE/wAIMPl1cfX7NN/8RVCb4j+FH5Gqc/8AXvL/APE186UUAe/3HxB8Muvy6nk+8Ev/AMTWLf8AjPQJMmPUN5P/AExk/wDia8aooA7nXNd066mjaG4DBVwfkYfzFa2g+KNGtNOijnu9sqkkjy3Pf2FeYUUAesnxdoqk7b7IOefKf/4mmReK9FDfPf47f6p//ia8pooA9vsfGvhmA/NqIz6iCT/4mti3+I3hZCP+JoVA6/6PLz/47XzxRQB9Px/FDwaBn+2cH0+zTf8AxFWk+KvgnbltZ+b/AK9Zv/iK+VqKAPqSX4reDtn7vWTvH/TrN/8AEVnXPxH8HT/vP7X2Td8W02D/AOOV82UUAfSNv8SvCaspbV9uOR/o8xwf++K63SfjH4GSHN1reyUDB/0Oc5/JK+QaKAPtSL42fD5WB/4SD/ySuP8A43T7v42/DyWIbfEPzD/pyuP/AI3XxRRQB9j6h8ZPAE9qUTXsuOR/odx1/wC/dcrqHxP8GzKwj1jr/wBOs3/xFfMVFAHr3iDxdoN2zfZ7/eD/ANMZB/Na5GbWLBmJFxnP+w3+FcfRQB0Q1G0z/reP90/4U8alZgj97/46f8K5qigDrItWsVxun/8AHG/wq/b67pqnL3OP+2bH+lcJRQB6dB4o0deGu/8AyE/+FXYvF2hKeb7j/rlJ/wDE15JRQB7KnjPw+P8Al/P/AH6k/wDiauWXjrw5HcRu2ogBWyf3En/xNeHUUAfVkHxX8Ei3CvrWG/69J/8A4inH4r+CMf8AIc/8lJ//AIivlGigD6sPxW8E841s8/8ATrP/APEUxPip4K3AnWsAf9Os/wD8RXytRQB9df8AC3vAotAg135/+vSf/wCIryvV/Gfh+fULmSHUC6NIzKfJkGQT/u14zRQB6hL4o0dhxeD/AL9P/hXnGpyJNqV3LE26N5XZTjGQSSKrUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) AP humerus. Observe the large metaphyseal unicameral bone cyst with a cortical fracture (white arrow). The fractured fragment is demonstrated in the most caudal portion of the radiolucent defect, representing a fallen fragment sign (yellow arrow), which is also known as a \"fallen leaf\" sign.",
"    <br>",
"     B) AP humerus. Observe the radiolucent unicameral bone cyst with soap-bubbled matrix located centrally within the proximal metaphysis of the humerus. There is a small cortical fracture (white arrow) with a fallen fragment sign within the cystic radiolucencies (yellow arrow). About 10 percent of patients with unicameral bone cyst present with a fallen fragment sign.",
"     <div class=\"footnotes\">",
"      AP: anteroposterior.",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced with permission from: Yochum TR, Rowe LJ. Yochum and Rowe's Essentials of Skeletal Radiology, Third Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4642=[""].join("\n");
var outline_f4_34_4642=null;
var title_f4_34_4643="Heartport bypass system";
var content_f4_34_4643=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F81959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F81959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heartport bypass system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 416px; height: 471px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The endoaortic balloon occlusion catheter is inflated in the ascending aorta and antegrade cardioplegia is delivered through the central lumen. The endopulmonary vent assists in ventricular decompression.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Standbridge RD, Hadjinikolaou LK, Cohen AS, et al. Ann Thorac Surg 1997; 65(6 Suppl):S53.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4643=[""].join("\n");
var outline_f4_34_4643=null;
var title_f4_34_4644="Flavocoxid (plant flavonoids and zinc): Patient drug information";
var content_f4_34_4644=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Flavocoxid (plant flavonoids and zinc): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/1/24595?source=see_link\">",
"     see \"Flavocoxid (plant flavonoids and zinc): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F729844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Limbrel 250&trade;;",
"     </li>",
"     <li>",
"      Limbrel 500&trade;;",
"     </li>",
"     <li>",
"      Limbrel&trade; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705946",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to flavocoxid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black stools.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699092",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the feet or hands.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026200\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11679 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-617C8121F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4644=[""].join("\n");
var outline_f4_34_4644=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F729844\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026192\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026191\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026196\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026197\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026199\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026194\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026195\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026200\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026201\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/1/24595?source=related_link\">",
"      Flavocoxid (plant flavonoids and zinc): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_34_4645="Ticlopidine: Patient drug information";
var content_f4_34_4645=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ticlopidine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=see_link\">",
"     see \"Ticlopidine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F227763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ticlopidine&reg;;",
"     </li>",
"     <li>",
"      Dom-Ticlopidine;",
"     </li>",
"     <li>",
"      Gen-Ticlopidine;",
"     </li>",
"     <li>",
"      Mylan-Ticlopidine;",
"     </li>",
"     <li>",
"      Novo-Ticlopidine;",
"     </li>",
"     <li>",
"      Nu-Ticlopidine;",
"     </li>",
"     <li>",
"      PMS-Ticlopidine;",
"     </li>",
"     <li>",
"      Sandoz-Ticlopidine;",
"     </li>",
"     <li>",
"      Teva-Ticlopidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700816",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ticlopidine may lower blood cell counts. You will need blood work to watch your counts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700530",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Stent patients: Talk with your heart doctor before stopping this drug, even if told to do so by some other doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop strokes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691270",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used after a heart treatment to protect the arteries.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691573",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to protect bypass grafts and stents in the heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691580",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to protect the kidney transplant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703032",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ticlopidine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Aplastic anemia, bleeding problems, blood disease, very bad liver disease, low platelet count, low white blood cell count, or thrombotic thrombocytopenic purpura.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697875",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pinpoint red spots on your skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11093 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-23AA9155C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4645=[""].join("\n");
var outline_f4_34_4645=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F227763\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022073\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022075\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022074\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022079\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022080\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022082\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022077\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022078\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022083\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022084\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/27/35255?source=related_link\">",
"      Ticlopidine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_34_4646="Percutaneous liver biopsy - high power";
var content_f4_34_4646=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F60062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F60062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Percutaneous liver biopsy in a 35-year-old man who had asymptomatic intermittent elevations of total and direct bilirubin (high power, H&amp;E)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the numerous deposits of lipofuscin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4646=[""].join("\n");
var outline_f4_34_4646=null;
var title_f4_34_4647="Tenofovir and emtricitabine: Pediatric drug information";
var content_f4_34_4647=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tenofovir and emtricitabine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"    see \"Tenofovir and emtricitabine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?31/46/32485?source=see_link\">",
"    see \"Tenofovir and emtricitabine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Truvada&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2934286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Truvada&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1010698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiretroviral Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       HIV Agents (Anti-HIV Agents)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nucleoside Reverse Transcriptase Inhibitor (NRTI)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nucleotide Reverse Transcriptase Inhibitor (NRTI)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1010720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"      see \"Tenofovir and emtricitabine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children  and Adolescents:",
"     <b>",
"      HIV infection, treatment:",
"     </b>",
"     Use in combination with other antiretroviral agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents &lt;12 years or &lt;35 kg: Oral: Not intended for use; product is a fixed-dose combination; safety and efficacy have not been established in these patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children and Adolescents &ge;12 years and &ge;35 kg: Oral: One tablet (emtricitabine 200 mg and tenofovir 300 mg) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HIV infection, treatment:",
"     </b>",
"     Oral: One tablet (emtricitabine 200 mg and tenofovir 300 mg) once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Recommended as a component of preferred regimens (in combination with atazanavir/ritonavir or darunavir/ritonavir or efavirenz or raltegravir) in antiretroviral-naive patients (DHHS [adult], 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pre-exposure prophylaxis (PrEP) for prevention of HIV infection in uninfected high-risk individuals:",
"     </b>",
"     Oral: One tablet (emtricitabine 200 mg and tenofovir 300 mg) once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment: Note:",
"     </b>",
"     Closely monitor clinical response and renal function in these patients; clinical effectiveness and safety of these guidelines have not been evaluated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      HIV infection, treatment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     Children &ge;12 years and Adolescents: Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or patients requiring hemodialysis: Use not recommended (DHHS [pediatric], 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:4em;\">",
"     Adults: Manufacturer&rsquo;s labeling",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;50 mL/minute: No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute: Administer every 48 hours.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or patients requiring hemodialysis: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pre-exposure prophylaxis (PrEP):",
"     </b>",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;60 mL/minute: No adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute: Use not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     There are no dosage adjustments provided in the manufacturer&rsquo;s labeling; however, no dosing adjustments are necessary for tenofovir in hepatic impairment. No specific data is available on emtricitabine in hepatic impairment, but given its limited hepatic metabolism, the impact of liver impairment should be minimal; need for dose adjustment is unlikely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Truvada&reg;: Emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F14633101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM312307.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM312307.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1010725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to food",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1010715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store tablets at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Keep container tightly closed; do not use if seal on bottle is broken or missing. Dispense only in original container.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1010699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV infection in combination with other antiretroviral agents (FDA approved in ages &ge;12 years weighing at least 35 kg and adults);",
"     <b>",
"      Note:",
"     </b>",
"     HIV regimens consisting of",
"     <b>",
"      three",
"     </b>",
"     antiretroviral agents are strongly recommended; pre-exposure prophylaxis (PrEP) in combination with safer sex practices for prevention of HIV infection in adults at high risk (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F164699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The adverse reaction profile of combination therapy has not been established. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1010704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to emtricitabine, tenofovir, or any component",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Additional contraindications:",
"    </p>",
"    <p style=\"text-indent:2em;margin-right:4em;\">",
"     Pre-exposure prophylaxis: Use in a patient with unknown or positive HIV-1 status",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     HIV treatment: Monotherapy",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F6102716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hepatic impairment. Significant drug interactions may occur. Fat redistribution and accumulation [ie, central obesity, peripheral wasting, facial wasting, breast enlargement, dorsocervical fat enlargement (buffalo hump), and cushingoid appearance] have been observed in patients receiving antiretroviral agents (causal relationship not established).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Immune reconstitution syndrome (an acute inflammatory response to residual or indolent opportunistic infections) may occur in HIV patients during initial treatment with combination antiretroviral agents; this syndrome may require further patient assessment and therapy. Autoimmune disorders (eg, Graves' disease, Guillain-Barr&eacute; syndrome, and polymyositis) have been reported in patients experiencing immune reconstitution; time to onset is variable and may occur many months after antiretroviral treatment is initiated.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Emtricitabine-associated hyperpigmentation may occur at a higher frequency in pediatric patients compared to adults [children: 32%; adults: 2% to 6% (may be higher in African-Americans)]; occurs primarily on palms and/or soles but may include tongue, arms, lips, and nails; generally mild, asymptomatic, nonprogressive, and without associated local reactions, such as pruritus or rash. Safety and efficacy have not been established in patients &lt;12 years of age.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Tenofovir-associated osteomalacia and reduced bone mineral density (BMD) may occur; long-term effects in humans are not known. Postmarketing cases of osteomalacia which may increase risk of bone fractures have also been reported in association with proximal renal tubulopathy. Recent studies suggest that tenofovir-related bone loss may be greater in children who are less mature (eg, Tanner stage 1-2) than in those who are more physically mature (Tanner &ge;3). A significant decrease in lumbar spine BMD (&gt;6%) was reported in five of 15 pediatric patients who received a tenofovir-containing regimen for 48 weeks. No orthopedic fractures occurred, but two patients required discontinuation of tenofovir. All five patients with a decrease in BMD were virologic responders and prepubertal (Tanner Stage 1). This study found a moderately strong correlation between decreases in bone mineral density z scores at week 48 and age at baseline. No correlation between decreases in bone mineral density z scores and tenofovir dose or pharmacokinetics was observed; BMD loss may limit the usefulness of tenofovir in prepubertal children [DHHS (pediatric), 2012; Giacomet, 2005; Hazra, 2005; Purdy, 2008]. Monitor BMD for potential bone toxicities during therapy; supplementation with calcium and vitamin D may be beneficial but has not been studied.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used for pre-exposure prophylaxis (PrEP), confirm HIV-1 negative status immediately before and at least every 3 months during therapy",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; increased risk of drug resistant HIV-1 variants with PrEP use if patient has undetected acute HIV-1 infection. Some HIV-1 tests (eg, rapid tests/HIV antibody test) do not detect acute HIV-1 infection; screen PrEP candidates for acute viral infections and potential exposure events &le;1 month of starting PrEP; if infections or events exist, wait 1 month to start PrEP and reconfirm HIV-1 negative status. Do not start PrEP if signs or symptoms of acute HIV-1 infection are present unless HIV-1 negative status is confirmed by a test approved by the Food and Drug Administration (FDA) as an aid to detect HIV-1 infection (including acute or primary infection). PrEP should be accompanied by a comprehensive HIV-1 prevention program (eg, risk reduction counseling, access to condoms), with particular emphasis on medication adherence; regular monitoring [eg, HIV status of patient and partner(s), risk behavior, adherence, adverse effects, sexually transmitted infections that facilitate HIV-1 transmission] is highly recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The use of antiretroviral regimens that only contain triple nucleoside reverse transcriptase inhibitors (NRTIs) are generally less effective than regimens containing two NRTIs and either a non-nucleoside reverse transcriptase inhibitor or protease inhibitor; use triple NRTI-containing regimens with great caution; early virological failure and high rates of resistance may occur; closely monitor for virologic failure and consider treatment modification.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1010705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cases of lactic acidosis, severe hepatomegaly with steatosis, and death have been reported in patients receiving nucleoside analogues, including emtricitabine and tenofovir",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most of these cases have been in women; prolonged nucleoside use, obesity, and prior liver disease may be risk factors; use with extreme caution in patients with other risk factors for liver disease; discontinue therapy in patients who develop laboratory or clinical evidence of lactic acidosis or pronounced hepatotoxicity.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Safety and efficacy during coinfection of HIV and HBV have not been established; acute, severe exacerbations of HBV have been reported following discontinuation of emtricitabine and tenofovir",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; monitor hepatic function closely for several months after discontinuing; initiate antihepatitis B therapy if needed. Not indicated for treatment of chronic hepatitis B. All patients with HIV should be tested for HBV prior to initiation of treatment. Use with caution in patients with known or suspected hepatitis B or C infection; monitoring of liver function is recommended.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Both emtricitabine and tenofovir are primarily eliminated by the kidney; when used for treatment of HIV, dosage adjustment is required in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute; do not use in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute or patients requiring hemodialysis); for pre-exposure prophylaxis, use should be avoided in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;60 mL/minute. Renal toxicity including acute renal failure and/or Fanconi syndrome (renal tubular injury with severe hypophosphatemia) have been reported with tenofovir use; risk may be increased in patients with pre-existing renal disease, underlying systemic disease, or those taking nephrotoxic medications; adults with a low body weight and those taking medications that increase tenofovir serum concentration may also be at increased risk for nephrotoxicity; cases of nephrotoxicity have been reported in adolescents receiving tenofovir-containing regimens. Avoid use with concurrent or recent nephrotoxic therapy. Evaluate and monitor renal function, including calculation of creatinine clearance, at baseline and during therapy in all patients (regardless of age); monitor serum phosphorus. Use with caution in patients with low body weight or concurrent medications which increase tenofovir levels.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Truvada&reg; contains emtricitabine and tenofovir as a fixed-dose combination; do not administer Truvada&reg; with other emtricitabine- or tenofovir-containing medications (eg, Atripla&reg;, Complera&reg;, Emtriva&reg;, Stribild&reg;, or Viread&reg;) or with medications that contain lamivudine (eg, Epivir&reg;, Epivir-HBV&reg;, Combivir&reg;, Epzicom&reg;, or Trizivir&reg;). Do not coadminister with adefovir; may diminish efficacy of tenofovir.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acyclovir-Valacyclovir: May decrease the excretion of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adefovir: May diminish the therapeutic effect of Tenofovir. Specifically, adefovir-associated mutations in Hepatitis B viral reverse transcriptase may decrease viral susceptibility to tenofovir. Adefovir may increase the serum concentration of Tenofovir. Tenofovir may increase the serum concentration of Adefovir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: May increase the serum concentration of Tenofovir. Tenofovir may decrease the serum concentration of Atazanavir. Management: When combined use required, tenofovir 300 mg and atazanavir 300 mg should be used with ritonavir 100 mg (adult doses), all given in single daily dose with food.   Atazanavir without ritonavir should not be used with tenofovir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: Tenofovir may diminish the therapeutic effect of Didanosine. Tenofovir may increase the serum concentration of Didanosine.  Management: Avoid concomitant treatment with tenofovir and didanosine.  Consider altering even existing, stable treatment to avoid this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: May enhance the adverse/toxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Hematologic toxicity is of specific concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ganciclovir-Valganciclovir: Tenofovir may increase the serum concentration of Ganciclovir-Valganciclovir. Ganciclovir-Valganciclovir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamiVUDine: May enhance the adverse/toxic effect of Emtricitabine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May enhance the nephrotoxic effect of Tenofovir. Lopinavir may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: Tenofovir may decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ribavirin: May enhance the hepatotoxic effect of Reverse Transcriptase Inhibitors (Nucleoside). Lactic acidosis may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1010714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Compared to the fasted state, a high fat or light meal delayed the time to peak concentrations of tenofovir; mean tenofovir AUC increased by 35% and peak concentrations increased by 15%; emtricitabine AUC and peak concentrations were not affected",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F164675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Although approved for use in combination with safer sex practices for the prevention of HIV-1 infection in adults who are at high risk for acquiring HIV (preexposure prophylaxis [PrEP]), data on use in heterosexual HIV serodiscordant couples wishing to conceive are limited. In addition, preconception use of PrEP in the uninfected partner when the HIV-infected partner is receiving antiretroviral therapy has not been studied.  Women of reproductive age should have a pregnancy test prior to starting PrEP and at regular intervals during therapy. In addition to pregnancy testing, uninfected women considering PrEP therapy should also undergo screening for HIV and other sexually transmitted diseases. Serodiscordant couples wishing to conceive should seek expert consultation to determine the safest approach for their specific situation.  If HIV infection is documented during PrEP therapy, the antiretroviral agents should be discontinued in order to minimize drug resistance. If pregnancy is detected during therapy, the potential risks and benefits of continuing PrEP during pregnancy should be discussed (DHHS [perinatal], 2012; CDC, 2012). Refer to individual monographs for additional information.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1010727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV treatment: Note:",
"     </b>",
"     Monitor CD4 percentage (if &lt;5 years of age) or CD4 count (if  &ge;5 years of age) at least every 3-4 months (DHHS [pediatric], 2012). Prior to initiation of therapy: Genotypic resistance testing, CD4, viral load, CBC with differential, LFTs, BUN, creatinine. At initiation and with any change in treatment regimen: CBC with differential, electrolytes, calcium, phosphorus, glucose, LFTs, bilirubin,  BUN, creatinine, albumin, total protein, lipid panel, CD4, and viral load. After 4-8 weeks of therapy: CBC with differential, viral load; then every 3-4 months: CBC with differential, electrolytes, glucose, LFTs, bilirubin, BUN, creatinine, CD4, and viral load. Albumin, total protein, calcium, phosphorus, lipid panel, and urinalysis every 6-12 months (DHHS [pediatric], 2012). Monitor for signs of opportunistic infections, lactic acidosis, hyperpigmentation, or bone abnormalities. Test patients for hepatitis B (HBV) prior to starting therapy; in patients coinfected with HBV, monitor hepatic function closely (clinically and with laboratory tests) for at least several months after discontinuing emtricitabine and tenofovir therapy. Monitor weight and growth in children. Consider bone mineral density assessment for all patients with a history of pathologic bone fractures or other risk factors for osteoporosis or bone loss.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV-1 pre-exposure prophylaxis (PrEP):",
"     </b>",
"     Pregnancy test for women receiving PrEP (every visit); documented negative HIV test (immediately prior to use, every 2-3 months, and following discontinuation of PrEP), assess risk behaviors and symptoms of sexually transmitted infections (STIs) or acute HIV-1 infection and provide condoms (immediately prior to use, then every 2-3 months during therapy); BUN and serum creatinine (prior to initiation, 3 months after initiation, then every 6 months); testing for HBV (prior to initiation) and STIs (prior to initiation, then at least every 6 months, even if asymptomatic) (CDC, 2011; CDC, 2012)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1010717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1010719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     One Truvada&reg; tablet is bioequivalent to one emtricitabine 200 mg capsule and one tenofovir 300 mg tablet (single dose study); see individual agents",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F6102718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/46/32485?source=see_link\">",
"      see \"Tenofovir and emtricitabine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Emtricitabine and tenofovir is not a cure for HIV; take emtricitabine and tenofovir every day as prescribed; do",
"     <b>",
"      not",
"     </b>",
"     change dose or discontinue without physician's advice; if a dose is missed, take it as soon as possible, then return to normal dosing schedule; if a dose is skipped, do not double the next dose. Report the use of other medications, nonprescription medications, and herbal or natural products. Long-term effects are not known. Notify physician if persistent severe abdominal pain, nausea, vomiting, rash, numbness, or tingling occur. May cause dizziness and impair ability to perform activities requiring mental alertness or physical coordination.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     HIV medications may cause changes in body fat, including an increase in fat in the upper back and neck, breasts, and trunk; a loss of fat from the face, arms, and legs may also occur. Some HIV medications (including emtricitabine and tenofovir) may cause a serious, but rare, condition called lactic acidosis with an increase in liver size (hepatomegaly). Do not take Truvada&reg; with other emtricitabine or tenofovir-containing medications (eg, Atripla&reg;, Complera&reg;, Emtriva&reg;, Stribild&reg;, or Viread&reg;) or with medications that contain lamivudine (eg, Epivir&reg;, Epivir-HBV&reg;, Combivir&reg;, Epzicom&reg;, or Trizivir&reg;). Do not take Truvada&reg; with adefovir (Hepsera&reg;).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F16057338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Emtricitabine is the (-) enantiomer of 2', 3'-dideoxy-5-fluoro-3'-thiacytidine (FTC), a fluorinated derivative of lamivudine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Mutation in the HIV reverse transcriptase gene at codon 184, M184V/I (ie, substitution of methionine by valine or isoleucine) is associated with resistance to emtricitabine. Emtricitabine-resistant isolates (M184V/I) are cross-resistant to lamivudine and zalcitabine. HIV-1 isolates containing the K65R mutation show reduced susceptibility to emtricitabine.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aberg JA, Kaplan JE, Libman H, et al, \"Primary Care Guidelines for the Management of Persons Infected With Human Immunodeficiency Virus: 2009 Update by the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2009, 49(5):651-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/34/4647/abstract-text/19640227/pubmed\" id=\"19640227\" target=\"_blank\">",
"        19640227",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2012, 61(31):586-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/34/4647/abstract-text/22874836/pubmed\" id=\"22874836\" target=\"_blank\">",
"        22874836",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Interim Guidance: Preexposure Prophylaxis for the Prevention of HIV Infection in Men Who Have Sex With Men,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2011, 60(3):65-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/34/4647/abstract-text/21270743/pubmed\" id=\"21270743\" target=\"_blank\">",
"        21270743",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, \"Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,\" February 12, 2013. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, \"Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,\" November 5, 2012. Available at:",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States,\" July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih1.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giacomet V, Mora S, Martelli L, et al, \"A 12-Month Treatment With Tenofovir Does Not Impair Bone Mineral Accrual in HIV-Infected Children,\"",
"      <i>",
"       J Acquir Immune Defic Syndr",
"      </i>",
"      , 2005, 40(4):448-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/34/4647/abstract-text/16280700/pubmed\" id=\"16280700\" target=\"_blank\">",
"        16280700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hazra R, Gafni RI, Maldarelli F, et al, \"Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2005, 116(6):e846-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/34/4647/abstract-text/16291735/pubmed\" id=\"16291735\" target=\"_blank\">",
"        16291735",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Purdy JB, Gafni RI, Reynolds JC, et al, \"Decreased Bone Mineral Density With Off-Label Use of Tenofovir in Children and Adolescents Infected With Human Immunodeficiency Virus,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2008, 152(4):582-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/34/4647/abstract-text/18346519/pubmed\" id=\"18346519\" target=\"_blank\">",
"        18346519",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13013 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-87E6A227E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4647=[""].join("\n");
var outline_f4_34_4647=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708729\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164681\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934286\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1010698\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1010720\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164669\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164659\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14633101\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1010725\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1010715\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1010699\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164699\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1010704\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6102716\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1010705\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299259\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164664\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1010714\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164666\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164675\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1010727\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1010717\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1010719\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6102718\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16057338\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13013\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13013|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=related_link\">",
"      Tenofovir and emtricitabine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?31/46/32485?source=related_link\">",
"      Tenofovir and emtricitabine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_34_4648="Mesothelioma MRI I";
var content_f4_34_4648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66436%7EPULM%2F78690%7EPULM%2F59287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66436%7EPULM%2F78690%7EPULM%2F59287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mesothelioma on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A coronal T1-weighted image shows a multilobular mass in the right paravertebral sulcus (arrow) extending into the minor fissure and along the diaphragm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mesothelioma with thickened fissures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal T2-weighted image shows high signal caused by tumor extending from the diaphragmatic pleura into the thickened major and minor fissures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mesothelioma with hemorrhagic pleural effusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 316px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A liquid-liquid level is demonstrated on a sagittal T1- weighted image (arrows), most likely representing a hematocrit effect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4648=[""].join("\n");
var outline_f4_34_4648=null;
var title_f4_34_4649="Overview of osteomyelitis in adults";
var content_f4_34_4649=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of osteomyelitis in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/34/4649/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/34/4649/contributors\">",
"     Tahaniyat Lalani, MBBS, MHS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/34/4649/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/34/4649/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/34/4649/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/34/4649/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/34/4649/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomyelitis is infection localized to bone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/1\">",
"     1",
"    </a>",
"    ]. An overview of the pathophysiology, classification, microbiology, clinical manifestations, diagnosis, and treatment of osteomyelitis is presented here. Issues related to diabetic foot infections, as well as osteomyelitis in the setting of trauma, vertebral osteomyelitis, and hematogenous osteomyelitis, are reviewed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10646?source=see_link\">",
"     \"Treatment and prevention of osteomyelitis following trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=see_link\">",
"     \"Vertebral osteomyelitis and discitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=see_link\">",
"     \"Hematogenous osteomyelitis in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Osteomyelitis is one of the oldest recorded diseases, with descriptions dating back to the time of Hippocrates (460-370 BC) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/2\">",
"     2",
"    </a>",
"    ]. Terms such as \"abscessus in medulla,\" \"necrosis\", and \"a boil of the bone marrow\" were used to describe the infection until Nelaton introduced the term \"osteomyelitis\" in 1844.",
"   </p>",
"   <p>",
"    Prior to the introduction of penicillin in 1940, the management of acute osteomyelitis was purely surgical, with large incisions for removal of all necrotic bone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/2\">",
"     2",
"    </a>",
"    ]. Wounds were packed with Vaseline gauze and left to heal by secondary intention after immobilization. Mortality rates remained high (about 33 percent) due to sepsis until the introduction of penicillin, which dramatically changed the treatment and prognosis of osteomyelitis. Complications such as sequestration, sinus formation, and sepsis became less common and the goals of therapy changed from disease containment to cure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomyelitis can occur as a result of hematogenous seeding, contiguous spread of infection to bone from adjacent soft tissues and joints, or direct inoculation of infection into the bone as a result of trauma or surgery. Hematogenous osteomyelitis is usually monomicrobial, while osteomyelitis due to contiguous spread or direct inoculation is usually polymicrobial.",
"   </p>",
"   <p>",
"    In long bone hematogenous osteomyelitis, the most common site of infection is in the metaphysis. The major blood vessel to long bones usually penetrates the midshaft of the bone and then travels towards both ends, forming metaphyseal vascular loops just before it hits the epiphyseal plates. Slowed blood flow in these loops (together with the absence of basement membranes) predisposes this site to osteomyelitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=see_link\">",
"     \"Hematogenous osteomyelitis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the setting of osteomyelitis, inflammatory exudate in the marrow leads to increased intramedullary pressure, with subsequent extension of exudate into the bone cortex where it can rupture through the periosteum. If this occurs, the periosteal blood supply is interrupted, leading to necrosis. The resulting pieces of separated dead bone (known as sequestra) can be visualized radiographically. New bone formation that forms in areas of periosteal damage is known as an involucrum. In some cases, a sequestrum can evolve into an involucrum as it is encased with new bone growth. Occasionally, pus may exist in an opening (cloaca) of involucrum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute osteomyelitis is infection in bone prior to development of sequestra. In some forms of infection, development of sequestra is relatively slow (such as vertebral osteomyelitis), while in others the development of sequestra occurs relatively rapidly (such as osteomyelitis in the setting of prosthetic devices or compound fractures) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/2\">",
"     2",
"    </a>",
"    ]. Following formation of sequestra, the infection is considered chronic osteomyelitis; other hallmarks of chronic osteomyelitis include formation of an involucrum, local bone loss, and sinus tracts (if there is extension of infection through cortical bone).",
"   </p>",
"   <p>",
"    In the setting of vertebral osteomyelitis, two endplates of neighboring vertebra are frequently involved in the infection. This observation can be explained by the blood supply anatomy; one arterial vessel splits to supply the neighboring endplates of two vertebra. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=see_link\">",
"     \"Vertebral osteomyelitis and discitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues related to bacterial adherence, host defense mechanisms and histopathology are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39269?source=see_link\">",
"     \"Pathogenesis of osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major osteomyelitis classification schemes: one described by Lew and Waldvogel and another described by Cierny and Mader [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lew and Waldvogel classified osteomyelitis based on the duration of illness (acute versus chronic) and the mechanism of infection (hematogenous or secondary to a contiguous focus of infection). Contiguous infection may be further subdivided depending upon whether vascular insufficiency is present. This scheme is an etiologic classification and does not imply a specific therapeutic strategy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hematogenous osteomyelitis occurs more commonly in children than adults; in children, long bones are most often affected, while in adults the vertebrae are the most common site [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/6\">",
"     6",
"    </a>",
"    ]. Contiguous osteomyelitis tends to occur in younger individuals in the setting of trauma and related surgery, and in older adults secondary to decubitus ulcers and infected total joint arthroplasties [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/5\">",
"     5",
"    </a>",
"    ]. Osteomyelitis associated with vascular insufficiency is usually seen in individuals with diabetes mellitus.",
"   </p>",
"   <p>",
"    Cierny and Mader classified osteomyelitis based on the affected portion of the bone, the physiologic status of the host and the local environment (",
"    <a class=\"graphic graphic_table graphicRef64015 \" href=\"UTD.htm?39/43/40636\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/7\">",
"     7",
"    </a>",
"    ]. This classification lends itself to the treatment and prognosis of osteomyelitis; stage 1 (medullary osteomyelitis) can usually be treated with antibiotics alone, while stages 2, 3 and 4 (superficial, localized and diffuse osteomyelitis) usually require aggressive debridement, antimicrobial therapy and subsequent orthopedic reconstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematogenous osteomyelitis is usually monomicrobial, while contiguous osteomyelitis may be either polymicrobial or monomicrobial. Staphylococcus aureus, coagulase-negative staphylococci, and aerobic gram-negative bacilli are the most common organisms; other pathogens including streptococci, enterococci, anaerobes, fungi and mycobacteria have also been implicated [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/4,8-10\">",
"     4,8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomyelitis can occur as a result of contiguous spread of infection to bone from adjacent soft tissues and joints, hematogenous seeding, or direct inoculation of infection into the bone as a result of trauma or surgery.",
"   </p>",
"   <p>",
"    Acute osteomyelitis typically presents with gradual onset of symptoms over several days. Patients usually present with dull pain at the involved site, with or without movement. Local findings (tenderness, warmth, erythema and swelling) and systemic symptoms (fever, rigors) may also be present. However, patients with osteomyelitis involving sites such as the hip, vertebrae, or pelvis tend to manifest few signs or symptoms other than pain. Subacute osteomyelitis generally presents with mild pain over several weeks, with minimal fever and few constitutional symptoms.",
"   </p>",
"   <p>",
"    Acute osteomyelitis can also present as septic arthritis. As noted above, in long bone hematogenous osteomyelitis, the most common site of infection is in the metaphysis. If infection spreading from the metaphysis breaks through the bone cortex within the capsular reflection of a joint, discharge of pus into the joint presents as a septic arthritis secondary to osteomyelitis. Joints in which the long bone metaphysis is within the joint capsular reflection include the knee, hip and shoulder. This is particularly important in infants, for whom the presence of transphyseal blood vessels and an immature growth plate allows early spread of bacteria from the metaphysis to the epiphysis of the bone and into the joint cavity. In these cases, infection that begins in the bone can spread into the joint quickly, leading to septic arthritis.",
"   </p>",
"   <p>",
"    Chronic osteomyelitis may present with pain, erythema, or swelling, sometimes in association with a draining sinus tract. The presence of a sinus tract is pathognomic of chronic osteomyelitis. The diagnosis of chronic osteomyelitis can be particularly challenging when prosthetic material, extensive skin or soft tissue ulceration, or ischemic changes due to vascular insufficiency are present [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/11\">",
"     11",
"    </a>",
"    ]. Deep or extensive ulcers that fail to heal after several weeks of appropriate ulcer care should raise suspicion for chronic osteomyelitis, particularly when such lesions overlie bony prominences [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Additional presentations of chronic osteomyelitis include nonhealing fractures and Brodie's abscess (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=see_link\">",
"     \"Management of diabetic foot lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=see_link&amp;anchor=H9#H9\">",
"     \"Hematogenous osteomyelitis in adults\", section on 'Brodie's abscess'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Diabetic patients with chronic osteomyelitis may present atypical physical findings. Diabetics who develop cutaneous ulcers often develop osteomyelitis before exposed bone is present on exam. If exposed bone is present, osteomyelitis is highly likely [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/11\">",
"     11",
"    </a>",
"    ]. If a diabetic foot ulcer is larger than 2 x 2 cm or if bone is palpable, osteomyelitis is so likely that additional noninvasive evaluation may not be needed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Probing to bone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probing for bone should be included in the initial assessment of all diabetic patients with infected pedal ulcers, since palpating bone on probing the pedal ulcer is sufficient for diagnosis of osteomyelitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. This was illustrated in a prospective study of 76 cases of infected foot ulcers; palpating bone on probing the pedal ulcer had a sensitivity, specificity, positive predictive value and negative predictive value of 66, 85, 89 and 56 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/14\">",
"     14",
"    </a>",
"    ]. If bone is palpated on probing, specialized roentgenographic and radionuclide tests to diagnose osteomyelitis are not necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Establishing an accurate diagnosis of osteomyelitis is critical, since the infection can require prolonged antibiotic therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aggressive surgical intervention. The reference standard for diagnosis of osteomyelitis is isolation of bacteria from a bone biopsy sample obtained via sterile technique, together with histologic findings of inflammation and osteonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/12\">",
"     12",
"    </a>",
"    ]. However, few studies evaluating adjunctive diagnostic modalities have used this standard.",
"   </p>",
"   <p>",
"    In addition to microbiologic and histopathologic evaluation, radiography and laboratory findings can be used. Radiography can be a useful tool although the interpretation of equivocal findings can be diagnostically challenging. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Laboratory findings are nonspecific and may include leukocytosis and elevated serum inflammatory markers (erythrocyte sedimentation rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C-reactive protein) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bone biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone biopsy (open or percutaneous) should be obtained for pathogen identification and to obtain susceptibility data when this is feasible; biopsy is also useful if the diagnosis of osteomyelitis is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. Cultures of bone biopsy material yield positive findings in up to 87 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/17\">",
"     17",
"    </a>",
"    ]. Swab culture or needle puncture data (eg, aspiration of material adjacent to the periosteum rather than bone) should not be used to establish an osteomyelitis pathogen, since the correlation between bone biopsy culture and these specimens is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Cessation of antibiotics 48 to 72 hours prior the procedure may increase the microbiological yield, but often bone cultures are positive regardless of prior antibiotic therapy because such infections occur in areas of simultaneous infection-induced bony infarction or ischemia.",
"   </p>",
"   <p>",
"    Open biopsy is preferable over needle biopsy. In circumstances where surgical debridement is required (such as decubitus ulcers or wounds with compromised vasculature), bone samples should be obtained at the time of surgical debridement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Percutaneous needle biopsy is an alternative to open biopsy, although this technique is less reliable than open biopsy given problems with sampling error. This was illustrated in a study including 31 diabetic patients in which culture results from needle biopsies were compared with open biopsies; the correlation between culture results obtained by needle biopsy and open biopsy was only 23 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, the sensitivity of needle biopsy can be particularly low in postoperative or posttraumatic settings [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/17,23\">",
"     17,23",
"    </a>",
"    ]. If the clinical suspicion for osteomyelitis is high in the setting of negative cultures from blood and needle biopsy, the needle biopsy should be repeated or an open biopsy performed.",
"   </p>",
"   <p>",
"    Percutaneous procedures should be performed through intact tissues (rather than inflamed or ulcerated skin) to obtain accurate culture results. Fluoroscopic or CT guidance for percutaneous procedures is preferable. Ideally the biopsy should be obtained prior to treatment with antimicrobial therapy. At least two specimens should be obtained, so that one can be sent for gram stain and culture (including aerobic, anaerobic, mycobacterial, and fungal cultures) and the other for histopathology.",
"   </p>",
"   <p>",
"    Bone biopsy may not be needed for patients with radiologic studies consistent with osteomyelitis in the setting of positive blood cultures or when prior bone cultures have been obtained in a patient with clear evidence for relapse of prior bone infection. In addition, it may be impractical to obtain a bone biopsy in some circumstances, since the biopsy site may heal poorly in the setting of advanced vascular disease. In such cases, empiric management should be pursued. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of the causative pathogen(s) is crucial and is best accomplished by bone biopsy (obtained surgically or by radiographically guided intervention). At least two specimens should be obtained, so that one can be sent for gram stain and culture (including aerobic, anaerobic, mycobacterial, and fungal cultures) and the other for histopathology [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cultures of superficial wounds and sinus tracts are of no value because the results do not correlate reliably with the pathogen in the underlying bone [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/20,23,25\">",
"     20,23,25",
"    </a>",
"    ]. Although sinus tract cultures may be of some use for prediction of osteomyelitis, if S. aureus or Salmonella spp are identified, in general, such cultures are not worthwhile [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In one report of 40 patients with chronic osteomyelitis, only 44 percent of sinus tract cultures contained the pathogen isolated from a deep surgical specimen [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/25\">",
"     25",
"    </a>",
"    ]. Isolation of S. aureus from the sinus tract culture had some predictive value, although the absence of S. aureus in the sinus tract did not preclude its presence on bone biopsy. Culturing other organisms is not predictive for those that will be found on bone biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sonication of explanted hardware may be useful to detect microorganisms that are highly adherent to fixation hardware, although this procedure is not routinely available in most microbiology laboratories [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/15,28,29\">",
"     15,28,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic features of osteomyelitis include necrotic bone with extensive resorption adjacent to an inflammatory exudate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/30\">",
"     30",
"    </a>",
"    ]. This area is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39269?source=see_link\">",
"     \"Pathogenesis of osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general role of radiographic studies in the diagnosis of osteomyelitis is discussed below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Suggested diagnostic approach'",
"    </a>",
"    below.) A more detailed discussion of radiographic modalities in the setting of suspected osteomyelitis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Laboratory tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory tests are usually nonspecific. Leukocytosis may be observed in the setting of acute osteomyelitis but is unlikely in the setting of chronic osteomyelitis. The erythrocyte sedimentation rate (ESR)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C-reactive protein (CRP) are usually elevated but may be normal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Blood cultures may be positive in about half of cases of acute osteomyelitis; their utility may be highest in the setting of hematogenous infection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/5\">",
"     5",
"    </a>",
"    ]. Blood cultures are also more likely to be positive in vertebral disease and when hematogenous osteomyelitis involves locations such at the clavicle or pubis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Positive blood cultures may obviate the need for invasive diagnostic testing if the organism isolated from blood is a pathogen likely to cause osteomyelitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Suggested diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial evaluation of patients with suspected osteomyelitis includes history and physical examination; predisposing factors or events should be elicited (such as underlying diabetes, vasculopathy, invasive procedures, injection drug use and other predisposing factors). If bone is palpated on probing of an infected diabetic pedal ulcer, this is sufficient for diagnosis of osteomyelitis; specialized roentgenographic tests are not necessary.",
"   </p>",
"   <p>",
"    If osteomyelitis is suspected based on clinical history and physical findings, plain radiographs of the involved area should be obtained along with laboratory evaluation (including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), white blood cell count, blood cultures). Findings of osteomyelitis on plain radiography should prompt bone biopsy for culture to guide therapy, unless blood cultures are positive for a likely pathogen (such as S. aureus, a gram-negative enteric rod, or P. aeruginosa).",
"   </p>",
"   <p>",
"    If plain radiographs are normal or have findings suggestive of osteomyelitis without characteristic features (in the clinical setting of risk factors such as diabetes, localized symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an elevated ESR), a more sophisticated imaging modality should be pursued. The type of imaging modality selected may depend upon the specific clinical circumstances and should be tailored accordingly for individual patients, in discussion with radiologist expertise if necessary.",
"   </p>",
"   <p>",
"    The following concepts may help guide radiographic modality selection (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=see_link\">",
"     \"Approach to imaging modalities in the setting of suspected osteomyelitis\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is diabetic and has symptoms referable to the foot, MRI is the test of choice.",
"     </li>",
"     <li>",
"      If the patient has symptoms referable to the spine, MRI is the test of choice to evaluate for vertebral osteomyelitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If MRI is not available, CT is the alternative test of choice.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If metal hardware precludes MRI or CT, a nuclear study is the test of choice. The limitations of nuclear studies are discussed separately and should be considered in interpretation of results.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evidence of osteomyelitis by these imaging modalities should prompt a bone biopsy to confirm the diagnosis and to guide antimicrobial therapy. In the absence of osteomyelitis by these alternative imaging modalities, osteomyelitis is unlikely.",
"   </p>",
"   <p>",
"    If blood cultures and needle aspirate cultures are negative and the clinical suspicion for osteomyelitis remains high on the basis of clinical and radiographic findings, repeat bone biopsy (either percutaneous or open) should be performed. If this specimen is also nondiagnostic, an empiric antimicrobial regimen should be initiated against common gram-positive and gram-negative bacterial pathogens (",
"    <a class=\"graphic graphic_table graphicRef58877 \" href=\"UTD.htm?42/10/43179\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    If there is evidence of soft tissue infection over a bony surface without radiographic evidence of osteomyelitis, an empiric course of therapy for soft tissue infection may be appropriate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of osteomyelitis includes consideration of issues related to debridement as well as antibiotic selection and duration. Adjunctive therapies and complications are also discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Debridement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomyelitis frequently requires both surgical therapy for debridement of necrotic material together with antimicrobial therapy for eradication of infection. In certain circumstances, surgical treatment may also require hardware placement or removal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10646?source=see_link\">",
"     \"Treatment and prevention of osteomyelitis following trauma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=see_link\">",
"     \"Management of diabetic foot lesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Antibiotic selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy should be tailored to culture and susceptibility findings. If culture results are not obtainable, broad spectrum empiric therapy should be administered. Bone penetration data are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef53786 \" href=\"UTD.htm?9/49/10012\">",
"     table 3",
"    </a>",
"    ). Suggested antibiotic regimens are outlined in the Table (",
"    <a class=\"graphic graphic_table graphicRef58877 \" href=\"UTD.htm?42/10/43179\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/35-40\">",
"     35-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For treatment of osteomyelitis due to gram-negative organisms fluoroquinolones are excellent agents (if susceptibility testing confirms their sensitivity to these agent) since fluoroquinolones have high bone penetration, even with oral administration [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteomyelitis due to methicillin susceptible Staphylococcus aureus (MSSA) is frequently treated with parenteral therapy. Parenteral agents for treatment of MSSA infections are as outlined in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\", section on 'Methicillin-susceptible S. aureus (MSSA)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral regimens for MSSA may also be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/42-44\">",
"     42-44",
"    </a>",
"    ]. In one study of 50 patients with chronic osteomyelitis treated with antibiotics following debridement, oral therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    -cotrimoxazole demonstrated comparable efficacy to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/45/31446?source=see_link\">",
"     cloxacillin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/42\">",
"     42",
"    </a>",
"    ]. In another study including 20 patients with osteomyelitis, prolonged oral therapy with rifampin-cotrimoxazole or rifampin-linezolid was equally effective; cure rates were 78 and 89 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the importance of biofilms in the pathophysiology of staphylococcal osteomyelitis (particularly in the setting of hardware), some experts favor use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    for activity against microorganisms in biofilms, although others oppose its use given limited evidence for improved outcomes over standard antimicrobial therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/45\">",
"     45",
"    </a>",
"    ]. If used for treatment of osteomyelitis, rifampin must be combined with another active antibacterial agent because rapid emergence of resistance in the setting of rifampin monotherapy is common. In addition, caution should be exercised regarding the risk of potential interactions between rifampin and other concurrently administered pharmaceutical agents [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=see_link\">",
"     \"Rifampin and other rifamycins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The approach to the treatment of osteomyelitis due to methicillin-resistant S. aureus is discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The approach to the treatment of osteomyelitis due to Pseudomonas is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=see_link\">",
"     \"Pseudomonas aeruginosa skin, soft tissue, and bone infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy of osteomyelitis requires a prolonged duration of treatment. This may be in part due to the observation in experimental models that S. aureus can persist following digestion by osteoblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/4,46\">",
"     4,46",
"    </a>",
"    ]. In addition, antibiotic penetration into bone may be unreliable in some patients, particularly in those with vasculopathy or prior extensive scarring from trauma.",
"   </p>",
"   <p>",
"    The optimal duration of antibiotic therapy is not certain; most experts favor continuing parenteral antimicrobial therapy at least until debrided bone has been covered by vascularized soft tissue, which is usually at least six weeks from the last debridement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/47\">",
"     47",
"    </a>",
"    ]. Antimicrobial therapy may be administered on an outpatient basis via a long-term intravenous catheter with close monitoring (depending on the antibiotic agent, monitoring may include weekly serum drug levels, renal function, liver function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematologic function).",
"   </p>",
"   <p>",
"    Serial measurements of serum inflammatory markers (erythrocyte sedimentation rate",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C-reactive protein) can be useful. If these test results have not normalized by the end of the planned treatment course, further clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiographic investigation may be pursued [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If orthopedic hardware that is known or presumed to be infected must be retained indefinitely, long-term antibiotic suppression with an oral agent may be warranted. Such long term oral therapy is usually preceded by parenteral therapy until clinical signs of acute infection have resolved. Note that the duration of preceding parenteral therapy may be shorter in such cases than when definitive cure is the goal.",
"   </p>",
"   <p>",
"    If the osteomyelitic bone has been fully resected (as when amputation is performed), a much shorter course of antibiotic therapy may be sufficient. In such cases, antibiotic therapy can usually be discontinued when operative wounds are healing without signs of infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Adjunctive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive therapies for osteomyelitis include hyperbaric oxygen (HBO) and negative pressure wound therapy (NPWT), also called vacuum-assisted closure. Osteomyelitis is often associated with reduced intraosseus blood flow and consequent reduced oxygen tension in infected bony tissue. This in turn may limit neutrophil and macrophage activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. As a result, hyperbaric oxygen may be a useful adjunctive therapy in a small percentage of patients with refractory osteomyelitis. In a series including 142 patients with refractory osteomyelitis treated with HBO, successful healing without relapse was observed in 73 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=see_link\">",
"     \"Hyperbaric oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NPWT is discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=see_link\">",
"     \"Negative pressure wound therapy\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of appropriate therapy acute osteomyelitis can be associated with disabling or life threatening complications. Suppurative infection may involve contiguous structures such as the joints and soft tissues, leading to sinus tract formation. Osteolysis and pathologic fractures have been described, although such complications are exceedingly rare with early recognition and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/53\">",
"     53",
"    </a>",
"    ]. Infrequently, hematogenous spread and sepsis can occur, although it may be difficult to determine whether the primary source of infection is the bloodstream or bone.",
"   </p>",
"   <p>",
"    Sinus tract formation may be associated with neoplasms, especially in the setting of longstanding infection (range 4 to 50 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/54\">",
"     54",
"    </a>",
"    ]. Squamous cell carcinoma is the most common tumor associated with chronic osteomyelitis; other tumors have been reported including fibrosarcoma, myeloma, lymphoma, plasmacytoma, angiosarcoma, rhabdomyosarcoma, and malignant fibrous histiocytoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4649/abstract/54-61\">",
"     54-61",
"    </a>",
"    ]. Most patients with neoplasm have a history of repeated surgical interventions. Development of a malignant tumor is heralded by an enlarging mass, increasing pain, foul-smelling drainage, bleeding, or radiographic evidence of bone destruction. Therefore, recalcitrant infection that does not respond to conventional therapy should prompt biopsy evaluation for malignancy from multiple sites (including the ulcer, sinus tract and underlying bone). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Chronic inflammation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/15/15601?source=see_link\">",
"       \"Patient information: Osteomyelitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteomyelitis occurs either as a result of hematogenous seeding, contiguous spread of infection to bone from adjacent soft tissues and joints, or direct inoculation of infection into the bone as a result of trauma or surgery. Hematogenous osteomyelitis is usually monomicrobial, while osteomyelitis due to contiguous spread or direct inoculation is usually polymicrobial. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Staphylococcus aureus, coagulase-negative staphylococci and aerobic gram-negative bacilli are the most common organisms; other pathogens including streptococci, enterococci, anaerobes, fungi and mycobacteria have also been implicated. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute osteomyelitis typically presents with gradual onset of pain over several days. Local findings (tenderness, warmth, erythema and swelling) and systemic symptoms (fever, rigors) may also be present. Chronic osteomyelitis tends to occur in the setting of previous osteomyelitis and presents with recurrent pain, erythema or swelling, sometimes in association with a draining sinus tract. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most cases of diabetic foot osteomyelitis occur in the setting of ulcers that develop in the absence of exposed bone. If a diabetic foot ulcer is larger than 2 x 2 cm or bone is palpable, osteomyelitis is so likely that additional noninvasive evaluation may not be needed. Positive results of a probe-to-bone test are sufficient for diagnosis of osteomyelitis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Probing to bone'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Establishing an accurate diagnosis of osteomyelitis is critical, since the infection can require prolonged antibiotic therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aggressive surgical intervention. An integrated diagnostic approach incorporating the various diagnostic tools is outlined in detail above (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Suggested diagnostic approach'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The reference standard for diagnosis of osteomyelitis is isolation of bacteria from a bone biopsy sample obtained via sterile technique, together with histologic findings of inflammation and osteonecrosis. Bone biopsy may not be needed for patients with radiologic studies consistent with osteomyelitis in the setting of positive blood cultures. Cultures obtained from sinus tract drainage are not reliable. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Open biopsy is preferable over needle biopsy; bone samples should be obtained at the time of surgical debridement if performed. Percutaneous needle biopsy is an alternative to open biopsy; ideally it should be performed via intact tissues and under radiographic guidance to optimize yield. Bone biopsy should be obtained prior to treatment with antimicrobial therapy whenever possible. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Bone biopsy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leukocytosis may be observed in the setting of acute osteomyelitis but is less common in the setting of chronic osteomyelitis. The erythrocyte sedimentation rate (ESR)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C-reactive protein (CRP) are usually elevated but may be normal. Blood cultures are most likely to be positive in the setting of hematogenous infection and vertebral disease; positive blood cultures may obviate the need for invasive diagnostic testing. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of osteomyelitis often requires both surgical debridement of necrotic material and antimicrobial therapy for eradication of infection. The optimal duration of antibiotic therapy is not certain; we suggest continuing parenteral antimicrobial therapy at least six weeks from the last debridement (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Suggested antibiotic regimens are outlined in the Table (",
"      <a class=\"graphic graphic_table graphicRef58877 \" href=\"UTD.htm?42/10/43179\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Berbari EF, Steckelberg JM, Osmon DR. Osteomyelitis. In: Principles and Practice of Infectious Diseases, 6, Mandell GL et al (eds) (Ed), Elsevier, Philadelphia 2005. p.1322.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/2\">",
"      Lew DP, Waldvogel FA. Osteomyelitis. Lancet 2004; 364:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/3\">",
"      Mader JT, Shirtliff M, Calhoun JH. Staging and staging application in osteomyelitis. Clin Infect Dis 1997; 25:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/4\">",
"      Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med 1997; 336:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/5\">",
"      Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med 1970; 282:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/6\">",
"      David R, Barron BJ, Madewell JE. Osteomyelitis, acute and chronic. Radiol Clin North Am 1987; 25:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/7\">",
"      Cierny G 3rd, Mader JT, Penninck JJ. A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res 2003; :7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/8\">",
"      Norden CW. Experimental chronic staphylococcal osteomyelitis in rabbits: treatment with rifampin alone and in combination with other antimicrobial agents. Rev Infect Dis 1983; 5 Suppl 3:S491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/9\">",
"      Henry NK, Rouse MS, Whitesell AL, et al. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med 1987; 82:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/10\">",
"      Pineda C, Vargas A, Rodr&iacute;guez AV. Imaging of osteomyelitis: current concepts. Infect Dis Clin North Am 2006; 20:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/11\">",
"      Newman LG, Waller J, Palestro CJ, et al. Unsuspected osteomyelitis in diabetic foot ulcers. Diagnosis and monitoring by leukocyte scanning with indium in 111 oxyquinoline. JAMA 1991; 266:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/12\">",
"      Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/13\">",
"      Butalia S, Palda VA, Sargeant RJ, et al. Does this patient with diabetes have osteomyelitis of the lower extremity? JAMA 2008; 299:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/14\">",
"      Grayson ML, Gibbons GW, Balogh K, et al. Probing to bone in infected pedal ulcers. A clinical sign of underlying osteomyelitis in diabetic patients. JAMA 1995; 273:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/15\">",
"      Donlan RM. New approaches for the characterization of prosthetic joint biofilms. Clin Orthop Relat Res 2005; :12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/16\">",
"      White LM, Schweitzer ME, Deely DM, Gannon F. Study of osteomyelitis: utility of combined histologic and microbiologic evaluation of percutaneous biopsy samples. Radiology 1995; 197:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/17\">",
"      Howard CB, Einhorn M, Dagan R, et al. Fine-needle bone biopsy to diagnose osteomyelitis. J Bone Joint Surg Br 1994; 76:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/18\">",
"      Mader JT, Ortiz M, Calhoun JH. Update on the diagnosis and management of osteomyelitis. Clin Podiatr Med Surg 1996; 13:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/19\">",
"      Wheat J. Diagnostic strategies in osteomyelitis. Am J Med 1985; 78:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/20\">",
"      Senneville E, Melliez H, Beltrand E, et al. Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis: concordance with ulcer swab cultures. Clin Infect Dis 2006; 42:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/21\">",
"      Senneville E, Morant H, Descamps D, et al. Needle puncture and transcutaneous bone biopsy cultures are inconsistent in patients with diabetes and suspected osteomyelitis of the foot. Clin Infect Dis 2009; 48:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/22\">",
"      Darouiche RO, Landon GC, Klima M, et al. Osteomyelitis associated with pressure sores. Arch Intern Med 1994; 154:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/23\">",
"      Perry CR, Pearson RL, Miller GA. Accuracy of cultures of material from swabbing of the superficial aspect of the wound and needle biopsy in the preoperative assessment of osteomyelitis. J Bone Joint Surg Am 1991; 73:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/24\">",
"      Gross T, Kaim AH, Regazzoni P, Widmer AF. Current concepts in posttraumatic osteomyelitis: a diagnostic challenge with new imaging options. J Trauma 2002; 52:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/25\">",
"      Mackowiak PA, Jones SR, Smith JW. Diagnostic value of sinus-tract cultures in chronic osteomyelitis. JAMA 1978; 239:2772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/26\">",
"      Khatri G, Wagner DK, Sohnle PG. Effect of bone biopsy in guiding antimicrobial therapy for osteomyelitis complicating open wounds. Am J Med Sci 2001; 321:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/27\">",
"      Zuluaga AF, Galvis W, Jaimes F, Vesga O. Lack of microbiological concordance between bone and non-bone specimens in chronic osteomyelitis: an observational study. BMC Infect Dis 2002; 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/28\">",
"      Trampuz A, Piper KE, Hanssen AD, et al. Sonication of explanted prosthetic components in bags for diagnosis of prosthetic joint infection is associated with risk of contamination. J Clin Microbiol 2006; 44:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/29\">",
"      Trampuz A, Piper KE, Jacobson MJ, et al. Sonication of removed hip and knee prostheses for diagnosis of infection. N Engl J Med 2007; 357:654.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson's Pathology, 10, Danjanov I, Linder J (Eds), Mosby Yearbook, 1996. p.2605.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/31\">",
"      Perry M. Erythrocyte sedimentation rate and C reactive protein in the assessment of suspected bone infection--are they reliable indices? J R Coll Surg Edinb 1996; 41:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/32\">",
"      Unkila-Kallio L, Kallio MJ, Eskola J, Peltola H. Serum C-reactive protein, erythrocyte sedimentation rate, and white blood cell count in acute hematogenous osteomyelitis of children. Pediatrics 1994; 93:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/33\">",
"      Nolla JM, Ariza J, G&oacute;mez-Vaquero C, et al. Spontaneous pyogenic vertebral osteomyelitis in nondrug users. Semin Arthritis Rheum 2002; 31:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/34\">",
"      Patzakis MJ, Rao S, Wilkins J, et al. Analysis of 61 cases of vertebral osteomyelitis. Clin Orthop Relat Res 1991; :178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/35\">",
"      Mader JT, Cantrell JS, Calhoun J. Oral ciprofloxacin compared with standard parenteral antibiotic therapy for chronic osteomyelitis in adults. J Bone Joint Surg Am 1990; 72:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/36\">",
"      Davey PG, Rowley DR, Phillips GA. Teicoplanin--home therapy for prosthetic joint infections. Eur J Surg Suppl 1992; :23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/37\">",
"      Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis 2005; 9:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/38\">",
"      Black J, Hunt TL, Godley PJ, Matthew E. Oral antimicrobial therapy for adults with osteomyelitis or septic arthritis. J Infect Dis 1987; 155:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/39\">",
"      Gentry LO, Rodriguez-Gomez G. Ofloxacin versus parenteral therapy for chronic osteomyelitis. Antimicrob Agents Chemother 1991; 35:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/40\">",
"      Lew DP, Waldvogel FA. Quinolones and osteomyelitis: state-of-the-art. Drugs 1995; 49 Suppl 2:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/41\">",
"      Huddleston PM, Steckelberg JM, Hanssen AD, et al. Ciprofloxacin inhibition of experimental fracture healing. J Bone Joint Surg Am 2000; 82:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/42\">",
"      Euba G, Murillo O, Fern&aacute;ndez-Sab&eacute; N, et al. Long-term follow-up trial of oral rifampin-cotrimoxazole combination versus intravenous cloxacillin in treatment of chronic staphylococcal osteomyelitis. Antimicrob Agents Chemother 2009; 53:2672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/43\">",
"      Nguyen S, Pasquet A, Legout L, et al. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 2009; 15:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/44\">",
"      Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis 2012; 54:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/45\">",
"      Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/46\">",
"      Norden CW. Lessons learned from animal models of osteomyelitis. Rev Infect Dis 1988; 10:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/47\">",
"      Guglielmo BJ, Luber AD, Paletta D Jr, Jacobs RA. Ceftriaxone therapy for staphylococcal osteomyelitis: a review. Clin Infect Dis 2000; 30:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/48\">",
"      Trampuz A, Zimmerli W. Diagnosis and treatment of infections associated with fracture-fixation devices. Injury 2006; 37 Suppl 2:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/49\">",
"      Mader JT, Guckian JC, Glass DL, Reinarz JA. Therapy with hyperbaric oxygen for experimental osteomyelitis due to Staphylococcus aureus in rabbits. J Infect Dis 1978; 138:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/50\">",
"      Haas DW, McAndrew MP. Bacterial osteomyelitis in adults: evolving considerations in diagnosis and treatment. Am J Med 1996; 101:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/51\">",
"      Chen CE, Ko JY, Fu TH, Wang CJ. Results of chronic osteomyelitis of the femur treated with hyperbaric oxygen: a preliminary report. Chang Gung Med J 2004; 27:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/52\">",
"      Calhoun JH, Cobos JA, Mader JT. Does hyperbaric oxygen have a place in the treatment of osteomyelitis? Orthop Clin North Am 1991; 22:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/53\">",
"      Gelfand MS, Cleveland KO, Heck RK, Goswami R. Pathological fracture in acute osteomyelitis of long bones secondary to community-acquired methicillin-resistant Staphylococcus aureus: two cases and review of the literature. Am J Med Sci 2006; 332:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/54\">",
"      Altay M, Arikan M, Yildiz Y, Saglik Y. Squamous cell carcinoma arising in chronic osteomyelitis in foot and ankle. Foot Ankle Int 2004; 25:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/55\">",
"      Akbarnia BA, Wirth CR, Colman N. Fibrosarcoma arising from chronic osteomyelitis. Case report and review of the literature. J Bone Joint Surg Am 1976; 58:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/56\">",
"      Bacchini P, Calderoni P, Gherlinzoni F, Gualtieri G. Angiosarcoma in chronic osteomyelitis. Ital J Orthop Traumatol 1984; 10:393.",
"     </a>",
"    </li>",
"    <li>",
"     Campanacci M. Carcinomas and sarcomas on chronic osteomyelitis. In: Bone and Soft Tissue Tumors, Wien, Springer-Verlag, 1990. p.661.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/58\">",
"      Czerwiski E, Skolarczyk A, Frasik W. Malignant fibrous histiocytoma in the course of chronic osteomyelitis. Arch Orthop Trauma Surg 1991; 111:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/59\">",
"      Johnston RM, Miles JS. Sarcomas arising from chronic osteomyelitic sinuses. A report of two cases. J Bone Joint Surg Am 1973; 55:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/60\">",
"      Kennedy C, Stoker DJ. Malignant fibrous histiocytoma complicating chronic osteomyelitis. Clin Radiol 1990; 41:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4649/abstract/61\">",
"      McGrory JE, Pritchard DJ, Unni KK, et al. Malignant lesions arising in chronic osteomyelitis. Clin Orthop Relat Res 1999; :181.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7668 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-41.222.196.37-062E1C4994-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4649=[""].join("\n");
var outline_f4_34_4649=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Probing to bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bone biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cultures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Histopathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Laboratory tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Suggested diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Debridement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Antibiotic selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Adjunctive therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7668\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7668|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/43/40636\" title=\"table 1\">",
"      Osteomyelitis staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/10/43179\" title=\"table 2\">",
"      Treatment of osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/49/10012\" title=\"table 3\">",
"      Bone penetration for selected antibiotics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12071?source=related_link\">",
"      Approach to imaging modalities in the setting of suspected osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/33/538?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/46/42726?source=related_link\">",
"      Hematogenous osteomyelitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5448?source=related_link\">",
"      Hyperbaric oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/28/37321?source=related_link\">",
"      Management of diabetic foot lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/41/26264?source=related_link\">",
"      Negative pressure wound therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/22/39269?source=related_link\">",
"      Pathogenesis of osteomyelitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/15/15601?source=related_link\">",
"      Patient information: Osteomyelitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=related_link\">",
"      Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/26/24998?source=related_link\">",
"      Rifampin and other rifamycins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10646?source=related_link\">",
"      Treatment and prevention of osteomyelitis following trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=related_link\">",
"      Vertebral osteomyelitis and discitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_34_4650="Treatment of ulcerative colitis in children and adolescents";
var content_f4_34_4650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of ulcerative colitis in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/34/4650/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/34/4650/contributors\">",
"     Athos Bousvaros, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/34/4650/contributors\">",
"     Alan Leichtner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/34/4650/contributors\">",
"     Tyler Burpee, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/34/4650/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/34/4650/contributors\">",
"     George D Ferry, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/34/4650/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/34/4650/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/34/4650/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/34/4650/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory bowel disease (IBD) is comprised of two major disorders, ulcerative colitis (UC) and Crohn disease (CD). These disorders have distinct pathologic and clinical characteristics (",
"    <a class=\"graphic graphic_table graphicRef74564 \" href=\"UTD.htm?40/50/41772\">",
"     table 1",
"    </a>",
"    ), but their pathogenesis remains poorly understood. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=see_link\">",
"     \"Definition, epidemiology, and risk factors in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 20 percent of patients with IBD develop symptoms as children or teenagers (younger than age 18). The development of IBD early in life has implications that are not encountered in adults. Clinicians caring for children and adolescents with CD or UC not only must treat the underlying disease and its complications but must also carefully monitor linear growth, skeletal development, and puberty. In addition, many children are unable to swallow pills or refuse topical enema therapy, rendering compliance with therapies typically used for older patients unfeasible.",
"   </p>",
"   <p>",
"    The treatment of UC in children and adolescents is reviewed here. The clinical manifestations and diagnosis of inflammatory bowel disease, differentiation between UC and CD, and the treatment of ulcerative colitis in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"     \"Management of severe ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ulcerative colitis (UC) in children principally occurs in teenagers but can also occur earlier in life [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/1\">",
"     1",
"    </a>",
"    ]. The presentation in children is similar to that in adults. Affected patients usually present with a subacute illness characterized by diarrhea frequently containing blood, weakness, anemia, abdominal pain, and sometimes weight loss. Those with a more fulminant presentation (acute severe UC) also may have severe abdominal pain, frankly bloody diarrhea, tenesmus, fever, leukocytosis, and hypoalbuminemia. Some children have more insidious onset of symptoms, with non-bloody diarrhea and sometimes poor weight gain prior to the development of more overt symptoms or signs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2794?source=see_link\">",
"     \"Growth failure and poor weight gain in children with inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link&amp;anchor=H184210419#H184210419\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extraintestinal manifestations of inflammatory bowel disease may precede the gastrointestinal symptoms and are somewhat different in UC as compared with Crohn&rsquo;s disease (CD), as is described in detail separately [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link&amp;anchor=H1351752#H1351752\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\", section on 'Extraintestinal manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23813219\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of UC is made on the basis of clinical, laboratory, and",
"    <span class=\"nowrap\">",
"     endoscopic/histological",
"    </span>",
"    information. Clinical manifestations are as described above. The steps in diagnosis, including the differentiation between UC and Crohn&rsquo;s disease (CD), are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MEDICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike Crohn&rsquo;s disease (CD), UC is limited to the colon; as a result, surgery essentially \"cures\" the disease. However, most patients do not desire surgery (at least initially), and colectomy in UC results in either a permanent ileostomy or the need for further surgery to create an ileoanal reservoir [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/4\">",
"     4",
"    </a>",
"    ]. Colectomy and ileoanal reservoirs may have significant complications, including bowel obstruction, pouchitis, fistulizing disease, and reduced fertility. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32759?source=see_link\">",
"     \"Pouchitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these reasons, medical therapy should be used to control the disease and allow the patient to retain the colon as long as feasible. The basic principles of medical therapy are similar to those in adults with UC, although there is greater concern with steroid-induced side effects because of impairment in growth. Patients who have medically unresponsive disease, experience intolerable drug side effects, or are at high risk of developing cancer should be referred for surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"     \"Management of severe ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Proctitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with disease limited to the rectum (ie, inflammation that extends no more than 15 cm proximal to the anal verge) are good candidates for receiving topical therapy. Moderately active inflammation is treated best with topical (rectal)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    enemas or foam, or a topical 5-aminosalicylate (5-ASA, eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    ) enema or suppository preparation. A combination of topical and oral mesalamine is also useful in inducing remission and may be necessary if topical therapy alone is ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/5\">",
"     5",
"    </a>",
"    ]. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    can treat proctosigmoiditis effectively and may have fewer side effects than conventional corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/6\">",
"     6",
"    </a>",
"    ], but it is not currently available in the United States. If topical administration of medication is not possible due to parent or child refusal, oral administration of 5-aminosalicylate medication is a reasonable alternative, although oral 5-ASA requires more frequent dosing and is probably less effective than topical 5-ASA for this disease location (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link&amp;anchor=H194953227#H194953227\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\", section on '5-ASA formulations'",
"    </a>",
"    ). Less commonly, immunosuppressive therapy or colectomy is required for refractory proctitis. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Refractory disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link\">",
"     \"Management of mild to moderate ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once a patient's symptoms are controlled, remission generally can be maintained either with topical or oral aminosalicylates [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/7\">",
"     7",
"    </a>",
"    ]. The choice of medication and route of administration depends on the child and family&rsquo;s preference and on the patient&rsquo;s individual responsiveness to the treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link\">",
"     \"Management of mild to moderate ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Relapses in proctitis may be caused by poor adherence to therapy or to proximal extension of the disease over time. As an example, in a study of 38 children with ulcerative proctitis, proximal extension to left-sided colitis or pancolitis occurred in 29 percent overall and in 7 of 13 (54 percent) followed for more than five years, and two children required colectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, patients with proctitis and recurrent or refractory symptoms should be reevaluated endoscopically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Left-sided disease and pancolitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with UC are more likely than adults to present with pancolitis (approximately 80 percent in children versus 40 to 50 percent in adults) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/9\">",
"     9",
"    </a>",
"    ]. Initial therapy should be adjusted to the severity of presentation.",
"   </p>",
"   <p>",
"    A pediatric ulcerative colitis activity index (PUCAI) has been developed to assess the activity of disease (",
"    <a class=\"graphic graphic_table graphicRef69607 \" href=\"UTD.htm?35/43/36540\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/10\">",
"     10",
"    </a>",
"    ]. Numerical scores are given to symptoms of abdominal pain, rectal bleeding, stool consistency, stool frequency, presence of nocturnal stools, and activity level, adding to a maximum score of 85. Of these components, rectal bleeding has the most impact on the score, contributing up to 30 points. PUCAI scores are interpreted as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 to 9 &ndash; remission",
"     </li>",
"     <li>",
"      10 to 34 &ndash; mild disease",
"     </li>",
"     <li>",
"      35 to 64 &ndash; moderate disease",
"     </li>",
"     <li>",
"      65 to 85 &ndash; severe disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Mild disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with mild disease extending beyond the rectum (ie, fewer than four bowel movements daily without significant abdominal pain, anemia, or fever, PUCAI score 10 to 34), we suggest a trial of oral 5-ASA (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ) as first-line therapy. These drugs are moderately effective for mild disease and have fewer side effects than systemic corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/11\">",
"     11",
"    </a>",
"    ]. Mild left-sided disease may also respond to topical treatment alone (eg, mesalamine enemas), and a trial of this approach is reasonable in patients who are willing and adherent to enema treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/12\">",
"     12",
"    </a>",
"    ]. However, we find that most children and families prefer orally administered medications and are more likely to adhere to an oral regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oral 5-ASA preparations include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       Mesalamine",
"      </a>",
"      , which is typically given at a dose of 50 to 75",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      divided twice or three times daily (up to the adult dose of 4.8 grams per day). Limited information in adults suggests that sustained-release preparations of mesalamine (MMX mesalamine) also are effective.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      , which is given as an initial dose of 25",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      divided twice or three times daily, and advanced over one week to the full dose of 50 to 75",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      divided twice or three times daily. In larger children and adults, initial doses are 1 to 2",
"      <span class=\"nowrap\">",
"       grams/day,",
"      </span>",
"      titrated to 4 to 6",
"      <span class=\"nowrap\">",
"       grams/day,",
"      </span>",
"      divided three to four times daily. Supplemental",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      should be given to all patients taking sulfasalazine. Sulfasalazine has the advantage that it can be compounded into a liquid, and easily taken by children. However,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      and other 5-ASA agents have fewer side effects than sulfasalazine, including reduced headache and skin rashes.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/53/8021?source=see_link\">",
"       Balsalazide",
"      </a>",
"      , which is split in the colon by colonic bacteria, releasing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      . Typical doses in children are 75 to 100",
"      <span class=\"nowrap\">",
"       mg/kg/dose",
"      </span>",
"      given three times daily, and 6.75 grams divided three times daily in adults. In adults, the initial dose is typically given for eight weeks, then reduced to a maintenance dose of 3 to 4 grams daily, divided into two doses. The adult dose cited above was used in a small clinical trial in children 5 to 17 years of age; there were no significant differences in adverse effects or efficacy as compared with a smaller dose of 2.25",
"      <span class=\"nowrap\">",
"       grams/day,",
"      </span>",
"      but this may have been because of the small size of the trial [",
"      <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/13\">",
"       13",
"      </a>",
"      ]. Studies in adults suggest that it may be more effective than mesalamine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link&amp;anchor=H194953227#H194953227\">",
"       \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\", section on '5-ASA formulations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/3/43059?source=see_link\">",
"       Olsalazine",
"      </a>",
"      , which is also split in the colon to release",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      (similar to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/53/8021?source=see_link\">",
"       balsalazide",
"      </a>",
"      ). Typical doses in adults are 1",
"      <span class=\"nowrap\">",
"       gram/day",
"      </span>",
"      divided twice daily. A dose of 30",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      has been used in children in a clinical trial [",
"      <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Few studies have compared the efficacy of different aminosalicylates in children. Most experience in children has been with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , but these drugs have not been directly compared. In our practice, we usually use mesalamine as the first-line choice because sulfasalazine has a higher risk for allergic reactions and side effects such as photosensitivity due to the sulfonamide component. However, sulfasalazine has the advantage of lower cost and is a reasonable alternative in patients without a history of sulfa sensitivity, provided that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplements are also given. Also, sulfasalazine may be helpful in managing IBD-associated arthritis, if present [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most children over five years of age can learn how to swallow pills. Techniques for learning to swallow pills, including practicing with small pieces of food or candy, are outlined on a",
"    <a class=\"external\" href=\"file://www.ccfa.org/assets/pdfs/PillSwallowing.pdf\">",
"     brochure",
"    </a>",
"    from the Crohn's and Colitis Foundation of America. Options for children who cannot swallow pills despite this training include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       Mesalamine",
"      </a>",
"      capsules (eg, Pentasa&reg;), which can be opened into water or acidic food (consumed immediately and without chewing)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      , which can be made into a suspension by a formulating pharmacy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Slight exacerbation of watery diarrhea is common during the first few weeks of therapy with 5-ASA preparations, and particularly with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/3/43059?source=see_link\">",
"     olsalazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/53/8021?source=see_link\">",
"     balsalazide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, approximately 3 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    have a paradoxical worsening of their colitis symptoms, with increased cramps, diarrhea, and rectal bleeding. In this case, patients should be considered allergic to mesalamine and it should no longer be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link&amp;anchor=H13#H13\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\", section on '5-aminosalicylic acid (5-ASA)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Moderate disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with moderate disease (PUCAI score of 35 to 64) typically have more than four bloody bowel movements per day and intermittent abdominal pain, but no tenesmus or fever. For such patients we suggest oral corticosteroid therapy.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    (1 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, to a maximum of 40 to 60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    usually induces remission [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/16\">",
"     16",
"    </a>",
"    ]. Steroid-responsive patients usually show some clinical signs of improvement within one week of oral treatment.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    (adult dose 9 mg daily in the morning for eight weeks) has been suggested as an alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    because it has fewer side effects. However, a meta-analysis of three studies in adults with UC found that budesonide was no more effective than placebo, and was significantly less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=see_link&amp;anchor=H432583317#H432583317\">",
"     \"Management of mild to moderate ulcerative colitis\", section on 'Treatment of mildly or moderately active disease'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    For patients who are unresponsive to oral steroid therapy within one to two weeks, or those with poor fluid intake, severe abdominal pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lack of nutrition, we suggest hospitalization and intravenous corticosteroids. We use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose, given every 12 hours to a maximum of 60",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    in two divided doses). Bowel rest and intravenous fluids have not been shown to speed remission but may relieve symptoms of abdominal cramping associated with oral intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H890512\">",
"    <span class=\"h4\">",
"     Steroid-responsive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;If clinical improvement is observed after one week of intravenous corticosteroid treatment, the patient can be transitioned to oral corticosteroids and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    or another 5-aminosalicylate) (see",
"    <a class=\"local\" href=\"#H23813502\">",
"     'Maintenance of remission'",
"    </a>",
"    below). A full dose of oral corticosteroids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day to a maximum of 40 to 60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    usually is continued for two to four weeks, then gradually tapered over the next two months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H889980\">",
"    <span class=\"h4\">",
"     Steroid-dependent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have been on high-dose steroids for more than two to three months or daily steroids for four to six months, or for those who frequently flare when the corticosteroid dose is reduced, either an immunomodulator or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    can be utilized to avoid the high morbidity associated with prolonged corticosteroid therapy. We generally choose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    (also known as 6-mercaptopurine, 6-MP) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/12\">",
"     12",
"    </a>",
"    ] because of the loss of response over time seen with infliximab [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior to initiating treatment with either 6-MP or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , it is important to measure the patient&rsquo;s thiopurine methyltransferase activity (TPMT phenotype) activity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    genotype (TPMT genotype). This is because about 10 percent of individuals are heterozygotes for a TPMT mutation and are at risk for toxicity if standard dosing of these drugs are used. Moreover, about 0.3 percent of individuals are homozygotes for a TPMT mutation, in which case treatment with either 6-MP or azathioprine is contraindicated because of a high risk for bone marrow suppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=see_link\">",
"     \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with normal TPMT activity or genotype, we dose 6-MP at 1 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    at 2 to 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. In one nonrandomized study, the addition of 6-MP permitted the discontinuation of steroids in 75 percent of 20 children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/20\">",
"     20",
"    </a>",
"    ]. In a more recent observational study that included nearly 1500 children with UC, 50 percent of those treated with 6-MP or azathioprine were in remission without corticosteroids one year later [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/21\">",
"     21",
"    </a>",
"    ]. Only subjects without previous or concomitant treatment with biologic agents or calcineurin inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) were included in this study.",
"   </p>",
"   <p>",
"    All patients treated with 6-MP or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    should undergo routine monitoring for the possible toxicities of bone marrow suppression and hepatotoxicity. We use the same approach to monitoring as for patients with Crohn&rsquo;s disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monitoring to detect bone marrow toxicity and hepatotoxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of the management of Crohn's disease in children and adolescents\", section on 'Dose and monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Measurement of 6-MP metabolite levels during therapy in selected patients to optimize drug therapy and limit toxicity. In particular, measurement of metabolite levels is useful in patients who have developed toxicity during treatment or in those who are not responding to what is believed to be a therapeutic dose of 6-MP or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=see_link&amp;anchor=H5#H5\">",
"       \"6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine\", section on 'Monitoring metabolites'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , another immunomodulator, in patients intolerant or unresponsive to 6-MP or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    has not been investigated extensively. One small, retrospective series in children suggested benefit, with 50 percent of patients responding or maintaining remission at 12 months follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/22\">",
"     22",
"    </a>",
"    ]. Experience with methotrexate in adults with UC also is limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H526355695#H526355695\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For corticosteroid-dependent patients who do not respond to immunomodulator therapy or develop an adverse event (ie, pancreatitis) and still wish to avoid surgery,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    can be offered. In both adults and children with active UC, the short-term response rate to infliximab is approximately 60 percent, though long-term corticosteroid free remission is probably closer to 30 percent. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Refractory disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Colectomy should be recommended for patients who wish to avoid taking immunosuppressive agents or who cannot be weaned off",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    despite immunomodulator or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Severe disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with severe disease (PUCAI score 65 to 85) have profuse bloody diarrhea, abdominal distention or tenderness, and signs of systemic illness (fever, tachycardia, anemia, hypoalbuminemia, leukocytosis). Such patients should be treated emergently with hospitalization and surgical consultation. These patients require fluid and electrolyte management, and frequently replacement of blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    albumin. There is substantial inter-physician variability in the medical and surgical management of children with acute severe colitis. A consensus statement developed by an international panel of experts makes recommendations regarding medical, surgical, and nutritional management of these children [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/12,16\">",
"     12,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most colitis flares are not triggered by pathogenic bacterial infection, and low fevers in UC are generally caused by the colitis itself. Nonetheless, infectious etiologies or superimposed infections should be excluded by blood and stool cultures and tests for C. difficile toxin; between 5 and 25 percent of children presenting with a flare of UC have underlying C. difficile [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/16,23\">",
"     16,23",
"    </a>",
"    ]. Antibiotics are clearly indicated in cases of suspected bacteremia, C. difficile infection, and toxic megacolon. Some physicians also utilize systemic antibiotic therapy empirically in the treatment of colitis flares, but there is little evidence to support this practice, and broad-spectrum antibiotics commonly are given only until blood and stool cultures are negative. Evaluation for infection with cytomegalovirus (CMV) by sigmoidoscopy should be considered in children with steroid refractory disease prior to institution of rescue therapy with calcineurin inhibitors or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    . Details of this evaluation to exclude other causes of colitis are discussed separately. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Refractory disease'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link&amp;anchor=H9479602#H9479602\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After blood and stool cultures have been obtained, patients should be given high dose corticosteroids (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose every 12 hours, up to a maximum of 30 mg every 12 hours). Oral 5-ASA preparations are usually stopped at the time of hospital admission because 5-ASA preparations are usually ineffective in acute severe exacerbations of colitis and are responsible for worsening colitis in approximately 3 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Mild disease'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link&amp;anchor=H13#H13\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\", section on '5-aminosalicylic acid (5-ASA)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If patients with a severe colitis flare can tolerate feeding, continuation of regular diet is appropriate; bowel rest tends to reduce stool volume but does not affect disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/24\">",
"     24",
"    </a>",
"    ]. However, many patients have severe pain when they eat, or cannot take in adequate calories. In these children, parenteral nutrition is required until clinical improvement is apparent or until the patient goes to surgery. Serial abdominal x-rays should be obtained to evaluate for the potentially life-threatening complication of toxic megacolon, the symptoms of which may be masked by the corticosteroids. Toxic megacolon occurs in approximately 5 percent of patients with severe UC and may be triggered by hypokalemia or opiate use. In adults, it is defined as an acute dilatation of the transverse colon to a diameter greater than 5 to 6 cm, with the loss of haustral folds, in a patient with a severe exacerbation of colitis. In children younger than ten years, a transverse colonic diameter of &gt;4 cm suggests toxic megacolon [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=see_link\">",
"     \"Toxic megacolon\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23813495\">",
"    <span class=\"h3\">",
"     Pain management",
"    </span>",
"    &nbsp;&mdash;&nbsp;No ideal agent is available to treat the abdominal pain from colitis. Opioids should be avoided in active colitis because of the resultant increased risk of developing toxic megacolon. Nonetheless, low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    (0.05",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    given infrequently) is sometimes utilized. Sedation often is helpful; we have used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    during in-hospital therapy with good results in some patients with severe tenesmus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23813502\">",
"    <span class=\"h3\">",
"     Maintenance of remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance with a 5-ASA agent is preferred for patients whose disease is in remission [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. Patients who are intolerant of, or do not remain in remission with, a 5-ASA agent alone can be treated with 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/20\">",
"     20",
"    </a>",
"    ]. However, given that colectomy will remove the disease without any significant recurrence risk in individuals with UC, the benefits of these drugs as maintenance therapy must be weighed against the risks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link\">",
"     \"Management of severe ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Refractory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colectomy should be considered in patients with uncontrolled hemorrhage, complications such as toxic megacolon or bowel perforation, or those who continue to deteriorate or do not improve after a 7- to 10-day course of corticosteroid treatment (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Surgery'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    For patients who are reluctant to undergo colectomy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    need more time to make the decision about surgery, medical therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    or calcineurin inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) can be offered. The limited data available suggest that these drugs induce remission in approximately 75 percent of children with acute severe colitis but that most patients ultimately require colectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Somewhat more robust data is available from studies of these therapies in adults with UC.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      is a chimeric monoclonal antibody against tumor necrosis factor that is effective in fistulizing, perianal, and steroid-unresponsive Crohn&rsquo;s disease, but its use in UC is less clear [",
"      <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/29\">",
"       29",
"      </a>",
"      ]. A review of six pediatric case series reported a pooled short-term response rate of 75 percent, and one-year response rate of 64 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. A multicenter study in 60 children found a similar short-term response rate (73 percent at eight weeks) but a long-term remission rate at 54 weeks of only 29 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/30\">",
"       30",
"      </a>",
"      ]. The authors of this study also noted, however, that &ldquo;stepping up&rdquo; therapy, by either increasing the dose or decreasing the time between infusions, could improve response rates in a subset of nonresponders. The efficacy and safety of infliximab therapy for UC, including large randomized trials in adults and limited experience in pediatric patients, is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26647?source=see_link\">",
"       \"Anti-tumor necrosis factor therapy in ulcerative colitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) has been used at some centers as an alternative to colectomy because it can achieve high rates of short-term clinical remission in adult patients with steroid-refractory colitis, although the majority of these patients ultimately require colectomy. Oral microemulsion cyclosporine also may be effective [",
"      <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/31\">",
"       31",
"      </a>",
"      ]. The use of this drug in adults with UC is described separately. Only a few small trials have addressed its use in children with UC, with outcomes similar to those seen in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/32\">",
"       32",
"      </a>",
"      ]. A systematic review of eight retrospective pediatric case series reported a pooled short-term response of 81 percent, but the majority of patients (60 percent) went on to colectomy in the long-term [",
"      <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=see_link&amp;anchor=H14#H14\">",
"       \"Management of severe ulcerative colitis\", section on 'Subsequent therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Small observational studies in children suggest that oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      (0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose) given twice daily may have comparable efficacy to intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      in treating fulminant UC or Crohn colitis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. An observational study reported short-term clinical improvement in 43 of 46 children treated with oral tacrolimus (93 percent), with a marked reduction in PUCAI score [",
"      <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/28\">",
"       28",
"      </a>",
"      ]. However, children treated with tacrolimus will require transition to a long-term maintenance agent such as a thiopurine, and approximately 50 percent will require colectomy within two years. The limited experience with this drug in adults with UC is described separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H12#H12\">",
"       \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Cyclosporine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neither",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      nor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      is a maintenance agent, and patients should either be transitioned to 6-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      or undergo surgery within six months. At least one-half of the patients who respond to cyclosporine or tacrolimus will relapse within a year and undergo colectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]. Furthermore, the benefits of using cyclosporine, tacrolimus or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      must be weighed against the serious risks of these drugs (infection, nephrotoxicity, and neurotoxicity for calcineurin inhibitors; and infection, infusion reactions, and psoriasis for infliximab). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=see_link\">",
"       \"Azathioprine and 6-mercaptopurine in inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Use of sequential therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      , or vice-versa) remains controversial [",
"      <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/16\">",
"       16",
"      </a>",
"      ]. For patients who fail one rescue agent and are treated with another, the long-term response or remission rate is poor, although there are some patients who can achieve long-term remission. In addition, one case series in adults reported high rates of serious infection and some mortality. Therefore, for patients with refractory disease who elect to try medical therapy but who do not have a sustained response to a single agent, we suggest that they be encouraged to proceed to colectomy rather than try an alternate rescue therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Superinfection with cytomegalovirus (CMV) is common in adults on chronic corticosteroid treatment, and is associated with a high rate of steroid resistance (40 to 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/35\">",
"     35",
"    </a>",
"    ]. Although the prevalence of CMV colitis in children with exacerbations is less clear, we suggest flexible sigmoidoscopy in patients with steroid-resistant disease and evaluation of biopsies for CMV using immunohistochemistry [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/16\">",
"     16",
"    </a>",
"    ]. Full colonoscopy usually should be avoided in patients with severe colitis because of risks of perforation. Case reports in adults suggest that treatment with antiviral agents may be effective for patients with UC and CMV superinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=see_link&amp;anchor=H89940949#H89940949\">",
"     \"Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis\", section on 'Stool studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with moderate to severe colitis who respond to rescue therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    can be restarted on enteral nutrition and transitioned to oral corticosteroids. Generally, for a patient with severe colitis, long-term maintenance with either an immunomodulator or infliximab is required. In addition, maintenance therapy with 5-aminosalicylate can be used as an adjunct to the immunomodulator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Risk of colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of developing colorectal cancer in patients with UC is an area of great concern. Cancer has been reported in children younger than 18 years, and the risk of developing cancer increases with increased duration of disease. Compared with an age-matched population, the risk begins to increase eight to ten years after the onset of symptoms. The approximate cumulative incidence of colorectal cancer in patients with pancolitis is 5 to 10 percent after 20 years and 12 to 20 percent after 30 years of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/37\">",
"     37",
"    </a>",
"    ]. Because children are more likely than are adults to have pancolitis at disease onset, they may be more susceptible in ensuing years to colorectal cancer. Patients with UC and concomitant primary sclerosing cholangitis also are at particularly high risk for colorectal cancer as well as for cholangiocarcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/38\">",
"     38",
"    </a>",
"    ]. The colon cancer associated with UC tends to be evenly distributed throughout the colon, and multiple simultaneous tumors can be present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40342?source=see_link\">",
"     \"Colorectal cancer and primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most authorities recommend beginning surveillance colonoscopy after disease duration of eight to ten years for patients with UC extending beyond the rectum, especially in patients with extensive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/37\">",
"     37",
"    </a>",
"    ]. In some patients (eg, those with primary sclerosing cholangitis), earlier surveillance should be considered. Full colonoscopy with multiple biopsies at 10 cm intervals and more in suspicious areas should be obtained. If the biopsies are negative for dysplasia, repeat colonoscopy with multiple biopsies is recommended in one to two years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23813399\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, urgent colectomy is indicated for uncontrolled hemorrhage, severe colitis failing to respond to aggressive medical management within two weeks, and complications such as toxic megacolon or bowel perforation. Elective colectomy is indicated in patients who are unresponsive to or cannot be weaned from steroids or immunomodulator therapy, who experience unwanted side effects (eg, growth failure from steroids), or who have surveillance biopsies that suggest a risk for developing cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/12,16\">",
"     12,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small proportion of patients with what appears to be ulcerative colitis will ultimately be diagnosed with Crohn&rsquo;s disease, in which case surgery will not be curative. Even a thorough preoperative evaluation (including review of small bowel imaging, endoscopic, histologic, and serologic data) cannot exclude this possibility. It is highly likely that a patient with diffuse continuous colitis, no granulomas on biopsy, and no macroscopic small bowel involvement will have UC. Nonetheless, Crohn's disease may still be diagnosed in 5 to 10 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/39\">",
"     39",
"    </a>",
"    ]. Some of these patients who are ultimately diagnosed with Crohn&rsquo;s disease may need a permanent ileostomy. Patients should be made aware of this possibility.",
"   </p>",
"   <p>",
"    The presence of anti-saccharomyces cerevisiae (ASCA) antibodies is somewhat predictive of which patients with an initial diagnosis of UC or indeterminate colitis may develop evidence of CD after colectomy. In one series, the positive predictive value of ASCA IgA antibodies was 0.17, and the negative predictive value was 0.94; the PPV is less than a family history of CD [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/39\">",
"     39",
"    </a>",
"    ]. Because of these limited predictive values, these tests should not be used as an important factor in making decisions about colectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link&amp;anchor=H9481834#H9481834\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\", section on 'Differentiation between Crohn's disease and ulcerative colitis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link&amp;anchor=H9480168#H9480168\">",
"     \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\", section on 'Antibody testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23813406\">",
"    <span class=\"h2\">",
"     Technique and outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly performed procedure is colectomy and rectal mucosectomy with an endorectal ileoanal pull-through, creation of a distal ileal reservoir, and ileorectal anastomosis (called ileal pouch anal anastomosis). In the urgent surgical setting, a subtotal colectomy, terminal ileostomy, and blind rectal stump are created. After the patient recovers, the rectal mucosectomy and ileoanal pull-through with anastomosis is performed. Patients who undergo this surgery average five to eight bowel movements per day, but continence usually can be achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/4,40\">",
"     4,40",
"    </a>",
"    ]. In one series, 89 percent of patients were continent two years after undergoing ileoanal anastomosis with creation of a J-pouch reservoir [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/41\">",
"     41",
"    </a>",
"    ]. In studies of adults undergoing the ileal pouch anal anastomosis procedure, there is a reduction in fertility among females [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/42\">",
"     42",
"    </a>",
"    ]. This and other surgical considerations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major complication occurring after ileoanal pull-through with pouch formation is inflammation of the pouch (\"pouchitis\"), which occurs in 10 to 30 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/41,43\">",
"     41,43",
"    </a>",
"    ]. Clinical symptoms of pouchitis include diarrhea, rectal bleeding, abdominal cramping, and malaise. Broad-spectrum antibiotics (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    ) or corticosteroid enemas usually are effective therapy; in some patients, systemic steroids are required [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/43\">",
"     43",
"    </a>",
"    ]. There have been encouraging results using oral bacteriotherapy (probiotics) for chronic maintenance therapy in patients with chronic pouchitis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/34/4650/abstract/12,44\">",
"     12,44",
"    </a>",
"    ]. A diagnosis of CD should be considered in patients in whom pouchitis is chronically debilitating. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32759?source=see_link\">",
"     \"Pouchitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/33/38418?source=see_link\">",
"       \"Patient information: Ulcerative colitis in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27249038\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 percent of patients with inflammatory bowel disease develop symptoms as children or teenagers. The treatment options depend on the disease location and severity and response to initial therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with UC that is limited to the distal rectum (proctitis) we suggest initial treatment with topical rectal 5-aminosalicylic acid (5-ASA, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      ) or steroid enemas, foam, or suppositories, with or without concurrent oral 5-ASA rather than treatment with systemic corticosteroids (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If the symptoms respond to this treatment, we suggest maintenance therapy with either topical or oral 5-ASA rather than no treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The choice of medication and route of administration depends on the child and family&rsquo;s preference and on the patient&rsquo;s individual responsiveness to the treatment. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Proctitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with left-sided UC (colitis primarily involving the rectum and descending colon) or pancolitis (involving the entire colon), the initial treatment options depend on the severity of the disease. We select the medical therapy based on disease severity, and escalate to more intensive therapies or consideration of surgical colectomy for patients whose disease is refractory to treatment. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Left-sided disease and pancolitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with mild left-sided disease or pancolitis (ie, fewer than four bowel movements daily without significant abdominal pain, anemia, or fever), we suggest initial treatment with oral 5-ASA (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      ) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , rather than systemic corticosteroids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Mild disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with moderate left-sided disease or pancolitis (ie, more than four bloody bowel movements per day, usually with intermittent abdominal pain but without tenesmus or fever), we suggest initial treatment with oral steroids rather than oral 5-ASA or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at a dose of 1 to 2",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      (maximum dose 60 mg daily). For patients with poor fluid intake, abdominal pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lack of nutrition, or for those who are unresponsive to oral corticosteroid therapy, we suggest hospitalization and intravenous corticosteroids. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Moderate disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with moderate left-sided disease or pancolitis who respond to corticosteroid therapy but experience recurrent flares when the corticosteroids are weaned, we suggest treatment with an immunomodulator (6-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       mercaptopurine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      ) rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ), because of the loss of response over time seen with infliximab. All patients should undergo testing for thiopurine methyltransferase (TPMT) activity or genotype prior to initiating treatment with mercaptopurine (also known as 6-mercaptopurine) or azathioprine. For patients who cannot be weaned off of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      despite immunomodulator therapy, we suggest colectomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). If these patients are reluctant to have surgery infliximab can be offered, although a minority of patients experience long-term remission on infliximab. (See",
"      <a class=\"local\" href=\"#H889980\">",
"       'Steroid-dependent disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"       \"Surgical management of ulcerative colitis\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Patients with severe disease (ie, profuse bloody diarrhea, abdominal distention or tenderness, and fever, tachycardia, anemia, hypoalbuminemia, or leukocytosis) should be urgently admitted to a hospital for replacement of fluids and electrolytes, blood and albumin as needed, parenteral nutrition, and serial abdominal radiographs to evaluate for the development of toxic megacolon. The blood and stool should be cultured and stool tested for C. difficile toxin, and the patient should be treated with broad-spectrum antibiotics until culture results are available. We recommend initiating treatment with high-dose intravenous corticosteroids rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Severe disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with uncontrolled hemorrhage, complications such as toxic megacolon, or bowel perforation should be treated with surgical colectomy. We also suggest colectomy for patients with severe disease who continue to deteriorate or do not improve during a one- to two-week period of corticosteroid treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe disease who continue to deteriorate or do not improve during a one- to two-week period of corticosteroid treatment who are reluctant to undergo colectomy, alternate treatment options include a trial of immunosuppressive or immunomodulating drugs such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      . The limited data available about the efficacy of these drugs suggest variable short-term remission rates and low long-term remission rates. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Refractory disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk for developing colorectal cancer in patients with UC increases with disease duration. Therefore, in patients with ulcerative colitis extending proximal to the splenic flexure or Crohn's colitis, we suggest initiating surveillance colonoscopy after eight years of disease followed by annual examinations (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In patients with left-sided UC, we suggest initiating surveillance colonoscopy after 12 years of disease. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Risk of colorectal cancer'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link\">",
"       \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2900770\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dr. Bousvaros would like to acknowledge the Clark, MacInnes, Rasmussen, Stefanis, Ward, and Wolfman families for support of his work.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/1\">",
"      Gryboski JD. Ulcerative colitis in children 10 years old or younger. J Pediatr Gastroenterol Nutr 1993; 17:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/2\">",
"      Werlin SL, Grand RJ. Severe colitis in children and adolescents: diagnosis. Course, and treatment. Gastroenterology 1977; 73:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/3\">",
"      Hyams JS. Extraintestinal manifestations of inflammatory bowel disease in children. J Pediatr Gastroenterol Nutr 1994; 19:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/4\">",
"      Weiss EG, Wexner SD. Surgical therapy for ulcerative colitis. Gastroenterol Clin North Am 1995; 24:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/5\">",
"      Vecchi M, Meucci G, Gionchetti P, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 2001; 15:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/6\">",
"      Hanauer SB, Robinson M, Pruitt R, et al. Budesonide enema for the treatment of active, distal ulcerative colitis and proctitis: a dose-ranging study. U.S. Budesonide enema study group. Gastroenterology 1998; 115:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/7\">",
"      Leichtner AM. Aminosalicylates for the treatment of inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1995; 21:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/8\">",
"      Hyams J, Davis P, Lerer T, et al. Clinical outcome of ulcerative proctitis in children. J Pediatr Gastroenterol Nutr 1997; 25:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/9\">",
"      Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology 2008; 135:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/10\">",
"      Turner D, Otley AR, Mack D, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007; 133:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/11\">",
"      Zeisler B, Lerer T, Markowitz J, et al. Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis. J Pediatr Gastroenterol Nutr 2013; 56:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/12\">",
"      Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr 2012; 55:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/13\">",
"      Quiros JA, Heyman MB, Pohl JF, et al. Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. J Pediatr Gastroenterol Nutr 2009; 49:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/14\">",
"      Ferry GD, Kirschner BS, Grand RJ, et al. Olsalazine versus sulfasalazine in mild to moderate childhood ulcerative colitis: results of the Pediatric Gastroenterology Collaborative Research Group Clinical Trial. J Pediatr Gastroenterol Nutr 1993; 17:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/15\">",
"      Hanauer SB, Smith M. Critical drug appraisal: Olsalazine. Drug Ther Bull 1991; 21:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/16\">",
"      Turner D, Travis SP, Griffiths AM, et al. Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. Am J Gastroenterol 2011; 106:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/17\">",
"      Sherlock ME, Seow CH, Steinhart AH, Griffiths AM. Oral budesonide for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010; :CD007698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/18\">",
"      Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/19\">",
"      Afif W, Loftus EV Jr, Faubion WA, et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/20\">",
"      Kader HA, Mascarenhas MR, Piccoli DA, et al. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999; 28:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/21\">",
"      Hyams JS, Lerer T, Mack D, et al. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study. Am J Gastroenterol 2011; 106:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/22\">",
"      Aloi M, Di Nardo G, Conte F, et al. Methotrexate in paediatric ulcerative colitis: a retrospective survey at a single tertiary referral centre. Aliment Pharmacol Ther 2010; 32:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/23\">",
"      Pascarella F, Martinelli M, Miele E, et al. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009; 154:854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/24\">",
"      McIntyre PB, Powell-Tuck J, Wood SR, et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986; 27:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/25\">",
"      Cuffari C, Lake A. 6-Mercaptopurine in chronic ulcerative colitis: two steps forward with another step back? J Pediatr Gastroenterol Nutr 1999; 28:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/26\">",
"      Turner D, Griffiths AM. Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 2011; 17:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/27\">",
"      Hyams JS, Lerer T, Griffiths A, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol 2010; 105:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/28\">",
"      Watson S, Pensabene L, Mitchell P, Bousvaros A. Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis. Inflamm Bowel Dis 2011; 17:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/29\">",
"      Hyams JS, Markowitz J, Wyllie R. Use of infliximab in the treatment of Crohn's disease in children and adolescents. J Pediatr 2000; 137:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/30\">",
"      Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012; 10:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/31\">",
"      Navazo L, Salata H, Morales S, et al. Oral microemulsion cyclosporine in the treatment of steroid-refractory attacks of ulcerative and indeterminate colitis. Scand J Gastroenterol 2001; 36:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/32\">",
"      Treem WR, Davis PM, Hyams JS. Cyclosporine treatment of severe ulcerative colitis in children. J Pediatr 1991; 119:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/33\">",
"      Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000; 137:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/34\">",
"      Ziring DA, Wu SS, Mow WS, et al. Oral tacrolimus for steroid-dependent and steroid-resistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2007; 45:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/35\">",
"      Ayre K, Warren BF, Jeffery K, Travis SP. The role of CMV in steroid-resistant ulcerative colitis: A systematic review. J Crohns Colitis 2009; 3:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/36\">",
"      Kambham N, Vij R, Cartwright CA, Longacre T. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol 2004; 28:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/37\">",
"      Levin B. Inflammatory bowel disease: role of endoscopic surveillance. Clinical Update 2000; 7:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/38\">",
"      Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut 1997; 41:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/39\">",
"      Melmed GY, Fleshner PR, Bardakcioglu O, et al. Family history and serology predict Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 2008; 51:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/40\">",
"      Pakarinen MP, Natunen J, Ashorn M, et al. Long-term outcomes of restorative proctocolectomy in children with ulcerative colitis. Pediatrics 2009; 123:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/41\">",
"      Koivusalo A, Pakarinen MP, Rintala RJ. Surgical complications in relation to functional outcomes after ileoanal anastomosis in pediatric patients with ulcerative colitis. J Pediatr Surg 2007; 42:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/42\">",
"      Oresland T. Review article: colon-saving medical therapy vs. colectomy in ulcerative colitis - the case for colectomy. Aliment Pharmacol Ther 2006; 24 Suppl 3:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/43\">",
"      Keighley MR. Review article: the management of pouchitis. Aliment Pharmacol Ther 1996; 10:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/34/4650/abstract/44\">",
"      Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119:305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5871 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4650=[""].join("\n");
var outline_f4_34_4650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27249038\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23813219\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MEDICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Proctitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Left-sided disease and pancolitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Mild disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Moderate disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H890512\">",
"      Steroid-responsive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H889980\">",
"      Steroid-dependent disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Severe disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23813495\">",
"      - Pain management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23813502\">",
"      - Maintenance of remission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Refractory disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Risk of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23813399\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23813406\">",
"      Technique and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27249038\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2900770\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5871\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5871|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/50/41772\" title=\"table 1\">",
"      Compare UC Crohns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/43/36540\" title=\"table 2\">",
"      Pediatric ulcerative colitis activity index",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44566?source=related_link\">",
"      6-mercaptopurine (6-MP) metabolite monitoring and TPMT testing in the treatment of inflammatory bowel disease with 6-MP or azathioprine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26647?source=related_link\">",
"      Anti-tumor necrosis factor therapy in ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24250?source=related_link\">",
"      Approach to adults with steroid-refractory and steroid-dependent ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=related_link\">",
"      Azathioprine and 6-mercaptopurine in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=related_link\">",
"      Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40342?source=related_link\">",
"      Colorectal cancer and primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=related_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/17/7450?source=related_link\">",
"      Definition, epidemiology, and risk factors in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2794?source=related_link\">",
"      Growth failure and poor weight gain in children with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/36/22090?source=related_link\">",
"      Management of mild to moderate ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/15/3319?source=related_link\">",
"      Management of severe ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=related_link\">",
"      Overview of the management of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/33/38418?source=related_link\">",
"      Patient information: Ulcerative colitis in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32759?source=related_link\">",
"      Pouchitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/30/18920?source=related_link\">",
"      Toxic megacolon",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_34_4651="Normal arterial Doppler velocities";
var content_f4_34_4651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61562&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Normal arterial Doppler velocities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal velocity (cm/sec)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Average",
"       </td>",
"       <td>",
"        30-150",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CFA",
"       </td>",
"       <td>",
"        115 +/- 25",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SFA",
"       </td>",
"       <td>",
"        90 +/- 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Popliteal",
"       </td>",
"       <td>",
"        69 +/- 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tibial",
"       </td>",
"       <td>",
"        61 +/- 20",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Color directed duplex Doppler study.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Division of Vascular Surgery at OHSU.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4651=[""].join("\n");
var outline_f4_34_4651=null;
var title_f4_34_4652="Causes of sellar masses";
var content_f4_34_4652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of sellar masses",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Benign tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Pituitary adenoma (most common sellar mass)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Craniopharyngioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Meningiomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pituitary hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Lactotroph hyperplasia (during pregnancy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thyrotroph and gonadotroph hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Somatotroph hyperplasia due to ectopic GHRH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Malignant tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Primary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Germ cell tumor (ectopic pinealoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Chordoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Pituitary carcinoma (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Metastatic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        Breast",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Cysts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Rathke's cleft",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Arachnoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Dermoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pituitary abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphocytic hypophysitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carotid arteriovenous fistula",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4652=[""].join("\n");
var outline_f4_34_4652=null;
var title_f4_34_4653="Richmond sedation scale";
var content_f4_34_4653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Richmond agitation-sedation scale (RASS)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Term",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +4",
"       </td>",
"       <td>",
"        Combative",
"       </td>",
"       <td>",
"        Overtly combative or violent, immediate danger to staff",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +3",
"       </td>",
"       <td>",
"        Very agitated",
"       </td>",
"       <td>",
"        Pulls on or removes tubes or catheters, aggressive behavior toward staff",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +2",
"       </td>",
"       <td>",
"        Agitated",
"       </td>",
"       <td>",
"        Frequent nonpurposeful movement or patient-ventilator dyssynchrony",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        +1",
"       </td>",
"       <td>",
"        Restless",
"       </td>",
"       <td>",
"        Anxious or apprehensive but movements not aggressive or vigorous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Alert and calm",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -1",
"       </td>",
"       <td>",
"        Drowsy",
"       </td>",
"       <td>",
"        Not fully alert, sustained (&gt;10 seconds) awakening, eye contact to voice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -2",
"       </td>",
"       <td>",
"        Light sedation",
"       </td>",
"       <td>",
"        Briefly (&lt;10 seconds) awakens with eye contact to voice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -3",
"       </td>",
"       <td>",
"        Moderate sedation",
"       </td>",
"       <td>",
"        Any movement (but no eye contact) to voice",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -4",
"       </td>",
"       <td>",
"        Deep sedation",
"       </td>",
"       <td>",
"        No response to voice, any movement to physical stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        -5",
"       </td>",
"       <td>",
"        Unarousable",
"       </td>",
"       <td>",
"        No response to voice or physical stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1.",
"       </td>",
"       <td colspan=\"2\">",
"        Observe patient. Is patient alert and calm (score 0)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        2.",
"       </td>",
"       <td colspan=\"2\">",
"        Does patient have behavior that is consistent with restlessness or agitation?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Assign score +1 to +4 using the criteria listed above.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        3.",
"       </td>",
"       <td colspan=\"2\">",
"        If patient is not alert, in a loud speaking voice state patient's name and direct patient to open",
"eyes and look at speaker. Repeat once if necessary. Can prompt patient to continue looking at speaker.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Patient has eye opening and eye contact, which is sustained for more than 10 seconds (score -1).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Patient has eye opening and eye contact, but this is not sustained for 10 seconds (score -2).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Patient has any movement in response to voice, excluding eye contact (score -3).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        4.",
"       </td>",
"       <td colspan=\"2\">",
"        If patient does not respond to voice, physically stimulate patient by shaking shoulder and then rubbing sternum if there is no response.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Patient has any movement to physical stimulation (score -4).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Patient has no response to voice or physical stimulation (score -5).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sessler, C, Gosnell, M, Grap, MJ, et al. The Richmond agitation-sedation scale. Validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med 2002; 166:1338. Copyright &copy; 2002 American Thoracic Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4653=[""].join("\n");
var outline_f4_34_4653=null;
var title_f4_34_4654="Doses of beta agonists for asthma exacerbations";
var content_f4_34_4654=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68683&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Doses of beta agonists for asthma exacerbations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Dosages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Child dose*",
"       </td>",
"       <td class=\"subtitle2\">",
"        Adult dose",
"       </td>",
"       <td class=\"subtitle2\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Inhaled Short-Acting Beta",
"        <sub>",
"         2",
"        </sub>",
"        -Agonists (SABA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Albuterol (salbutamol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Nebulizer solution",
"        <br/>",
"        (0.63 mg/3 mL, 1.25 mg/3 mL, 2.5 mg/3 mL, 5 mg/mL)",
"       </td>",
"       <td>",
"        0.15 mg/kg (minimum 2.5 mg, maximum 5 mg) every 20 minutes for 3 doses then 0.15 to 0.3 mg/kg up to 10 mg every 1 to 4 hours as needed, or 0.5 mg/kg/hour by continuous nebulization (maximum 20 mg per hour).",
"       </td>",
"       <td>",
"        2.5 to 5 mg every 20 minutes for 3 doses, then 2.5 to 10 mg every 1 to 4 hours as needed, or 10 to 15 mg/hour continuously.",
"       </td>",
"       <td>",
"        Only selective beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonists are recommended. For optimal delivery, dilute aerosols to minimum of 3 mL at gas flow of 6 to 8 L/min. Use large volume nebulizers for continuous administration. May mix with ipratropium nebulizer solution.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        MDI",
"        <br/>",
"        (90 microgram/puff)",
"       </td>",
"       <td>",
"        4 to 8 puffs every 20 minutes for 3 doses, then every 1 to 4 hours as needed. Use VHC; add mask in children less than 4 years.",
"       </td>",
"       <td>",
"        4 to 8 puffs every 20 minutes up to 4 hours, then every 1 to 4 hours as needed.",
"       </td>",
"       <td>",
"        In mild-to-moderate exacerbations, MDI plus VHC is as effective as nebulized therapy with appropriate administration technique and coaching by trained personnel.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Levalbuterol (R-albuterol, levosalbutamol)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Nebulizer solution",
"        <br/>",
"        (0.63 mg/3 mL, 1.25 mg/0.5 mL 1.25 mg/3 mL)",
"       </td>",
"       <td>",
"        0.075 mg/kg (minimum 1.25 mg, maximum 2.5 mg) every 20 minutes for 3 doses, then 0.075 to 0.15 mg/kg up to 5 mg every 1 to 4 hours as needed.",
"       </td>",
"       <td>",
"        1.25 to 2.5 mg every 20 minutes for 3 doses, then 1.25 to 5 mg every 1 to 4 hours as needed.",
"       </td>",
"       <td rowspan=\"2\">",
"        Levalbuterol administered in one-half the mg dose of albuterol provides comparable efficacy and safety. Has not been evaluated by continuous nebulization.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        MDI",
"        <br/>",
"        (45 microgram/puff)",
"       </td>",
"       <td>",
"        See albuterol MDI dose.",
"       </td>",
"       <td>",
"        See albuterol MDI dose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Bitolterol",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Nebulizer solution",
"        <br/>",
"        (2 mg/mL)",
"       </td>",
"       <td>",
"        See albuterol dose (thought to be half as potent as albuterol on mg basis).",
"       </td>",
"       <td>",
"        See albuterol dose (thought to be half as potent as albuterol on mg basis).",
"       </td>",
"       <td>",
"        Has not been studied in severe asthma exacerbations. Do not mix with other drugs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        MDI",
"        <br/>",
"        (370 microgram/puff)",
"       </td>",
"       <td>",
"        See albuterol MDI dose.",
"       </td>",
"       <td>",
"        See albuterol MDI dose.",
"       </td>",
"       <td>",
"        Has not been studied in severe asthma exacerbations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Pirbuterol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        MDI",
"        <br/>",
"        (200 microgram/puff)",
"       </td>",
"       <td>",
"        See albuterol MDI dose (thought to be half as potent as albuterol on a mg basis, but same number of puffs).",
"       </td>",
"       <td>",
"        See albuterol MDI dose (thought to be half as potent as albuterol on a mg basis, but same number of puffs).",
"       </td>",
"       <td>",
"        Has not been studied in severe asthma exacerbations.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Systemic (injected) beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonists",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Terbutaline",
"       </td>",
"       <td>",
"        <p>",
"         0.01 mg/kg (maximum 0.4 mg) every 20 minutes for 3 doses then every 2 to 6 hours as needed subcutaneously or intramuscularly.",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"         as intravenous infusion initiated with 10 microgram/kg (maximum 0.4 mg) bolus over 10 minutes followed by 0.3 to 0.5 microgram/kg per minute. Every 30 minutes infusion may be increased if needed by 0.1 to 0.5 microgram/kg/minute up to maximum 10 microgram/kg per minute.",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        0.25 mg every 20 minutes for three doses, subcutaneously or intramuscularly.",
"       </td>",
"       <td>",
"        <p>",
"         Subcutaneous/intramuscular administration is reserved for patients with poor inspiratory flow or who cannot cooperate with inhaled therapy. No proven advantage over aerosol.",
"        </p>",
"        <p>",
"         Intravenous terbutaline is rarely indicated. Selected patients who are poorly responsive to standard therapies may receive parenteral terbutaline or epinephrine, NOT both. See text.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\">",
"        Epinephrine",
"        <br/>",
"        1:1000 (1 mg/mL)",
"       </td>",
"       <td>",
"        0.01 mg/kg (maximum 0.4 mg) every 20 minutes for 3 doses, subcutaneously or intramuscularly.",
"       </td>",
"       <td>",
"        0.3 mg every 20 minutes for 3 doses, subcutaneously or intramuscularly.",
"       </td>",
"       <td>",
"        Subcutaneous/intramuscular administration is reserved for patients with anaphylaxis or poor inspiratory flow or who cannot cooperate with inhaled therapy. No proven advantage of systemic epinephrine over aerosol except in the treatment of anaphylaxis.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MDI: metered dose inhaler; VHC: valved holding chamber.",
"     <br>",
"      * Children &le;12 years of age. For additional information see Pharmacotherapy sections in these UpToDate topics: Acute asthma exacerbations in children: Outpatient, inpatient or intensive care unit management.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       Not available in United States or Canada.",
"       <br>",
"        &Delta; The use of systemic terbutaline or epinephrine requires cardiopulmonary monitoring, such as that available in a critical care setting. Orally administered systemic beta",
"        <sub>",
"         2",
"        </sub>",
"        -agonists are not recommended.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         For patients who require doses of intravenous terbutaline above 3 microgram/kg per minute, prompt transfer to an intensive care unit is advisable due to potential cardiac toxicity and respiratory failure. See \"Acute asthma exacerbations in children: Outpatient management\".",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). Available at",
"     <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"      www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4654=[""].join("\n");
var outline_f4_34_4654=null;
var title_f4_34_4655="Autonomous thyroid nodule scan";
var content_f4_34_4655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79487&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autonomous thyroid nodule: Appearance on thyroid scintigraphy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 293px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAElAWADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UopTSUAFFFFABRRRQBftLizj0+5inty9y/8Aq5Afu1TJBXkHcO/rTKKACiiigAooooAKKKKACiiigAqWCaSB98LlHwRkehqKigBTSUoBIJAOB1pKACiiigApSMUlS20JuLiKFSqtI4QFjgDJxzQBFRU11C1tcywOys0bFCVOQSDjioaANXWrGK0trB4g2ZoyzE9zmsqnFmIAJJx0yelNoAKKKKACiiigAooooAKKKKACiiigCa1lWGdJHiWVVPKN0NRkguTjGTkAdqbSg4oAkVl5BXr+VDN8uMkfTpTAc1JbztbzpLGBvQ5GRkUAQ1e0P/kNaf8A9fEf/oQqrNK00rSPjcxycDFWdE/5DVh/18R/+hCgCmcZ46UlFFABRRRQAUUUUAFS28zQSb1VGOCMMMioqKAFY5JPrSUUUAFFFFAE0k7SRRxlUATgEDBP1qGiigAooooAt2lvDNDKXufLmUfu4vLLGQ+mR0qvLE8LlJVZHHUMMEURSPDKskTFXU5Vh2Na1tpGr63/AKTDDJdM+fm3DJx16mgCtaapNa6dd2UccBjuQA7MmWGDkYNZ9WobC6mvxZRws10WKeX3yO1WtVsoNPjFtKlzHqkZxPHJt2rxnjH4UAUbSOKW4RJ5vIjJ5k2lsfgKbOqJNIsUnmRhiFfGNw9cdqjq3ZfYsS/bhcfd/d+Tt6++e1AFSlBwcjrSUUAKTk5PWkoooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAFFBOaSigAq7ov/IYsP+u8f/oQqlVzR/8AkL2P/XdP/QhQBTooooAKKKKACiiigAqWCIzPtDonGcucCoqKAFIwSOD9KSiigAooooAntrcziUiSJPLXcd7Yz7D1NQ0lFABRRRQAVPbXdxatutp5IjgjKMR1qzpd++mO0n2eKXzEIXzUyPqKZe/abvffPbFIWOC8cRWPPT6UAdd/wguo2egvrz6jbK6xC5j8uTcSDz19aw9E1mCPWLi81yD7d50ZVtwBO7jB/SrWg6NqetaNfzfbbqO1tIgVRg7JIOflHOBjFM1XxOt94SsNFFjFG1qwYzj7z4BHp70Ac7cMjzyNGuyNmJVfQZ4FR1f1e/GozRyCCOEqgQhB1x3qhQAp4pKKKACiiigAoq3ZW9tNHObi7Fu6IWRTGW3n0z2qsoUg5OKAG0UUUAFFFL2oASpEhleGSVI3aKPG9wOFz0ya6jSNE0nVNKj8q9canjLx7TgDNYkF5c29veaZBtaO6dVcFeSVPGPTmgDOoq3Dp91NcywRxEyx53j+7jrmqlABRRRQAUUUUAFFFPijeWRY4kZ5GOFVRkk+woAZVvSTjVLM/wDTZP8A0IV1VxFb+DtMlt5ljuPEF3EUkQgOlrGwGVPOCxGDkdP58ppn/IStMdfNT+YoAq0UUUAFFFFABRRRQAUUUUAFFewfAz4V3Xi++t9YulsptDgkInhkkId8cYx/npX0o3wj8AFSf+EatAPY0AfBgGaSvo/9prwR4Z8MaDpk/h/SorGaRvmZCfm5Ir5woAs2ZtAJftgmPy/u/LI+9757VXpKKACiiigDTjt9Q1OxLRQmS3sYzuYYARepzSnW7s6CNIyotA27GOSc5/nTQ99plkvlzbIL6M5VTncucEGrfg250i01tJfENubix2MCgGfm7GgDe8HeJNclsW0GwghktZE2SNtO5Fz1zn+lR6v4Y0rR4lkv5rsAsEwpXOevpV3wFqGlDWtVtLW3dJ752WxkxxGMkgH04q38SND1DTvC1pLqd1Hcz/aAryLwSSCRx9MUwF8P+E9D0zTXXx00lhc3LB7dWkAzGMc8H3rnoNF0WLVLwajPcx6az4spkI/eDPc49MVF46XXlbTx4ivUuj5X7gqQdq8ccAe1WNOtpvE9ha21gI45NOUPIZm2hh7Yz6UAHjHRvD+kWgTT7u5mvyw+R2UgD1OBXG1reJdSi1TUPtECMilQCG61k0gLElncR2UV28RFvKxVH7EjqKgHNTJJNMkVr5hMYf5FJ4BNX/EWhXegXEMN60LPLH5i+UxYY/IUAZNL2pKu6RNaQXyyX8Hn24DZTOMnHH60AUqKcxBYkDaCeB6U2gAq9eiwFpbfYzObgqPO3425x2qjUkDrHMjvGJEVgShOA3tQBchhvbKzXUIXaFGbywytgn/OKpCRxJ5gY787t3fPrVzW76PUdRluYbZLSJ8bYEOVXAA4ohsN1pPLPKsEiBTGknymQHrigCut3cLLJIs0gkkzvYNy31qCiigAooooAKKKs2VlLduBGAse5VeV+ETPQsewoArgEngZroYLmDQLOGexnSfVp0DeYvItVIPA7iTPfpg1A2pPo5ltdIn+8Nk8wAYSkdlzn5euDwTmsSgB8sjyyPJIxd3JZmJyST1NS2BxfW5HaRf51Xqa0OLqE+jr/OgCGiiigAooooAKKKKACiiigD7A/ZIb/ihbxcf8tG/9Dr20xkfSvjX4PfGNPAGhz6fJpz3PmMWDLt7nPevQU/aitwMNoc54PTZTA1f2u2VfCGnDKFmYY55+9XyNXS+OvFt/4s1q5u7q4nNs77ooHfKxj2HQdTXNUgCiiigAooooAvXt+bqzs7cxhRbIVDd2yc1q/wCi/wDCE9IftXm+2/G7865yigDt7Twcnl2E9trSLcXCh41RMMDjPHzZq/q/2/UbNfD1/wCbElk2/wC3z7sSkDGOe/Pqelcp4elk0bXdNvrpDHEGDhmGQVIxn9a9B8WQeJ/GJdNLsI59Fdlmt5wApkG0epz1z2pgVL3VpvEEttqaaNIX0geUtuoL/aNwAz07Yzjmi5Z/FMMsRtj4eltR5jMylTKCD8v8PpXpfwx0rVbDQLjUPEdqbKa0ICcjG0AckA1xfxis01y00++0jfeSTyklkOVKkcGgR4vS11EfhO7Fs0EsLrrG7fHbFh88fHP5+9NsdEtLJmXxP51nIxHlAdGA+90z7UhnM5Oc96knuJrhg1xLJKwGAXYsQPTmrGrraJfyLpzs9t/CW61T6UASeRMPLzFJ+9/1fyn5/p60XEE1tJ5dxFJFJjO11Kn8jWjPrl1KNMyIwbD/AFWB7g8/kKj1/WbrXdQN5fFPO2hPkGBgUAZ1FKM4OPxpBQBua3qV54ilhdLIBYY1jAgiz0HUkCi61eTULfT9M1FYra2tSEMiQ/OABjnua6bSJ4rP4X3ktpLJHqZlXBXPA384/CotRstD1bQNMl0vzJNXQLJqbM2CRg7iM8ZzQByfiC0tLPVZ4dOuDc2q42yY68V0+ti48WadBNpUIlTTYcTkLsxkDHHf7prK1XQJf7EbXbGNo9IeURokjAuDjqefUGrfg3xFBoujaxBI0izXSqF298Z/xoA5CirbyWh06KNIpBeCQl5CflK9gBVSgAoq1PZvFZ2tySClxv2gdRtODmtjSbPSbCO0vtdkknSRj/oUGBIAOVZs8bT6e9ABofhs3dq1/qlx/Z+mJ1mZCzP/ALq9SPeq2v6sl2UtNPi+zaZblhDEGJLZOSzE8kk889M4qDXNXudZu/OuAkaKNsVvCCsUK4A2ouTtHHQVm0AFFFKBmgBKkg/18eP7w/nTAM0qHa4I6g5oAbRRRQAUUo4INWL2ZZpQyABcYwBjFAFaiiigAooooAKKKKACiiigAooooAKuJJaf2a0bxN9r35Vx0x6VTooA09L0a51K0vbi3MYjtIzLJubBwBnisypI5pYldYpXQONrBWI3D0PrUdAHX+HPC2ueMbGR7WaA29koUec+3A9BgV6l8NdH8T6XMkGp30EmmRwFIoUbJRs8dhx1rzv4W6Fc68+owQazNpqKi7vLJ+fJ7/lXpviuZvBvgO2gjuxe3FvIsTSBtrSZxk9Se9NCNB9Z1G0+GviW01m5MmoOk3kOnRV52/kMVh3t9YaZ8OPC7eS63csUcRcDOXKcfrXnvhSyvtSgudTk1GUrDIT9kLlvNB5I5PvUWteJ57u70xbrTpbW3trlJQshIzgjjBHpQM63QtA8Spri6jq15BPKsflhlOSB1x0AqD4gaFLrX2P7GESaHcHL5Gcn/wCtXQ+OL6+uJIfEOlWs72kEXlmCEErITt5yPTFcxdaBe3djcX11q09kXjMqROdo6Zx+tAHmuq6dcaXdG3ugofGcqcgitXSLjRV8NalFfW7PqZybeQKTtGBjn65o0K/vLQSXMmnS6hEykeY6sQvHPODXO0gL99NZSadYR20LJcxq4uHPRyT8v6VQpaSgBelbLaFNb6PaavNJbvZzSBNiud45OcjHHQ96paNfDTdTt7wwrMIm3eW3Q8VNr+qvq+p3F35fkRykEQq2VXAA4/KgD6AurbRsab4c+xRLNfwh42C/IAoBOfzrxHWtMmt/Fep6VZusS+cY2O7C7cjr7VmW0mq3c0csEt5JJGNqyB2Owem7tXa+FNX+2RX1nq7xRG3hAVm5d2GQck9T0pgcxq1jf2d5JoVvdG+hRhII4SSucdcdutY0OILtDNGCI3G+Nu+DyDXReApdXt/ELyaDbLc3vlsDHIM5XIyf5ViXcdzdaxcLLGBdPM29R0Vi3P4A0gItRnjuL2aWCBII3bKxp0UVLYaZcXoV1CxW5cRtcSnEaHr8zdqu3Wm2ul4+3XEc9yPm+zwklWU9DvHT6Vmy3k8lsluZCIUGAi8A+5A6n3oA2Pt1poyvHo5aa+J2NdOAQmDz5fqD6msS6WZZibhWEj/MdwwTnvUasVYMOoORU17dzXswluH3vtC5xjgUAFzHCkUDQyl3dMuP7p9Kr0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBZs0tmWc3MjIVTMYA+83pSWNncX9ysFpGZJW6KCB/Oq9WLG8uLG4We0laKZejCgB1taltTitJgUYzCJx3B3YNanjPSYNF1dbW1ZmjMSv8xzySf8KxjPKbk3Bc+cX8zf33Zzn86kv7651Cfzr2ZppcBdzenpQBWooooA9N+Cc+lxaheQ6ldiCS4CKingtg9q1PGVsmr/EObw/HMzaagEq7fvE+5rkvEw02y0Lw9caTG1vqXko8sijGTt5P516b4R8MX1zoGn+J5ZopLq6jGZD9888ZpgXtX+Gdt4VFtq9lFPHBBCZJ2kkLKBjJOD9K4fxLoWv+KzY3Vpp3maTI4kSZGAYocfMQenGa9j8VReJPEOmpYWV5brayw+TOJj1BXHGMV5lYanrPgm5j0XX7s3No+22sjCBhO3PHoR60COu1PxJZeFfh1daVpU8b+WmYo5ASSQMAfnXlfivUNQ8Q3Wgf8JVaDTrGLK+YrD5kOCxwOnQfnXrtx4f0PSbKS88VWdvcrGuXkK7sJ1/wrA8XWOk+JdOB0qGNkSFvJY9BkcEfpQB554g8UwaG50jwpLBcaQqllkkUs25s55Jrk7GHS20W7kupnXUFP7mMZwwwP/r1taD4KvLvXBazmELDskkBJwyk8gfgDXXePfBFtqU0Fx4Ytrazhii2zIxK7m9RjPvQM8nldWhhVeqg5/Ooa7eTw1H4bsJbrxCkc6TxmOBYSSVY9znGK5bRtNm1a/jtLdo1kcEgucDgZpASW9iLe8sv7WVobWdRJuB5KHoRimav9jS8lj01ma1BGxm6njmnazLcGeO1upN7WieQOmAB6e1UoIjNKsalQzcDccCgD0/4Qa54a06eCDxFPJDCzM0pOSvbFZfxQu/Dd9qUreFleR2uSxkCnBUgAfritXQPhLNqc0LXF/HbQOoJGOTxzg5r0zw/8PtP8HWtzLE8F01zGUWWRsyL1PI6D8KYjyPwVpWr6Nrxka5+zan5RItshnli4zhwcDnHWsrxml6mpwKLe3tXmZwphwJHLEZ8xh15Nbur+GDofgh9Vtp83wufmuIyQxUkjHXpyM1xenWseoQXt1dXyx3EeGXe3LHrSGNHh+/OovZeWnnIu9vnGAKyqfLI8zl5XLse7HJqOgAooooAWpryZbi4aRY1jBA+VRgDjFQUUAFFFFABRRRQAUUUUAFFFFADirBQxUhT0OODTa3NB8N6z4gtrqTTLZ5re0QySOWwqADJ696zNOsbnUbyK1sYXmuJDtVEGT/9Ye9AFaiun8ReBfEPh7T1vdVsRHas+zzI5UlAOM87ScfjWVHomoyaLLq0dszafE4jeYEYBPTjrQBm0Vq6n4f1PS9Ptb2/tHgtrr/VMxHzcZ6dayqACtXwxq40PWIb82yXXlg/unOAcjFZVFAF3WL7+0tUubzylh85y/lr0X2qlRRQAUUUUAFWdPt1urpYXmjhU5y7nAFVqKAPeJfCNp4n0PR7H7SLZLWJFE6qDvAGM1r6fpqXMo8B2mtPHJp8InN1D1IB6Y6D/wCvXnFz46Gm+FtPstGljkuPs6RTF4z8mBzjPfNZvwz1zVdN8UXF9p9qdRu5IHWRWcA4JGWyaYj0jwTc6vqvxEt9Paa5XTLcSRvOoJjdg2BlumeOlWPirbW+paxLpCORdWDfaVmUdSchf1HSsv4VeM2sdO1i0lMS37XbSx2xHzHLZI/A5otH1NvEF5q3iu1/s6C58uO3y6kMQckZHegC54K8R6hrOjPo/iDSbtGfO69mhYRFemCW4z7e1N0nQrXwpLdXA1eO5ikbzfKLAbQOwH+egr0+zudK1uwk8PXNz/o1wnz+WSrYx2IPFfO3xA8KWeh+JrODTTPJaPIQxdtxUBvX6ZoA7DxzfXWr+HTeaJYXEUkpGGhUhlGeenNZfhYT32v2lq926qWxJ8x4ODwRXtWjR6Gng22+z3Z+1FirJu7HiuJ1nwjaeHvGOnT6ejrp9wTPeyvISVYjqM9uaAJfFHhhfFelvpaytD9g+YSom7zPavHH8Ba9bXbyR2l2lkhIF0Fx/Wvpfw9b3Ua3U1ige2kUlXPcUmvapqUfg6eyiVTG0inke/NOwHyVcaDqyPcMdPvXSInfKIWKj3JxiukNlLceCNOW4txa2zS/8fjLkHk173eGDT9GaNnZbW6jzdZyceuK4Tx/FazfDG007w9vnt0mTyUGWJXPWlYZveHL++trex0/R7H+0rd0GbnfypAH864HUtb1++8Xahp0dhL+5n2zhZGPlJwCevHrXQfB6TxTol1bQXEMFvpqBmHAL5yCOhrY13SL+11y51PRtsd3qc2Lt5MsHTHYdjQI5nXLsReHU8H+E9moyY3ltwLIARuz75NeUa5ZWlg8cNrdPNOuVnVk27HHGB685rvdS0HVdB8eLF4b2Q3k0DSEMcLjIz+uK851DzTf3IuRm6MreZg/x5Of1pDFm067hsI72WB0tpGKK5GASKqE5rRaXUrmzWzklla3iYsIpGwFP41m0AWp/sv2G28nd9qy3nZ6dflx+FVaKKAClpWYFVGAMDGfWkoAUD2yamYxeWgWM7/4jnioc4PepGIbAHGKAI2Aye3tSEYxnNOfJY/1pGJONxyaAG0UtJQAU+LZ5qebu8vI3beuO+KZRQB9JeH49HktpNN8Pa9pq6UunybrRWy5YqN0kvsp9K8t+Eq/YviE0EdzFIFinjEsZykmFPIz2OM1yGiazf6JcTT6ZOYJZYWgdgoOUbqORVWyup7G6iubSVop423K6nkGmBs+H5vEP9kaxDorz/2d5Ba+VMbfL7k5/pzXe+BNXXQPhrdXs8TS2xu0WWNcZZScHr7Vw/iHxvr/AIgs1tNTvg9uG3bI4kiycY52gZHsapL4j1FfDcmheap055BJsKjIIOev1oA9F+Ml8mp+GdDu4xiJ5G8oYxtj2/KPyryKtfUvEOo6npVnp95MJLa0/wBUNoBHGKyKQBRRRQAUUUUAFFFWVuIhZNCbdDIW3CXJyB6YoArUVYubhZobdBEqGJSpYH7/ADnJqc2UY0kXf2mLzC23yc/N164oAZZy2sdrdrcxO80iAQsMYU55JrS8IHUl1Jzo0qxXIjO4v02ZGR0+lM0eza1xqd4ipDDiSOOX5fP9lz1r0PRNb0+7lF/5dpDPLH80QcZUUAcnpNlJrfi2CHwy72l+25pJJm+Xd3I68HNep7Zbq5OjeIjFeXGnqszFV+XJJGR78GsH4SaVaSWeq6/9qiW6SchYeMqM5wO/P+FdraPbam904uIo5vLLFd3zE4PBpoQ9WtLi0lu/C8UUeqhdkcr5xn0OO3WtLStEtpYp28RQQ3V1IB5bYyFOOcfjXNfDvVbjStEEmoaNOjxuVMZQkkZPNeuR6FDb6XcXzXqs00XnLE2MqcZwPzpgZGgaBYWr7pLVCmMKADwa37Xw0L2+jj1SKKdHOArA4C+lbXw9t1fS4ruUKWkH3GGcV1mmRF70SmLaBwOP1pXA5+58PRrpv2XSI47Vo1IJ6Csey8LPJoDW9+YJpjITvOemeK9DnV2uJVWMhem4DrVa2s3gfbhmXOcketFwON1Dw1YR6f8AZrizgleRdqHBwtZumeCrTTo/OvLe0ntmBVIRk7D616RqGji5eJ/NI8vnGKzrmyt2QxPcBSOxNFwPM/EGgRaXayXlvDEAnISL7xzWOZoWhtJZIQ+cMUPVfrXpMukWjSLeXNyY2jOArcqfzryXx/paeD75tZ8NxHU77VbjZNDJMVRFxkFe35UwMX4tWQ1FBqemqLW7jGxNow+DjIH1xXk+ty6dousaPdmygkUFmn+X5ieOT75ya9E8R6j4jn01LmLTYk1YuB9mV96hfXtmvILRrK/u75vFN3LDLFIQqIM4JJ3DHtSYFfxzrUGu6693aReVCECBcYBxnmueq5qqWcd666bJJLbD7rSDBNVPxpDEpSc0lFABRRRQAoOKUEjkHHam0UAOYMXweWpCCDg9aP50lAC0lKeKSgAooooAKmuGhYp5EbIAgDbmzlu5qGigAooooAKWigkk5PWgBKKKKAJrcw4k84MTt+THY1DRRQAUUUUAWbWO3dJzcTGNljJjAUnc3Ye1VqKKANPU9au9RsrO1uPL8q0QJHtXBwBjmp7yDSY9AtZrS7d9TZgJotpAUYP4elYtbnhHw7ceJtSks7WWOJ0iMpL9MDH+NAGp4hm0vRLrTpfCd9JISge4XcSu4YwCO/U03whY6xr/AImN3Yq7bZ0muTG+0BS4Pr04PHtXMXFu0F7JbOQWjkMZI6ZBxXrPhK7iksZLfwj5dpfQIouXkTiTqBnHXmgD2LxHqEFkpitHV5ygIRup6V13hfw5D4p0o3NzNKjW4AVUbAJIzzXlHhGK41LVo7LWmim1cReZ5iA7AmT0z9K+i/h5BDb6dPFEoUAqGx64qhFrQtESwsIodrBQc8nNb5dIAFHI+tJcSeVF8mN3YGs+RsqzKCDUjNAXI/un86PtIz93j61SiY7ASPzqRiGxgc0AXyQVOMHismTS0mZpXTLt3zVy2lREIdgOe9RXV95ODGAyE44oAzYdEedtmpKskRJ4XjHpXG+L9GtIrpFaMmGNz5YBwRXoEupfZ1ElxgRdyOtcb440macLqEd2fKclliGcnimhHlHxFSa30yXUNMYI6sAGY5/CvMLLwpY6Xp+oTa3Gl9d36mWMqu4qSMnGPcmul+K13cT6RNEZJrNN4JzxwCK4KO91TwBqNjcaozajb3ahlWTOVC4+7k+9AHm8lvNbzGO5glRwMlHQqwH0NFlLHDdxSTR+bErAsmfvD0rrPE3jI6t4tm1e3sI0Dw+SIZBwBnOeO9cZSGWL1o5Lh5LeJooXJKqTnH41XqxNdPLaW9uwUJBu2kDk7jk5qvQAUUUUAPhkMUqSKFJRgwDDIOPWp9SvHv76a6kSNHlOSsa7VH0FVaKAFFJRRQAp60lTXZBuZCq7Rnp6VDQAUUUUAFFFFAD4wpkUSEhM8kDJolCCQiMkp2JGDTKlS3mdN6QyMn94KSKAIqKUgg4IwaSgAooooAKKKKACiiigAooooAtWttHNbXUjzJG0ShlRjguScYFd3ofhrToNAtNWXxKtlczrtkRZFUrn+GvOqKANTxBp40+82rdR3O/Lb1OT1716P8B7SG/bXVkkWFoYFkB7v14/T9a4Tw1plrf3BuNRdo9PhA85x2J6dK6TStb0Hw1qD/2NczSxXLrHKWU4RAevPXqaAPSPDGsNJpJvGgNveBivlsfnwCRX0v8ADm1FtpDSecZvNCOf9k46V8rWd1YXvi2OXTLhZ9PFthmU/wAeRj+tfSfw4S6tNIuJ9S/cygBoombG8Y7UxHWazcmBx5aGR+PlHUA1YVRxkVjWN+bq/e6uYjb7lChc5rZBpDA8Dg0xsjBHSlD5OFI460rHJzQBGWJzS5yp46UrYI6VBOZdgEOOuGz6UAQ38ytYSPGQ+CB61e0mVbuzQvHtCDHzDiqi28McJiCEKxyRnvUek6nafaJbNpCsm4oqnvTEeFftUQ2v9nvdHaYMbC0YHUkccV4z8X76S7stBN9mOSKI+RsGcjC5z+le/wDx9/sqxhWwntnmjkPmMmC4PIr5lufEVtcW9/bavAbmfdtsty48pSMY9qBmBpNnqniC4khtf3pABk6DAzVzx1pthpt1aR6cjoGiy4bPXNYEFxc2Ur/Z55YX+6xicrn8qjmmkmOZpHkb1ZiaQEdFFFABRRTkRnbCKWPoBmgBtFKeOtJQAUUUUAT3oxdSDGOagq5q4xqVwOPvdqp0AFFFFABRRRQAV93/AAu0DRm8AaMZNJscmIknyzyeOetfCFfcvwv8XeHP+Ff6NE+t2KTJGQyPL8ynjg8UwNXxP4R8O3HhnVmfQ9OJWFmBMZOCFJB618C1+g2t+IdDk8MasI9XsnzA4AEnU7T7V+fpEXkAgt5u7kY4xQwI6KKKQBRRRQAUUUUAFFFFAFiwtZL68itoceZI20ZPFaOueHrvRlLXJQrv2AqevGax60LnVZZ9JgsGRRHC24Nk5PX/ABoAqxXM8UEkMcjrFJguoOA2PWtqDw5IkVjNdMoivGVExwVJ9c1Zi8XbNestSOm25NtH5flZOG461tePZ4ta0qwvdPZZJnYySQQHd5QIzzjpigDovBVvZ+GfFY0u6UOHtxN5gIwW3EevXkV9ReEJ5PGekyy3qoklntjtmj4AyO9fF3hTwl/bWmnUr29mtgH2pJkY475NfWnwguVso/sceoo8bbPkJ5bAFMR2Vnpt1DcGC5mVnUBiR0NdAh6AnpVfXLVII5LwOd+Qu01X04O3zTKyYPQ0AXoXV3dVUgqeTUpApOO2KC4AyxxSGByAcnikCnaSelNkfBAHfvUc9wsETNI4T03dzQBV1a/TT7R7hkZ9hHyg8msjSdK/tS+h1RJhEqSeZ5Z61R8T6hDc6TL5kiC6DDEYPUetWvAN1Pe6DqMc6BXUskezqRzimIj+K9rZN4da5uFg3iZR5zEEgenWvhLxtJHJrEoiKEB25X0zxXrvx2vPEenaM2kXIdLP7RyzOQ554GPTpXgTMT94k8Y5oGIDikoopAamrwabFaWLadO8szoTcBuinjGOPrWXRRQAVJBNJBJvhdkfGMqajooAViWYsxyTyTSUUUAFFFFAF3WMf2lcY/vf0qlVzV/+Qlcf71U6ACiiigAooooAU8daSlZixyTk0lAEgmlEZQSOEbqoY4P4VHRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWxay6lolt58QEcV4m0EqDkf5NY9TS3M0sSRyyu8cf3FZshfpQB1/hrxLbf8I/JoWsuUsC25WRTk89CRXqPhG88LybBbahL5ygCIJKQenpmvALNEedVkwF9TXqfh/VtIl8Na1PaaYltd2sB8qUhchthwR+IpoD7Ie9sofCNg+oSuImCgMeSWz3q3NLerqUTFf+JdsG845zXE29hfeIvhVokcDAXMcKyuz85wM1haRqGsanIZDfyRQo2xkkyMkd6BHsce51YgEp/CQKpkzS3ZjfHkYHHQ5rz++1q9ne1tbWa5iYHY0gzgn16VrWniBtPl/s6eK4uLhOTcDOCD26UWA7J8ImZCfl9qydTvrSSNhJlhF8zcdqrLqMmrT/2fDFNEZl/1+cha3rrSIZbW3i3xK8bAsT/GB1BoAwUstP8AEXhprjTLctI77QzDaRg81u6XpMel2kcdtGyuw/eck81yeu+JU8NeNIbSWLytJ8skqgAG4jr+deF+KfjLfC88Si01Jofs0rLaxNJywwMfrkUAYP7XNxcf8J2kBlfyMMwTJxnivB67O+8US+Mb7Piy824Vn88A7mbPA+mP5Vx0oVZXEZ3IGIU+opDLd1eRTWFvbx2yxvFy0gOS9Uu1JRQAUUUUAFFFFABRRRQAUUUUAXNW/wCQjP8A71U6u6yANTuAOm6qVABRRRQAUUUUAFFFOLEqFOMDpQA2iiigByuyggHAPWm0UUAFFFFABRRRQAUUUUAFFFFABRRRQApOTW/ceJp5ruxm+zxItqMeWpO1x71z9FAH0T8EfjW9hrN1a+Kbi4ltLsxQWNtGoMcDFsHtnnIr6J1y70vUdaPhR0MM1zbicXMQGFGRxn1r4f8ACljoljbSXniyKRoZ1H2Qwu2Qwzknb07dauXfir7MpuNCvrpGXvPM7vn2JOcYzTA+yLbx7pcfiAeHbOykuZrZ1glnCAqhxwSce2a6mPWrP+2bnTZEjjaNAfNIG1s+hr4X8O+OodM0vWZFknj1S7+dWJL5fbgHP17Vq6z8Q0vPhtb2xvLv+3nbDSLuToRk7gaBH1hqfivTPBlwLZpBcR3DGdpO0ee1eW63471q58YXGoWqH+x45FliAY/OBnIx+VeEeE/GSLbtBrk9zdSvIeXy/wAuOn51Bd69qWqSaqdM1H7Lp8MZKRPhWKgcgd6APSvjB8W49dtp2ssWuoLsVY8HgZ5PPtXgup3K3dybjc5ml+eXPTceuPaq2WkYlmyx5JJplIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBe1pSuqXAPXd/SqNaGuDGqT8HOeaz6ACiiigAooooAKKKKACiiigAoopVxn5s49qAEopT146UlABRRRQAUUUUAFFFFABRRRQBq+HtQttNvWmvLNLuMoVCOAQD681nTOJJndVChmJCjoPao6KAHtI7IqM7FV6AngfSmUUtAADg5qae5eZEQhVROiqMCoKKALOn3clhexXMKo0kZyA4yOmORUdzM1xcSTOFDOdxCjAqKigAooooAKKKKACiiigAooooAKKKKACiiigAooooA0NdAGpS46Vn1o68CNSlB7VnUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUASQsiTI0ieYgYFkzjcPTNFw8bzu0MflRkkqm7dtHpmo6KACil7UlABRS9qSgAooooAKKerYVhgHI6+lMoAKKKKACiiigAooooAKKKKANPXWha8ZoZRLk8kVmU+b/AFhplABRRRQAUUUUAFFFFABRRRQApOQOAKSiigAooooAKKKKACiiigAopztuI4AwMU2gAoorb8K+HbjxDevHC6Q28IDTzyHCxr6mgDEorp/FnhddGt4byx1C21LT3bymnt5AwSTGdpx3xzWpongA3ulRz6hqdrp97cg/ZLW4cI8pzgDB55JH50AcJRXUeE/CU2ueI7nSJpVt5rYSeZzk7kyCB+Iqi2iMvhNtZaQgrffYzERjB2bs0AYtFFami6xLpS3Iijjfz0CEuOnX/GgDLooooAKKXPFJQAUUUUAFFFFABRRRQAUvY0qruOBirEUXTGMkc80AVwuenWn7QBzwe2elTugCkbenY8VEMKBzgkcnFAEiqjKGC8HrimvGCuUVlxk80igFjlsn8s1KE3RsFxwpPX2oAqOMMcHNNp0gw5Gc1bubmGXTrOCO3RJoS/mSgcyZORn6UAUqKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK7r4Vi7bUL5bFop28sFtOkIX7YOfl3HhcE/rXC1Na3E1pcJPbSNFMhyrqcEUAep/FPSYLTwdp13Ppa6DqUt1sOnQ3CvG8exv3u1eN2cDPXBxW5otjdz6PpSXul22uWePm1QzpHJaRkjLLn5sgcgg54rxfUtTvdTkjfULmS4eNdilznA9KW31W/trSS1gu5o7dwQ0at8pB68UwPQ/heIIPHuszWlwJo4fO8meVwTIu44Yk9cgA0zxfqOm6t8LLW9sYBb3c2rl7yMHgy+UckD0xivM43aNg0bFWHQg4NL5j+V5W9vL3btueM+uKQDK9y/Zn8A6H4xOvXHiO1a5itViEAV9uGLfNkd+CK8Nr6b/Y7ytn4oYHr5Qx6YYUAenJ8I/A8B+XRh0xywP9Kw/iP8P/AAppnw9166stIjjuIbSRo34+U4+ler4WTq3zVx3xfzF8MPEOeM2sg/SmI+DKKKKQwooooAKKKKACl70uMdetHrigCwiqgJ7Y6mpkw4yq8D8M1TUjaSck/wAqsxTKIUUjkZOaAJAGJIIA44HWodiN05JPrU6bWI/h7+xp3kmJQ3GGP8IoArBcElV6D60hYhCSOoOD+FWWEwbcM7T19aqyxSv8wjk2jPVTxQB3fxK8J2Wk77uwJiXIBiA+X8PSvO6KKACiiigApRRRQArAA4ptFFABRRRQAUUUUAFFFFABRRRQAUUUUAFPZcBfcZoooAZRRRQAUUUUAFFFFABXoXws+KGofDyHUY7Czhulvdu7zHK7cHtj8KKKAO1f9pLxAWJXTbZT7St/hWJ4t+OniHxJod1pdxDFFBcKUchyeDRRTA8jooopAFFFFABTh0oooAUHBPGRTT1oooAAasW6jDDtRRQBZt12gAHn1rrPCmnQ3rO8wGI+cY69aKKAOltNBspbnzXjUhT9zHFdRLpdmbDy/IQIQeMUUUxH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    123-I thyroid scan demonstrating an autonomous (\"hot\") nodule with suppression of isotope uptake elsewhere. The total 24-hour isotope uptake was normal (12 percent).",
"    <div class=\"footnotes\">",
"     SSN: suprastenal notch.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas Ross, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_34_4655=[""].join("\n");
var outline_f4_34_4655=null;
